

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Cc: [CSTE Novel Coronavirus 2019](#)
Subject: CSTE COVID-19 Response | Digest for Aug. 26 (CSTE Position Statement, CDC Webinar Series, CDC ELC School Testing Toolkit, CSTE PH Law Webinar, and more)
Date: Thursday, August 26, 2021 4:11:47 PM
Attachments: [image001.png](#)
[image002.png](#)
[Jajosky 2021 State Epi Letter New 2021 COVID-19 Case Definition for NNDSS WebSite Cleared 08242021.pdf](#)
[COVID19 Vaccine Effectiveness Transmission Impact Studies - Summary Tables 20210819.pdf](#)
[COVID-19 Partner Updates August 25 2021.msg](#)
[CDC Health Alert Network \(HAN\) Health Advisory Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.msg](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [CSTE COVID-19 Position Statement – State Epi Letter](#) [Attachment, [Link](#)]
 - Yesterday, **August 25**, CSTE shared a letter (attached) with State and Territorial Epidemiologists providing implementation information for the new 2021 COVID-19 case definition in the National Notifiable Diseases Surveillance System (NNDSS). For cases identified beginning September 1, 2021, jurisdictions should use the case definition approved by the Council on June 17, 2021 in 21-ID-01 ([linked here](#)). Jurisdictions should **not** retroactively change the classification of cases reported prior to September 1, 2021.
 - If you have any questions related to this letter, please send them to positionstatements@cste.org and we will triage them with CDC.
- [Webinar Series: CDC Awardee COVID-19 Vaccine Response Planning](#) [[Link](#)]
 - CDC hosts a weekly webinar series every Wednesday at 3:30 pm ET to provide key on-the-ground stakeholders with the latest information on COVID-19 vaccine planning and distribution. These calls are an opportunity for a focused discussion on vaccine logistics

and other critical planning information. Call information is available below:

- Weblink: <https://cdc.zoomgov.com/j/1617032262?pwd=cG4zdWhzT2c5WWWhRTzB5d2dnVzRFQTO9>

Web Passcode: [REDACTED]

One-Tap Mobile: [REDACTED]

Telephone: [REDACTED]

Meeting ID: [REDACTED]

Phone Passcode: [REDACTED]

- IVAC/WHO Vaccine Effectiveness Weekly Literature Review [Attachment, [Link](#)]
 - John Hopkins University's International Vaccine Access Center (IVAC), in collaboration with the World Health Organization (WHO), have released an updated COVID-19 Vaccine Effectiveness (VE) literature review as of August 19 (attached and [linked here](#)).
 - Note a section has been added to highlight duration of protection data that is not calculating a VE estimate, but can inform the duration of protection of COVID-19 vaccines.
- Resource: CDC ELC School Testing Toolkit [[Link](#)]
 - CDC has developed a COVID-19 School Testing Toolkit ([linked here](#)) featuring a suite of free resources including flyers, posters and social media content highlighting the benefits of COVID-19 testing programs in schools. The toolkit also includes customizable letters and FAQs for teachers, parents, and guardians that address frequently asked questions about school COVID-19 testing programs.
 - If you have questions or have suggestions for additional toolkit materials, please contact CDC's School Support Section at eocevent335@cdc.gov.
- CDC Health Alert Network (HAN) 449: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19 [Attachment, [Link](#)]
 - This CDC HAN Update (attached and [linked here](#)) was issued today, **August 26**, 2021. It summarizes known information about the increased use of Ivermectin, a medication used to treat certain infections caused by internal and external parasites, during the COVID-19 pandemic. Adverse effects associated with Ivermectin misuse and overdose are increasing, as shown by a rise in calls to poison control centers reporting overdoses and more people experiencing adverse effects.
- CSTE Webinar: "Back to School" [[Link](#)]
 - The CSTE Public Health Law Subcommittee will host a webinar **tomorrow, Friday, August 27**, at 2:00 pm EDT. This call will be an open discussion on the issue of back-to-school, quarantine and other school-related legal issues, including whether schools can require quarantine of infected students.
 - Questions may be sent to Sunbal Virk at publichealthlaw@cste.org to have them asked anonymously. Call information is below:
 - Weblink: [REDACTED]
 - Web Passcode: [REDACTED]
 - Telephone: [REDACTED]

[REDACTED]
Meeting ID: [REDACTED]
[REDACTED]
[REDACTED]

Standing Updates

- [CDC Partner Updates – August 25](#) [Attachment]
 - Please see attached for the latest updates from CDC’s State, Tribal, Local, and Territorial (STLT) Task Force.
- [Press Briefings: White House COVID-19 Response Team and Public Health Officials](#) [Link]
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays** at **11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- [CSTE COVID-19 Response Resource Repository](#) [Link]
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this link](#).
- [Request Form for CSTE COVID-19 Call Topics](#) [Link]
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
preparedness.cste.org

Subject: EIS Prematch Office Hours
Location: Virtual

Start: Tue 10/5/2021 1:00 PM
End: Tue 10/5/2021 2:00 PM
Show Time As: Tentative

Recurrence: (none)

Meeting Status: Not yet responded

Organizer: Thoroughman, Douglas (CHFS DPH)
Required Attendees: Winter, Kathleen T (CHFS DPH DEHP); Spicer, Kevin B (CHFS DPH DEHP);
Cavanaugh, Alyson (CHFS DPH DEHP)

Hello, Alyson, Kathleen and Kevin,

We have scheduled our EIS Prematch Office Hours block for 1:00 - 2:00 on Tuesday, October 5th. Dr.

Winter has graciously provided her Zoom Link so that we can call in and this will be provided to the EIS

Class of 2022 candidates. The session will be for them to learn more about the assignment and to ask questions.

Candidates may come in at the beginning or any time during the session. We are supposed to record the session and then provide a link to the EIS program so that those who want to learn about us but didn't attend can view the recording. I think we should be prepared to talk about our EIS slot here in Kentucky so that if no one shows up we can fill the time so that others can learn about us (thought that will probably come across as lame to others viewing if no one shows up!). In that case, I would suggest that we do introductions first, and then go around and each of us talk about what projects we have available, our state, whatever comes to mind that we want to talk about to entice EISO candidates to consider Kentucky as their top option.

I have attached the position descriptions that we put together - I could only submit one, but put both Kathleen and Kevin as secondary supervisors. We will hold the other one for the actual match, but projects and supervision for either can be fluid in my mind.

Look forward to seeing you at the session (and if you can access a camera, that would be good, so that

the candidates can actually see us each). ??

Doug

Topic: EIS Prematch

Time: Oct 5, 2021 01:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
[redacted]

Or Telephone:

One tap mobile:
[redacted]

Dial:
[redacted]
Conference code: [redacted]

Find local AT&T Numbers:
[redacted]

Kathleen Winter, PhD, MPH
State Epidemiologist
Director, Division of Epidemiology and Health Planning
Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
Desk: 502-564-3418 ext. 4310
Cell: 502-892-9895

Subject: CDC All-State, Tribal, Local, and Territorial (STLT) Update Call
Location: Zoom Webinar

Start: Mon 8/16/2021 2:00 PM
End: Mon 8/16/2021 2:45 PM
Show Time As: Tentative

Recurrence: (none)

Meeting Status: Not yet responded


Organizer: CDC IMS 2019 NCOV Response STLT Partner Engagement

****CAUTION**** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.

Call Purpose: CDC's 2019 Novel Coronavirus (COVID-19) response team will continue to host a national call series every Monday from 2:00 p.m. to 2:45 p.m. EST to provide state, tribal, local, and territorial (STLT) partners with the latest information on the COVID-19 outbreak and U.S. preparedness efforts.

Invited call participants include STLT preparedness directors, epidemiologists, health officials, public health laboratory directors, and nongovernmental partners.

CDC will continue to share the agendas and call notes weekly.

Participant Information: The CDC All-STLT Update Call will now be held as a Zoom webinar and requires a one-time registration. After registering, you will receive a unique participant link via email. Please note that your unique participant link will be the same for all calls in the series, through December 2021; you do not need to register for each individual call. [Click here to register for the call series.](#) The link can also be found here: 

Please do not share your participant link. After registering, the link you receive is unique to you and should not be shared. If you would like to invite a colleague to this call series, please request they email eocevent424@cdc.gov.

Add the link to your calendar as a reoccurring weekly event: To add this link to your calendar, select the "Add to Calendar" link within the email you receive. This will download the .ics file. Open the file and save the event to your calendar. Please ensure that you set this invitation to reoccur weekly.

All-STLT Update Call Dates 2021

The All-STLT Update Call will be on Mondays from 2 to 2:45 PM EST except for the dates below where the call will be held on a Tuesday.

- * Tuesday, June 1 (Memorial Day May 31)
- * Tuesday, July 6 (Independence Day July 5)
- * Tuesday, September 7 (Labor Day September 6)
- * Tuesday, October 12 (Columbus Day October 11)

Subject: FW: CSTE COVID-19 Response | Digest for Aug. 26 (CSTE Position Statement, CDC Webinar Series, CDC ELC School Testing Toolkit, CSTE PH Law Webinar, and more)

Date: Friday, December 10, 2021 10:51:18 AM

Attachments: [image001.png](#)
[image002.png](#)
[Jajosky 2021 State Epi Letter New 2021 COVID-19 Case Definition for NNDSS WebSite Cleared 08242021.pdf](#)
[COVID19 Vaccine Effectiveness Transmission Impact Studies - Summary Tables 20210819.pdf](#)
[COVID-19 Partner Updates August 25 2021.msg](#)
[CDC Health Alert Network \(HAN\) Health Advisory Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.msg](#)

To: [Alexander, Kelly N \(CHFS DPH\)](#); [Stack, Steven J \(CHFS DPH\)](#); [White, Connie \(CHFS DPH\)](#); [Dunlap, Susan \(CHFS\)](#)
Subject: FW: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 3:40:12 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF.pdf](#)
[mm7032e1 - Reinfection - vaccination status FINAL PROOF.docx](#)
Importance: High

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

To: [Alexander, Kelly N \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 5:46:21 PM

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 5:13 PM
To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>
Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>
Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

**Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥ 65 Years
— 13 states, COVID-NET, February–April 2021**

**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June
2021**

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:06:50 PM
Attachments: [MMWR_ER_-_Effectiveness_of_COVID-19_Vaccines_in_Preventing_Hospitalization_Among_Adults_Aged_≥65_Years_-_COVID-NET_13_States_-_August_6,_2021.pdf](#)
[MMWR_ER_-_Rapid_Increase_in_Circulation_of_the_SARS-CoV-2_B.1.617.2_\(Delta\)_Variant_-_Mesa_County_Colorado_-_August_6,_2021.pdf](#)
[MMWR_ER_-_Reduced_Risk_of_Reinfection_with_SARS-CoV-2_After_COVID-19_Vaccination_-_Kentucky_-_August_6,_2021.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>
Sent: Friday, August 6, 2021 11:08 AM
To: CDC MMWR ER Ebook <MMWRERbook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release

MMWR

Morbidity and Mortality Weekly Report



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Delta variant case study

Rapid increase in Mesa County, CO, April-June 2021

Mesa County, CO

COVID-19 vaccination low: **36%***

Hospitalizations
ICU use
Deaths

TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places

*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Cavanaugh_08.02_track
Date: Monday, August 2, 2021 4:36:30 PM
Attachments: [Cavanaugh_08.02_track.docx](#)

Here are the track changes of manuscript. I sent revised table 3 earlier. I am not going to submit Supplementary Figure. Instead, I will submit manuscript and 3 tables unless anyone opposes that plan.

I am working to revise the tables and will send them off to OS review.

Thanks!
Alyson

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: COI_disclosure forms - due COB Monday
Date: Saturday, July 31, 2021 8:30:17 AM
Attachments: [coi_disclosure.docx](#)

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Cc: [CSTE Novel Coronavirus 2019](#)
Subject: CSTE COVID-19 Response | Digest for Aug 6. (Early MMWRs, CDC Media Statement on Post-Vaccination COVID-19 Infection Rates, Updated Guidance for COVID-19 Prevention in K-12 Schools and more)
Date: Friday, August 6, 2021 4:26:50 PM
Attachments: [image001.png](#)
[image002.png](#)
[mm7032e1-H.pdf](#)
[mm7032e2-H.pdf](#)
[mm7032e3-H.pdf](#)
[Webinar_DOJ-ConfinementFacilities_Final.pdf](#)
[Webinar_DOJ-ConfinementFacilities_QA-Summary.pdf](#)
[Webinar_DOJ-ConfinementFacilities_Transcript.pdf](#)
[ELC Enhancing Detection PM Guidance 8 5 2021_FINAL.pdf](#)
[COVID-19 Partner Updates August 04 2021.msg](#)
[HHS COVID-19 Update - 85.msg](#)
[COVID-19 Partner Updates August 06 2021.msg](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [Early MMWRs - Vol. 70, No. 31](#) [Attachments, Links]
 - The **August 6** edition of CDC's Morbidity and Mortality Weekly Report (MMWR) includes the following COVID-related articles:
 - [Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado, April–June 2021](#)
 - [COVID-19 Vaccine Administration, by Race and Ethnicity — North Carolina, December 14, 2020–April 6, 2021](#)
 - [Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021](#)
 - [Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021](#)
- [New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection](#) [Link]
 - In response to today's MMWR on post-vaccination COVID-19 infection rates ([linked](#))

[here](#)), CDC issued a media statement, announcing in part: “In today’s MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.”

- Read the CDC’s full media statement [here](#).
- Updated CDC Guidance for COVID-19 Prevention in K-12 Schools [Links]
 - On **August 5**, CDC updated its Guidance for COVID-19 Prevention in K-12 Schools to align with CDC’s [existing guidance for fully vaccinated people](#) and assist K-12 schools in opening for in-person instruction and remaining open. Additionally, the [Considerations for Case Investigation and Contact Tracing in K-12 Schools and Institutions of Higher Education \(IHEs\)](#) has been updated to align with new CDC guidance.
 - The full updated Guidance is [linked here](#).
- CDC COCA Call: Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People [Links]
 - CDC Clinician Outreach and Community Activity (COCA) will host a webinar **Thursday, August 12 at 2:00 pm EDT** to discuss the FDA’s role in issuing EUAs for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters will also cover preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations.
 - Weblink: [REDACTED]
[REDACTED]
 - Telephone: [REDACTED]
 - Webinar ID: [REDACTED]
 - Passcode: [REDACTED]
 - Access materials post-call:
[REDACTED]
- ELC & DOJ Webinar: Detection & Mitigation of COVID-19 in Confinement Facilities [Attachments, [Link](#)]
 - On **August 5**, CDC’s Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) and the Department of Justice (DOJ) hosted a webinar, “Detection & Mitigation of COVID-19 in Confinement Facilities.”
 - In case you missed it, you may watch/download the [full webinar here](#). Also attached are a transcript and summary of the Q&A portion of the webinar.
- Updated ELC Enhancing Detection Performance Measures Guidance [Attachment]
 - Today, **August 6**, CDC released an updated ELC Enhancing Detection Performance Measures Guidance document (attached) for this new budget year that started August 1, 2021.
 - This guidance provides details for all ELC Enhancing Detection performance measures including all data elements, reporting frequency, and reporting timelines.

Updated CDC Public Health Science Priority Questions [\[Link\]](#)

- The CDC's [Public Health Science Agenda](#) for COVID-19 articulates key areas of scientific inquiry and opportunities to guide the development of actionable, evidence-based public health guidance to limit the spread and impact of SARS-CoV-2 and ultimately end the COVID-19 pandemic. As the evidence base and public health response to the COVID-19 pandemic continues to evolve, this Public Health Science Agenda has helped promote efforts to fill critical, time-sensitive scientific gaps and to inform evidence-based decision making.
- On **August 4**, a second update to the Priority Public Health Science Questions was released ([linked here](#)) to help achieve the objectives outlined in the Public Health Science Agenda for COVID-19. The newest update includes 15 Priority Public Health Science Questions that were systematically developed to be relevant, actionable near-term, and reflective of the evolving needs of the ongoing public health response.

Standing Updates

- CDC Partner Updates – August 4 & August 6 [Attachments]
 - Please see attached for the latest update from CDC’s State, Tribal, Local, and Territorial (STLT) Task Force.
- HHS COVID-19 Update – August 5 [Attachment]
 - Please see attached for the latest COVID-19 updates from the HHS Office of Intergovernmental and External Affairs. Updates typically include highlights from any recent COVID-19 Response Team briefings, as well as vaccine, testing, treatment and research updates, toolkits, and resources.
- Press Briefings: White House COVID-19 Response Team and Public Health Officials [\[Link\]](#)
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays at 11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- CSTE COVID-19 Response Resource Repository [\[Link\]](#)
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this link](#).
- Request Form for CSTE COVID-19 Call Topics [\[Link\]](#)
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).



Council of State and Territorial Epidemiologists

Emergency Preparedness & Response Mailbox
preparedness.cste.org

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Cc: [CSTE Novel Coronavirus 2019](#)
Subject: CSTE COVID-19 Response | Digest for Aug. 10 (MMWR Early Release, CDC/CSTE 19 K-12 School Surveillance Guidance, CSTE Webinar, and more)
Date: Tuesday, August 10, 2021 4:51:31 PM
Attachments: [image001.png](#)
[image002.png](#)
[MMWR ER - Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Johnson & Johnson and mRNA COVID-19 Vaccines - August 10, 2021.pdf](#)
[COVID19 Vaccine Effectiveness Transmission Impact Studies - Summary Tables 20210805.pdf](#)
[CSTE Standardized COVID-19 K-12 School Surveillance Guidance for Classification of Clusters and Outbreaks.pdf](#)
[COVID-19 Partner Updates August 09 2021.msg](#)
[HHS COVID-19 Update - 89.msg](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [MMWR Early Release: "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen \(Johnson & Johnson\) and mRNA COVID-19 Vaccines \(Pfizer-BioNTech and Moderna\): Update from the Advisory Committee on Immunization Practices — United States, July 2021"](#) [Attachment, [Link](#)]
 - From the summary: "On July 22, 2021, the Advisory Committee on Immunization Practices reviewed updated benefit-risk analyses after Janssen and mRNA COVID-19 vaccination and concluded that the benefits outweigh the risks for rare serious adverse events after COVID-19 vaccination."
- [CSTE and CDC Release Standardized COVID-19 K-12 School Surveillance Guidance for Classification of Clusters and Outbreaks](#) [Attachment, [Link](#)]
 - In an effort to standardize and better understand the impact of COVID-19 in the K-12 setting, CSTE and CDC have developed standardized surveillance definitions for classification of K-12 school-associated COVID-19 cases, transmission, clusters and outbreaks. Utilization of standardized surveillance definitions is necessary to

characterize the epidemiology of COVID-19, measure the burden of disease and inform public health action in the school setting.

- The new guidance is attached to this email and also available on the CSTE website ([linked here](#)).
 - [Webinar: CSTE Assessment of Outbreak Responses & Protocol for Health Department Notification of Infectious Persons with Recent Travel to CDC's Quarantine Stations](#) [[Link](#)]
 - CSTE will host a webinar **Thursday, August 12, at 2:30 pm EDT** on the CSTE Assessment of Outbreak Responses & Protocol for Health Department Notification of Infectious Persons with Recent Travel to CDC's Quarantine Stations. The webinar will be hosted by consultants Kristen Allen, MPH, and Kristina Lai, MPH. Call information is below:
 - Weblink: [REDACTED]
 - Telephone: [REDACTED]
 - Meeting ID: [REDACTED]
 - One-Tap Mobile: [REDACTED]
 - [WHO Vaccine Effectiveness Literature Review Update](#) [Attachment]
 - The World Health Organization's International Vaccine Access Center has released an updated COVID-19 Vaccine Effectiveness (VE) literature review as of August 5 (attached).
 - Note a new section has been added to highlight duration of protection data that is not calculating a VE estimate, but can inform the duration of protection of COVID-19 vaccines.
-

Standing Updates

- [CDC Partner Update – August 9](#) [Attachment]
 - Please see attached for the latest update from CDC's State, Tribal, Local, and Territorial (STLT) Task Force.
- [HHS COVID-19 Update – August 9](#) [Attachment]
 - Please see attached for the latest COVID-19 updates from the HHS Office of Intergovernmental and External Affairs. Updates typically include highlights from any recent COVID-19 Response Team briefings, as well as vaccine, testing, treatment and research updates, toolkits, and resources.
- [Press Briefings: White House COVID-19 Response Team and Public Health Officials](#) [[Link](#)]
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays at 11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- [CSTE COVID-19 Response Resource Repository](#) [[Link](#)]
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this](#)

[link](#).

- [Request Form for CSTE COVID-19 Call Topics \[Link\]](#)
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
preparedness.cste.org

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Cc: [CSTE Novel Coronavirus 2019](#)
Subject: CSTE COVID-19 Response | Digest for Aug. 16 (NACCHO Webinar, COCA Call, CDC Media Statement, ELC Webinar Recap, and more)
Date: Monday, August 16, 2021 4:40:39 PM
Attachments: [image001.png](#)
[image002.png](#)
[CDC Media Statement Statement from CDC Director Rochelle P. Walensky MD MPH.msg](#)
[Webinar_DMI-DataModernization_Slides.pdf](#)
[Webinar_DMI-DataModernization_Transcript.pdf](#)
[Webinar_DMI-DataModernization_QA-Summary.pdf](#)
[COVID-19 Partner Updates August 13 2021.msg](#)
[HHS COVID-19 Update - 812.msg](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [NACCHO Webinar: CDC Federal Snapshot: K-12 Guidance Update](#) [[Link](#)]
 - The National Association of County & City Health Officials (NACCHO) will host a webinar tomorrow, **Tuesday, August 17 at 3:00 pm EDT**, where CDC will provide an update on the Guidance for COVID-19 Prevention in K-12 Schools and the COVID-19 Guidance for Operating Early Childhood Education & Child Care Programs. Representatives from Janssen Pharmaceuticals will also be on hand to present the latest data on the J&J vaccine.
 - Registration is required and available via [this link](#).
- [CDC COCA Call: Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People](#) [[Link](#)]
 - CDC Clinician Outreach and Community Activity (COCA) will host a webinar tomorrow **Tuesday, August 17 at 2:00 pm EDT** to discuss the current data on COVID-19 vaccines in immunocompromised people; the role of additional doses of mRNA COVID-19 vaccines, patients who should be considered to receive these additional

COVID-19 vaccine doses, results from the August 13, 2021, Advisory Committee on Immunization Practices (ACIP) meeting, and CDC's guidance on additional COVID-19 doses in immunocompromised people. Call information is below:

■ Weblink: [REDACTED]

Telephone: [REDACTED]

Webinar ID: [REDACTED]

Passcode: [REDACTED]

Post-Event Recording:

- [CDC Media Statement on Additional COVID -19 Dose Recommendation](#) [Attachment, [Link](#)]
 - On Friday, **August 13**, CDC Director Rochelle P. Walensky, MD, MPH, issued a media statement (attached) on signing the CDC's ACIP recommendation endorsing the use of an additional dose of COVID-19 vaccine for people with moderately to severely compromised immune systems after an initial two-dose vaccine series.
 - From the statement: *"Emerging data suggest some people with moderately to severely compromised immune systems do not always build the same level of immunity compared to people who are not immunocompromised. In addition, in small studies, fully vaccinated immunocompromised people have accounted for a large proportion of hospitalized breakthrough cases (40-44%). Immunocompromised people who are infected with SARS CoV-2 are also more likely to transmit the virus to household contacts ... At a time when the Delta variant is surging, an additional vaccine dose for some people with weakened immune systems could help prevent serious and possibly life-threatening COVID-19 cases within this population."*
 - The full statement is also available on CDC's website [here](#).
- [ELC Webinar Recap: Accelerating Data Modernizations in Jurisdictions](#) [Attachments, [Link](#)]
 - On **Wednesday, August 11**, the CDC's Epidemiology and Laboratory Capacity (ELC) and Project C2 teams hosted a webinar covering the recently announced *Accelerating Data Modernization in Jurisdictions* supplement. Please see attached for a PDF of the webinar slides, as well as a transcript and summary of the Q&A portion. A recording of the webinar is also available to view [here](#).
- [ASHTO Webinar: Leading Through Uncertainty](#) [[Link](#)]
 - The Association of State and Territorial Health Officials (ASTHO) will host a webinar **Wednesday, August 18 at 4:00 pm EDT** as part of its monthly webinar series *Insight and Inspiration: Monthly Conversations for Public Health Leaders in the Era of COVID-19*. This month's topic is "Leading Through Uncertainty" and the featured speaker is LTG (Ret.) Nadja West, the First African American Army Surgeon General and Former Commanding General, U.S. Army Medical Command.
 - Registration is required and available via [this link](#). Read more about LTG Nadja West [here](#).
- [Town Hall on COVID-19 Vaccines and School Reopening](#) [[Link](#)]
 - The [Latinx Voces en Salud Campaign](#) will host a virtual town hall **Thursday, August 19 at 12:00 pm EDT**, in both English and Spanish for community conversations about COVID-19 vaccines and school reopening. Community advocates and medical experts

will engage in an open conversation to address concerns and answer questions about the COVID-19 vaccine and school reopening guidelines.

- Registration is required and available via [this link](#).

Standing Updates

- [CDC Partner Update – August 13](#) [Attachment]
 - Please see attached for the latest update from CDC’s State, Tribal, Local, and Territorial (STLT) Task Force.
- [HHS COVID-19 Update – August 12](#) [Attachment]
 - Please see attached for the latest COVID-19 updates from the HHS Office of Intergovernmental and External Affairs. Updates typically include highlights from any recent COVID-19 Response Team briefings, as well as vaccine, testing, treatment and research updates, toolkits, and resources.
- [Press Briefings: White House COVID-19 Response Team and Public Health Officials](#) [Link]
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays** at **11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- [CSTE COVID-19 Response Resource Repository](#) [Link]
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this link](#).
- [Request Form for CSTE COVID-19 Call Topics](#) [Link]
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
preparedness.cste.org

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Cc: [CSTE Novel Coronavirus 2019](#)
Subject: CSTE COVID-19 Response | Digest for Aug. 26 (CSTE Position Statement, CDC Webinar Series, CDC ELC School Testing Toolkit, CSTE PH Law Webinar, and more)
Date: Thursday, August 26, 2021 4:11:47 PM
Attachments: [image001.png](#)
[image002.png](#)
[Jaiosky 2021 State Epi Letter New 2021 COVID-19 Case Definition for NNDSS WebSite Cleared 08242021.pdf](#)
[COVID19 Vaccine Effectiveness Transmission Impact Studies - Summary Tables 20210819.pdf](#)
[COVID-19 Partner Updates August 25 2021.msg](#)
[CDC Health Alert Network \(HAN\) Health Advisory Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.msg](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [CSTE COVID-19 Position Statement – State Epi Letter](#) [Attachment, [Link](#)]
 - Yesterday, **August 25**, CSTE shared a letter (attached) with State and Territorial Epidemiologists providing implementation information for the new 2021 COVID-19 case definition in the National Notifiable Diseases Surveillance System (NNDSS). For cases identified beginning September 1, 2021, jurisdictions should use the case definition approved by the Council on June 17, 2021 in 21-ID-01 ([linked here](#)). Jurisdictions should **not** retroactively change the classification of cases reported prior to September 1, 2021.
 - If you have any questions related to this letter, please send them to positionstatements@cste.org and we will triage them with CDC.
- [Webinar Series: CDC Awardee COVID-19 Vaccine Response Planning](#) [[Link](#)]
 - CDC hosts a weekly webinar series every Wednesday at 3:30 pm ET to provide key on-the-ground stakeholders with the latest information on COVID-19 vaccine planning and distribution. These calls are an opportunity for a focused discussion on vaccine logistics

and other critical planning information. Call information is available below:

- Weblink: <https://cdc.zoomgov.com/j/1617032262?pwd=cG4zdWhzT2c5WWWhRTzB5d2dnVzRFQTO9>

Web Passcode: [REDACTED]

One-Tap Mobile: [REDACTED]

Telephone: [REDACTED]

Meeting ID: [REDACTED]

Phone Passcode: [REDACTED]

- IVAC/WHO Vaccine Effectiveness Weekly Literature Review [Attachment, [Link](#)]
 - John Hopkins University’s International Vaccine Access Center (IVAC), in collaboration with the World Health Organization (WHO), have released an updated COVID-19 Vaccine Effectiveness (VE) literature review as of August 19 (attached and [linked here](#)).
 - Note a section has been added to highlight duration of protection data that is not calculating a VE estimate, but can inform the duration of protection of COVID-19 vaccines.
- Resource: CDC ELC School Testing Toolkit [[Link](#)]
 - CDC has developed a COVID-19 School Testing Toolkit ([linked here](#)) featuring a suite of free resources including flyers, posters and social media content highlighting the benefits of COVID-19 testing programs in schools. The toolkit also includes customizable letters and FAQs for teachers, parents, and guardians that address frequently asked questions about school COVID-19 testing programs.
 - If you have questions or have suggestions for additional toolkit materials, please contact CDC’s School Support Section at eocevent335@cdc.gov.
- CDC Health Alert Network (HAN) 449: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19 [Attachment, [Link](#)]
 - This CDC HAN Update (attached and [linked here](#)) was issued today, **August 26**, 2021. It summarizes known information about the increased use of Ivermectin, a medication used to treat certain infections caused by internal and external parasites, during the COVID-19 pandemic. Adverse effects associated with Ivermectin misuse and overdose are increasing, as shown by a rise in calls to poison control centers reporting overdoses and more people experiencing adverse effects.
- CSTE Webinar: “Back to School” [[Link](#)]
 - The CSTE Public Health Law Subcommittee will host a webinar **tomorrow, Friday, August 27**, at 2:00 pm EDT. This call will be an open discussion on the issue of back-to-school, quarantine and other school-related legal issues, including whether schools can require quarantine of infected students.
 - Questions may be sent to Sunbal Virk at publichealthlaw@cste.org to have them asked anonymously. Call information is below:
 - Weblink: [REDACTED]
 - Web Passcode: [REDACTED]
 - Telephone: [REDACTED]

[REDACTED]
Meeting ID: [REDACTED]
[REDACTED]
[REDACTED]

Standing Updates

- [CDC Partner Updates – August 25](#) [Attachment]
 - Please see attached for the latest updates from CDC’s State, Tribal, Local, and Territorial (STLT) Task Force.
- [Press Briefings: White House COVID-19 Response Team and Public Health Officials](#) [Link]
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays** at **11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- [CSTE COVID-19 Response Resource Repository](#) [Link]
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this link](#).
- [Request Form for CSTE COVID-19 Call Topics](#) [Link]
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
preparedness.cste.org

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: EIS Prematch Applications
Date: Thursday, September 2, 2021 12:31:09 AM
Attachments: [2022 Prematch Host Site Application KY-1.docx](#)
[2022 Prematch Host Site Application KY-2.docx](#)

Hello, Kevin and Kathleen!

CDC's Epidemic Intelligence Service Prematch applications are due Friday. Just to update you, Kevin, the EIS Program announced on a recent nationwide CDC call that CDC has been funded to expand the EIS Program pretty dramatically with a focus on field-based positions, and so they are encouraging states and municipalities to consider requesting as many EISO's as they think they can adequately supervise and for which they can provide valuable experiences. Kathleen and I discussed this a few days ago and both felt that we could handle up to two EIS Officers, so we would like to put in a request for that for the Prematch process. Kathleen thought I should remain the primary supervisor for both, but that you and she could be the secondary supervisors for one each. They actually have a spot for a secondary and additional supervisor on the application, so what I did was alternate you as the first secondary supervisor on one (KY-1) and Kathleen as the first secondary on the other (KY-2).

The two applications are almost identical, except for four places.

- The secondary supervisor section (1) has both of you listed on both applications, but switched, as noted above.
- On the Analytic and Surveillance Project sections (2 & 3), I put different possible projects so that the assignments would be seen as somewhat different.
- On the Supervisor Publications Section (4), I switched things around a bit to highlight each of your more recent publications on the application where you are listed as the first secondary supervisor.

I don't feel that great about all the project ideas, so if either of you have some better thoughts and want to substitute something else you think would be good on one or the other application, or can think of more to add or a better way to present the ideas that I put in there, I welcome any and all suggestions. None of this is written in stone and is really just a mechanism to help the candidate EISO's to see that we have exciting and reasonable projects that might interest them in coming to Kentucky. Just note that there are word limits on every section and I am bumping up on those limits in almost every case, so if you want to add something, you can suggest what needs to come out to do that.

Also, both of you have a publication that was listed as "in press" on my most recent documentation. If you have an update on those, please go ahead and revise those where applicable on both applications. NOTE that I didn't use standard reference formats for publications in the interest of including the maximum number of publications with our

authorship noted on each, with enough information for them to be searched up on the web, but not all the specific detail that was driving up the word counts (e.g., I excluded author first initials, used "et al" to cover additional authors, did not keep the authors in order to keep our names on the list, and left out the specific volume, page number and/or DOI references). If they can't find the articles based on what is there, they shouldn't be in EIS anyway!

These are due Friday, as I noted, so if you can do a quick review and let me know of any suggested revisions as soon as you are able, I will be greatly in your debt. I guess I should ask if that arrangement for supervision is all right with both of you? I think this will be very similar to what we have done with Alyson, Kevin, and I would expect the officer with you as the first secondary supervisor to focus more of their time and energy in areas that fit into your assignment here in Kentucky so that your supervision is in line with what we have done with Alyson. Hopefully, you are willing and able to continue in that role, because I think it has been a great success having you as a secondary EIS supervisor for Kentucky and for the EIS Officer! I think it will be very much the same with you, Kathleen!!

Thank you for your help with this! EIS is one of the great ways I feel that we can help Kentucky public health to continue to get better and get on the map (witness all the EIS-generated publications on the short list!).

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Subject: EIS Prematch Office Hours
Attachments: [2022 Prematch Host Site Application KY-1 Final.docx](#)
[2022 Prematch Host Site Application KY-2 Final.docx](#)

Hello, Alyson, Kathleen and Kevin,

We have scheduled our EIS Prematch Office Hours block for 1:00 – 2:00 on Tuesday, October 5th. Dr. Winter has graciously provided her Zoom Link so that we can call in and this will be provided to the EIS Class of 2022 candidates. The session will be for them to learn more about the assignment and to ask questions.

Candidates may come in at the beginning or any time during the session. We are supposed to record the session and then provide a link to the EIS program so that those who want to learn about us but didn't attend can view the recording. I think we should be prepared to talk about our EIS slot here in Kentucky so that if no one shows up we can fill the time so that others can learn about us (thought that will probably come across as lame to others viewing if no one shows up!). In that case, I would suggest that we do introductions first, and then go around and each of us talk about what projects we have available, our state, whatever comes to mind that we want to talk about to entice EISO candidates to consider Kentucky as their top option.

I have attached the position descriptions that we put together – I could only submit one, but put both Kathleen and Kevin as secondary supervisors. We will hold the other one for the actual match, but projects and supervision for either can be fluid in my mind.

Look forward to seeing you at the session (and if you can access a camera, that would be good, so that the candidates can actually see us each).

Doug

Topic: EIS Prematch

Time: Oct 5, 2021 01:00 PM Eastern Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:

[REDACTED]

Or Telephone:

One tap mobile:

[REDACTED]
[REDACTED]

Dial:

[REDACTED]
[REDACTED]
[REDACTED]

Find local AT&T Numbers:

[REDACTED]

Kathleen Winter, PhD, MPH

State Epidemiologist

Director, Division of Epidemiology and Health Planning

Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

Desk: 502-564-3418 ext. 4310

Cell: 502-892-9895

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Cc: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: 22-00035-FOIA: Request for Documents
Date: Wednesday, October 20, 2021 3:51:24 PM
Attachments: [Request for underlying Data regarding report in MMWR August 13, 2021 Vol. 70 No. 32.pdf](#)
[FOIA Response Form.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hello, Kelly,

Alyson received, through CDC, a FOIA request asking CDC to provide the underlying data for the MMWR article on risk of reinfection comparing vaccinated to unvaccinated individuals. This is probably something that will need to go to legal. Alyson can provide a dataset with deidentified data, and hopefully she can do it in a way that protects us against HIPAA violations. My biggest concern is that the person requesting doesn't seem to know a lot about testing for COVID-19 and so I would say that there is a high potential for mis-use of this data. But I don't know that we have a call in that.

Let us know what next steps are.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Wednesday, October 20, 2021 3:01 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Beavers, Suzanne (CDC/DDPHSS/CSELS/DSEPD) <fgx5@cdc.gov>
Subject: FW: 22-00035-FOIA: Request for Documents

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

From: Macomber, Jonathan (CDC/DDPHSS/CSELS/OD) <qxf1@cdc.gov>
Sent: Wednesday, October 20, 2021 2:55 PM
To: Rutledge, Terisa (CDC/DDPHSS/CSELS/OD) <txr7@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Henry, Roberto (CDC/DDPHSS/CSELS/OD) <ypj7@cdc.gov>; Macomber, Jonathan (CDC/DDPHSS/CSELS/OD) <qxf1@cdc.gov>
Subject: 22-00035-FOIA: Request for Documents

Good Afternoon All,

Below please find an incoming FOIA request regarding [this MMW article](#). **The requestor has asked for CDC to:** "Please provide the agency records of the background data related to the study upon which the paper in question was based upon." Please provide a response to this request by COB Friday 10/29, thank you!

Please note: The FOIA office has informed me the attached original request is for background only, the requestor has limited the scope of their inquiry to just the highlighted question above.

Best,
Jon Macomber, MPA
Public Health Analyst (Policy & Issue MGT)
CSELS | CDC
M: 337-238-8129
E: jmacomber@cdc.gov

From: [Parry, Carolyn \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#); [Berryman, Misty](#); [Gaither, Melanie L \(CHFS DPH DEHP\)](#); [Gillion, Grant T \(CHFS DPH DPHPS\)](#); [Gillis, Rebecca L \(CHFS DPH EPB\)](#); [Herrington, Amy \(CHFS DPH DEHP\)](#); [Higgins, Sue](#); [Hume, Robbie \(CHFS DPH DPHPS\)](#); [Johnson, Rick D \(CHFS DPH DPHPS\)](#); [Kik, Angela M \(CHFS DPH DPHPS\)](#); [Miracle, Julie \(CHFS DPH\)](#); [Michele Pinkston](#); [Robeson, Sara \(CHFS DPH\)](#); [Sanders, Kimberly \(CHFS DPH DEHP\)](#); [Taylor, Ida \(CHFS DPH\)](#); [White, Connie \(CHFS DPH\)](#); [Wible, Sarah C \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: AIM COVID Update 8/7/2021
Date: Monday, August 9, 2021 8:02:05 AM
Attachments: [CDC TEMPLATE_Incentive Plan.docx](#)
[CDC Incentives FAQs final_updated_30July2021.pdf](#)
[CDC Incentives with Immunization Funding_7.30.2021.pdf](#)
[image005.png](#)
[image006.png](#)
[image007.png](#)
[image008.png](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

From: Claire Hannan <CHannan@Immunizationmanagers.org>
Sent: Sunday, August 8, 2021 10:00 PM
To: Claire Hannan <CHannan@Immunizationmanagers.org>
Subject: AIM COVID Update 8/7/2021

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

AIM members –

It was great seeing a few of you at the AIRA conference, plus immunization program and IIS staff from many awardee jurisdictions. Great discussion of successes and challenges for IIS in the pandemic, and brainstorming for the future. We will be working with AIRA to share the highlights with you in the near future. Also a lot of activity this week to continue to increase COVID vaccination progress.

ACTION REQUESTED – GET INVOLVED!

- **AIM SITUATIONAL AWARENESS SURVEY:** [Complete Survey Here](#). Covers nursing homes, feedback on vaccine manufacturer resources, etc.
- Please share any materials you may have related to **school-located vaccination**. Letters to parents or providers, flyers, consent forms, work plans, MOUs, school contacts.... Send to Emily Less at emilyless@gmail.com.
- **Participate in a Virtual Roundtable on School-Located Vaccination Clinics:** AIM is collaborating with the National Association of School Nurses (NASN) and Mathematica to support partnerships between IPs and K-12 schools. We are hosting virtual roundtable conversations with IPs and school nurses to learn more about school-based vaccination clinics, how these programs are implemented, and the factors and resources that influence them. [RSVP here](#).
- **Member Assistance Program Focus Group:** We are recruiting participants for a virtual focus group discussion to share how AIM can assist you through our Member Assistance

Program (MAP) and to identify what tools and resources would be most useful to your jurisdiction. The event will bring together other immunization managers from around the country with experience planning and implementing Supplement 3 and 4 Work Plan activities. The focus group will be held on Thursday August 12th from 1:00-2:00 PM ET. RSVP to mwaterman@immunizationmanagers.org

- **Share your CDC “Program Effectiveness Non-Influenza VFC Vaccine Doses Ordered VTrcks Report” (Jan-May 2021).** Jurisdictions recently received a program effectiveness report with county-level data (July 15 email from from CDC Program Effectiveness Team). There has been interest and CDC has encouraged sharing this report with stakeholders and advocacy groups for state/local level strategic planning. If willing, please pass on the report to your coalitions, partners, providers, local AAP chapter, local American Cancer Society network, or to AIM (info@immunizationmanagers.org). Thank you!

CALENDAR:

- **AIM/Moderna Webinar: RESCHEDULED TBD.** We will be cancelling the AIM/Moderna webinar at this time, and will be rescheduling after the adolescent EUA is passed and ACIP holds their emergency meeting.
- **AIM Health Equity Committee Meeting: Tuesday 8/10, 2-3pm ET.** The AIM Health Equity Committee will meet the first Tuesday of each month. An agenda will be shared prior to each meeting. Email Jasmine at jberry@immunizationmanagers.org with questions. [Join here](#) on Tuesday.
- **Virtual Exhibit Hall - Pfizer/Traceable: Wednesday 8/11, 1-2pm ET.** Attendees will learn about updates to Traceable storage and handling products and receive Pfizer updates on vaccine products, sales trends, and expectations for the coming season. Click [HERE](#) to join the virtual exhibit hall.
- **AIM Executive Committee Meeting: Thursday 8/12, 11-12pm ET.** Executive Committee members should have received an updated calendar invite with a Zoom join link (rescheduled from 8/5).
- **AIM Member Meetup: Friday 8/13, 2pm-3pm ET.** Email ajensen@immunizationmanagers.org if you need the meeting invite.
- **ACIP Meeting: Friday, 8/13, 11am ET.** No agenda available yet.

UPDATES:

- **CDC updates incentive allowance to \$100:** In alignment with newly announced White House initiatives CDC updated their policy (announced in NCIRD all-awardee e-mail Fri 7/30/@ 4:49pmET) regarding the use of COVID-19 supplemental funding to purchase incentives for vaccine recipients.
 - The new per person incentive cap is \$100. This is an increase over the previously established cap of \$25 per person.
 - The updated policy and FAQs are **attached** to this message. Also **attached**, are the incentive template for IP19-1901 recipients and previously shared information about the ‘hybrid plan’ which allows CDC to approve one plan and still offers your local partners the flexibility to select incentives.
 - In developing your plans for the use of incentives, please ensure that they reflect responsible and reasonable uses of federal funding. Federal funds, including those allocated to incentives, are subject to audit requirements as outlined in the HHS Grants Policy Statement 45 CFR Part 75.
 - Incentive plans must be submitted as a grant note in GrantSolutions. Program Operations Branch (POB) project officers will review the plans and provide a response (also as a grant note in GrantSolutions) within 3 – 5 business days.
 - CDC approval must be obtained prior to the implementation of an incentive plan or obligation of funds.
 - If you have any questions, please reach out to your POB project officer.

- **LTC 2.0 Office Hours:** CDC held LTC 2.0 office hours on Tuesday 8/3. CDC is encouraging jurisdictions to begin planning for additional doses of COVID vaccine for LTC residents and staff.
 - Priorities are to understand SNFs + their pharmacy partnerships, and to enumerate non-SNFs for more insight.
 - If you need unofficial notes from this call, please email mdoan@immunizationmanagers.org
- **8/5 - Daily Vaccinations Hit Highest Level In A Month, White House Says—With States Where Covid-19 Is Surging Leading The Way:** Thursday, the U.S. just registered its highest daily number of vaccinations since early July, and that states with particularly high case rates—and particularly low vaccination rates—are recording the biggest increases. Read the [Forbes article](#).
- **AMA - Families of men in notorious syphilis study speak up for vaccination:** Really cool [AMA article](#) and [short documentary](#)! Descendants of the men who participated in the Tuskegee study are working to reframe the narrative and build trust through public service and public health....especially for COVID vaccines!
- **San Francisco is giving extra COVID vaccine dose to Johnson & Johnson recipients:** San Francisco will provide an extra dose of the COVID-19 vaccine for people who got the single-shot Johnson & Johnson variety but public health officials aren't calling it a booster, authorities said Tuesday. Read the [KTLA article](#).
- **WHO calls for moratorium on booster vaccine shots through September, citing global disparity:** The World Health Organization on Wednesday called for a halt on booster shots of coronavirus vaccines through at least September, as poorer countries struggle to access doses. Read the [Washington Post article](#).

LEGISLATION:

- **State Legislative Round-Up - A Review of COVID-19 Vaccine Mandates:** Since the beginning of the COVID-19 pandemic, state legislators have considered a number of bills to alter or limit the powers granted to public health officials across the nation. An emerging trend in the 2021 sessions was a focus on prohibiting the ability of public health officials, businesses, and educational institutions to implement COVID-19 vaccine requirements. [This brief](#) provides an overview of enacted legislation; highlights litigation that could alter the policy landscape; and concludes with future considerations, suggested resources, and talking points to help AIM members navigate this emerging debate.
- [N.Y.C. will require workers and customers show proof of at least one dose for indoor dining and other activities](#)
 - The program, similar to [mandates](#) issued in France and Italy last month.
 - Program will start on Aug. 16, and after a transition period, enforcement will begin on Sept. 13, when schools are expected to reopen and more workers could return to offices

RESOURCES:

- **AIM Immunization Communications Resources:** We've partnered with the National Public Health Information Coalition (NPHIC) to increase information sharing and collaboration between immunization program managers and public information officers. [Here's what's new in the resource portal:](#)
 - GBS and J&J Talking Points. AIM has developed talking points to help address questions about the rare nervous system condition known as Guillain-Barré Syndrome (GBS) and the J&J vaccine.
 - AIM and NPHIC Webinar: Immunization and Communication Collaboration

Recording. AIM and NPHIC hosted a joint panel discussion on lessons learned throughout the pandemic for working together to communicate key health information. 8/6:

- **New CDC MMWRs:**

- 8/6: [COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021](#)
- 8/6: [Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021](#)
- Early Release 8/6: [Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021](#)
- Early Release 8/6: [Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado, April–June 2021](#)
- Early Release 8/6: [Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged >65 Years — COVID-NET, 13 States, February–April 2021](#)

Claire Hannan, MPH

Executive Director

301-424-6080

immunizationmanagers.org



From: [Parry, Carolyn \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#); [Berryman, Misty](#); [Gaither, Melanie L \(CHFS DPH DEHP\)](#); [Gillion, Grant T \(CHFS DPH DPHPS\)](#); [Gillis, Rebecca L \(CHFS DPH EPB\)](#); [Herrington, Amy \(CHFS DPH DEHP\)](#); [Higgins, Sue](#); [Hume, Robbie \(CHFS DPH DPHPS\)](#); [Johnson, Rick D \(CHFS DPH DPHPS\)](#); [Kik, Angela M \(CHFS DPH DPHPS\)](#); [Miracle, Julie \(CHFS DPH\)](#); [Michele Pinkston](#); [Robeson, Sara \(CHFS DPH\)](#); [Sanders, Kimberly \(CHFS DPH DEHP\)](#); [Taylor, Ida \(CHFS DPH\)](#); [White, Connie \(CHFS DPH\)](#); [Wible, Sarah C \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: ALL AWARDEE WEEKLY SUMMARY: August 12, 2021
Date: Thursday, August 12, 2021 6:49:35 PM
Attachments: [image003.png](#)
[Awardee Meeting_COVID_08-04-21_USED.pdf](#)
[326116_VaccinePregnancy_SM.zip](#)
[PartnerKM_COVID-19vax_Pregnancy.pdf](#)
[Weekly Reader 8921 Highlights from VDAPS.msg](#)
[21.08.05 White House Incentives Presentation_V1.pdf](#)
[Dr. Mysheika W. Roberts_Columbus Public Health_Vax Cash Incentive_8,5.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

From: NCIRD Immunization Grantee Mailbox (CDC) <nipgrant@cdc.gov>
Sent: Thursday, August 12, 2021 5:11 PM
To: NCIRD Immunization Grantee Mailbox (CDC) <nipgrant@cdc.gov>
Subject: ALL AWARDEE WEEKLY SUMMARY: August 12, 2021

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

ALL AWARDEE WEEKLY SUMMARY
National Center for Immunization and Respiratory Diseases (NCIRD)
Immunization Services Division
August 6 – August 12, 2021

In This Summary

- [New Vaccine Information Statements](#)
- [CDC Update on COVID-19 Vaccination During Pregnancy](#)
- [CDC COVID-19 Partner Update: Vaccine Safety Call](#)
- [Presentations on use of \\$100 Vaccine Incentives](#)
- [Communication and Education Inventory Update 8/9/21](#)
- [Resources for Partnering for Vaccine Equity](#)
- [2019-2021 VFC Management Survey \(VMS\) Now Available](#)
- [Vaccine Planning Updates](#)
- [Weekly Reader Highlights](#)

Awardee News and Reminders

NEW VACCINE INFORMATION STATEMENTS


CDC has released 14 updated vaccine Information statements (VISs), including updated VISs for this year's flu season. The VISs can be found at [Vaccine Information Statement | Current VISs | CDC](#).

CDC UPDATE ON COVID-19 VACCINATION DURING PREGNANCY

On August 10, CDC published a new analysis: [Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21](#), showing the cumulative risk of miscarriage after receiving an mRNA COVID-19 vaccine (13%) was similar to previously published estimates (11-16%). This report included 2,456 pregnant people enrolled in the v-safe pregnancy registry who received at least one dose of an mRNA COVID-19 vaccine just before pregnancy or prior to 20 weeks of pregnancy (as of July 19, 2021). These data do not suggest an increased risk for miscarriage after receiving an mRNA COVID-19 vaccine just before or within the first 20 weeks of pregnancy. These preliminary findings are reassuring and can help inform discussions about COVID-19 vaccination during pregnancy between pregnant people and their healthcare providers.

Growing evidence about the safety and effectiveness of COVID-19 vaccination during pregnancy demonstrates that the benefits of receiving a COVID-19 vaccine outweigh any known or potential risks. [CDC recommends that pregnant people should be vaccinated against COVID-19](#). COVID-19 vaccination is recommended for all people 12 years and older, including people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future.

Additionally, we've heard reports that clinicians have seen the number of pregnant people infected with COVID-19 rise in the past several weeks. The increased circulation of the highly contagious [Delta variant](#), the [low vaccine uptake among pregnant people](#), and the increased risk of severe illness and pregnancy complications related to COVID-19 infection among pregnant people make vaccination for this population more urgent than ever.

We encourage you to share these preliminary findings and our strengthened recommendation widely with your partners and networks and on your organization's social media pages (graphics are attached as well as a key message document). CDC is committed to learning about COVID-19 vaccination during pregnancy and will continue to share new information as it becomes available. 

CDC COVID-19 PARTNER UPDATE: VACCINE SAFETY CALL

We invite you to join us for a CDC COVID-19 Partner Update: Vaccine Safety call, **Friday, August 13, 2021 from 3:00-4:00PM ET**. CDC subject matter experts will provide some remarks and then there will be time for questions and answers.

The call will be held via Zoom and the connection details are noted below.

Connection Details:

You are invited to a Zoom webinar.

When: Aug 13, 2021 03:00 PM Eastern Time (US and Canada)

Topic: CDC COVID-19 Partner Update: Vaccine Safety

Please click the link below to join the webinar:



Passcode: [REDACTED]

US: [REDACTED]

[REDACTED] higher quality, dial a number based on your current location):

US: [REDACTED]


Webinar ID: [REDACTED]

Passcode: [REDACTED]

International numbers available: [REDACTED]

PRESENTATIONS ON USE OF \$100 VACCINE INCENTIVES

On August 5th, the White House, Department of the Treasury, and Department of Health and Human Services hosted a meeting for state, territorial, and local government leaders on use of federal dollars for \$100 vaccine incentives to further promote COVID vaccinations. Incentives may increase the number of people who choose to get vaccinated, including motivating people to get vaccinated sooner than they otherwise would have.

The two attached presentations  were given during that meeting, and we think you may find them helpful as you work out your own incentives program and as you consider offering incentives up to \$100.

COMMUNICATION AND EDUCATION INVENTORY UPDATE 8/9/21

The CDC COVID-19 Vaccine Task Force maintains a Communication and Education Product Inventory on the Awardee SharePoint portal in the "COVID-19 > Communication Content" folder. Check out the 'New Content' tab with the latest webpages.

The product inventory is an index of key content compiled to support awardee needs, organized by product category and by stakeholder. It is updated at least once a week. Recent updates to the Communication and Education Product Inventory include:

[V-safe Print Resources](#)

[Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States](#)

[Vaccinating Homebound Persons With COVID-19 Vaccine](#)

[Ensuring COVID-19 Vaccine Safety in the US](#)

[COVID-19 Vaccination Program Operational Guidance](#)

[COVID-19 Vaccine Effectiveness Research](#)

RESOURCES FOR PARTNERING FOR VACCINE EQUITY

[Join the National Adult and Influenza Immunization Summit](#)

The NAIIS is dedicated to addressing and resolving adult and influenza immunization issues and improving the use of vaccines recommended by CDC's Advisory Committee on Immunization Practices. The NAIIS consists of over 700 partners, representing more than 130 public and private organizations. Broad-based leadership of the NAIIS is conducted through the members of the Summit Organizing Committee (SOC).

[Sign up to receive the Immunization Action Coalition \(IAC\) Express weekly email](#)

Delivered via email every Wednesday, IAC Express keeps you informed about new and updated vaccine

recommendations from the Centers for Disease Control and Prevention and new vaccine licensures by the Food and Drug Administration. You'll read about newly posted Vaccine Information Statements (VISs) and their translations, new immunization education materials from IAC, and the latest resources from CDC and other organizations.

[CMS Health Observances: Get Vaccinated During National Immunization Awareness Month](#)

During National Immunization Awareness Month, CMS OMH is encouraging minority and underserved people to stay up-to-date on routine vaccines and get vaccinated. With the flu season getting closer and the country continuing to combat COVID-19, we're calling on providers and communities to help us share resources that may help high-risk individuals learn about the benefits of vaccines and talk to their providers about necessary vaccinations. This page contains resources you can share with your community to help them learn more about the vaccinations that are available at no or low cost under most health coverage.

[FEMA Releases Emergency Operation Center Toolkit Documents](#)

FEMA has released two Emergency Operations Center (EOC) Toolkit documents. The toolkit is a collection of guidance and best practices for emergency management, specifically the emergency operations center community. These documents assist jurisdictions with developing emergency operations centers that can successfully meet their needs. The toolkit covers topics such as hazard vulnerability assessments, physical site selection, mitigation, considerations, emergency operations center capabilities and requirements, information management systems, and training and exercises.

[SARS-CoV2 Vaccines Information Equity and Demand Creation Project \(COVID\)](#)

GHC3 and its partners (project team, including Emory and Johns Hopkins University, and a variety of other groups) have implemented a systematic approach to provide interpretable, context- and culture-specific accurate and trusted information about the vaccines to package and deliver this information to susceptible populations at risk for COVID and demonstrating vaccine hesitancy as a means to substantively reduce the disproportionate impact of COVID illness and death associated with this pandemic. *GHC3 also has a series of Digital & Social Assets available for (free) download [here](#).*

[Higher-Ed COVID-19 Community of Practice \(HECCOP\) Student Ambassador Toolkit](#)

Student ambassadors can be a powerful force for behavior change on campus. This toolkit can help you create a student ambassador program that works for your campus efforts to stop the spread of COVID-19. We've also provided materials that your student ambassadors can use in their outreach efforts: a Communication Plan, Workshop Lesson Plan, and campaign materials.

[Partnering for Vaccine Equity Program Website](#)

We are thrilled to announce the launch of our *Partnering for Vaccine Equity* program website! On this website you will find information on the partner network, support for partners including the Learning Community and Data-Informed Technical Assistance, and guides and resources for increasing vaccine equity. We hope you will take advantage of this central hub for the program and we look forward to adding more information about other partners in the network soon!

[Partnering for Vaccine Equity Event Recording](#)

The recording of the Spotlight on Community-Based Organizations (CBOs) event that took place on June 30, 2021, is now available with subtitles and transcripts in English, Spanish, Korean, Vietnamese, and Chinese.

2019-2021 VFC MANAGEMENT SURVEY (VMS) NOW AVAILABLE


Grantees:

The 2019-2021 VFC Management Survey (VMS) is now ready for data entry in PEAR. The VMS is an annual survey to collect information on awardee-level vaccine management practices and indicators of program performance. As a reminder, this year's VMS data collection will require two submissions and will cover two budget periods (7/1/2019 – 6/30/2020 and 7/1/2020 – 6/30/2021). Once the VMS module is selected under TOOLS in PEAR, there will be a budget period drop down at the top of the VMS landing page. Two optional fillable PDFs are available for awardees to complete before entering data into PEAR, if desired. These can be accessed from the PEAR HELP TAB under VMS Templates.


Please complete VMS data entry for both budget periods by October 12, 2021.

Vaccine Planning

8/4/21 ALL AWARDEE CALL MATERIALS

The completed slide deck from the 8/4 call is available. 

WEEKLY READER HIGHLIGHTS

Weekly Reader Highlights related to COVID-19 vaccines were distributed August 9th. 

Key highlights for this week include:

- We Have a New Name!
- MMWR Launches a New Site Focusing on COVID-19 Vaccine Effectiveness and Safety
- A Message From the Desk of Chris Duggar
- New Guidance on Coadministration of COVID-19 Vaccine with Other Vaccines
- Be Sure to Screen for Previous COVID-19 Vaccination
- School-based Immunization Program FAQs
- Topline Messages for the Week

Important Dates

August 1st - 31st: National Immunization Awareness Month

August 31st: eGratis is permanently closed

September 3rd: MMWR Published: "National, Regional, State and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years – United States, 2020"

PLEASE DO NOT RESPOND OR REPLY DIRECTLY TO THIS E-MAIL

This message has been sent to program managers and field staff. Please review the individual announcements for contact information. If you do not see any contact information and need additional information, please contact your program manager. If you need access to the ISD Awardee SharePoint site, please contact your supervisor or your CDC project officer for more information.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection
Date: Friday, August 6, 2021 12:22:57 PM
Attachments: [image002.png](#)
[EMBARGOED UNTIL 1PM Media Statement MMWR.pdf](#)
[MMWR ER - Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States - August 6, 2021.pdf](#)
[MMWR ER - Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado - August 6, 2021.pdf](#)
[MMWR ER - Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky - August 6, 2021.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Sorry for flooding e-mail but this went out to media and has more info than the previous message I forwarded.

I also heard from AP reporter that there is a JAMA article being released today that again finds higher antibody response after vaccination of previously-infected individuals.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Friday, August 6, 2021 12:20 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

This went out to CDC's media list while we were talking to Mike. Just FYI

From: Media@cdc.gov (CDC) <sohco@cdc.gov>

Sent: Friday, August 6, 2021 11:49 AM

To: Media@cdc.gov (CDC) <sohco@cdc.gov>

Subject: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection



CENTERS FOR DISEASE
CONTROL AND PREVENTION

The MMWR is Embargoed until Friday, August 6, 2021 at 1PM ET



Morbidity and Mortality Weekly Report

know what matters.

August 6, 2021

Please see the attached E-books for:

“Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

“Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

“Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Thank you,

CDC News Media Branch
404-639-3286



CENTERS FOR DISEASE
CONTROL AND PREVENTION

The Media Statement is Embargoed until Friday, August 6, 2021 at 1PM ET

Media Statement

EMBARGOED FOR 1PM ET
Friday, August 6, 2021

Contact: [CDC Media Relations](#)
(404) 639-3286

New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

In today's MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.

"If you have had COVID-19 before, please still get vaccinated," said CDC Director Dr. Rochelle Walensky. "This study shows you are twice as likely to get infected again if you are unvaccinated. Getting the vaccine is the best way to protect yourself and others around you, especially as the more contagious Delta variant spreads around the country."

The study of hundreds of Kentucky residents with previous infections through June 2021 found that those who were unvaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated. The findings suggest that among people who have had COVID-19 previously, getting fully vaccinated provides additional protection against reinfection.

Additionally, a second publication from MMWR shows vaccines prevented COVID-19 related hospitalizations among the highest risk age groups. As cases, hospitalizations, and deaths rise, the data in today's MMWR reinforce that COVID-19 vaccines are the best way to prevent COVID-19.

COVID-19 vaccines remain safe and effective. They prevent severe illness, hospitalization, and death. Additionally, even among the uncommon cases of COVID-19 among the fully or partially vaccinated vaccines make people more likely to have a milder and shorter illness compared to those who are unvaccinated. CDC continues to recommend everyone 12 and older get vaccinated against COVID-19.

###

[U.S. Department of Health and Human Services](#)

CDC works 24/7 protecting America's health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Tuesday, August 3, 2021 9:58:21 PM
Attachments: [COPY EOC Cavanaugh 08.03 clean.docx](#)
[COPY EOC Cavanaugh 08.03 track.docx](#)
[COPY EOC TABLE 2 08.3.21 clean.docx](#)
[COPY EOC TABLE 2 08.3.21 track.docx](#)
[COPY EOC TABLE 1 08.03.21 clean.docx](#)
[COPY EOC TABLE 1 08.03.21 track.docx](#)

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Tuesday, August 3, 2021 6:38 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,

Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 6:30 PM

To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.

Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Tuesday, August 3, 2021 4:45 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 2:27 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by

OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:	MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Targeted Completion Date:	8/3/2021
Forecasted Completion:	8/16/2021
Intended Use:	Publication: MMWR: Recommendations & Reports
Path:	/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Audience:	Public health, medical professionals, and general public
Topics:	
Description:	A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.
CDC ADS Notification Criteria:	Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review
Date: Thursday, August 5, 2021 1:54:11 PM
Attachments: [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review.docx](#)
[Reinfection - vaccination status FINAL TO DTP.docx](#)

Hi all,

Here is the revised Comms package, not yet fully approved. If you think there needs to be additional edits, let me know before 4 pm.

Interestingly, a comment by the media team made me recognize an edit needed for final proof. December 31 to May 1 is (>4 months) not (>=5 months) as stated in discussion.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Thursday, August 5, 2021 1:28 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: coi_disclosure_kwinter_ Revised - please confirm
Date: Monday, August 2, 2021 9:16:17 AM
Attachments: [coi_disclosure_kwinter_revised.docx](#)

Kathleen,

You checked off the bottom “x” that you have no COI. I added an x to each of the 13 marks next to the “none.” I wanted to make sure to get your okay/approval on this revised form and that it is correct. Can you please confirm this is okay and/or revise and send back?

Thanks,
Alyson

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Final comments - revisions in analysis
Date: Tuesday, August 3, 2021 7:07:06 PM
Attachments: [COPY EOC Cavanaugh 08.02 clean for OS-OS-BPZ.docx](#)
[COPY EOC TABLE 1 08.02.21 clean For OS-BPZ.docx](#)
[COPY EOC TABLE 2 08.02.21 cleanFor OS-BPZ.docx](#)
[COPY EOC TABLE 3 08.2.21 clean For OS-BPZ.docx](#)
Importance: High

FYI - They have requested we flip the OR using essentially comparing cases to controls with no vaccination as reference group. It will place all of our OR below 1. I can do this, but find this harder to interpret.

Other comments are much easier to address.

Dr. Spicer – if you have any good resources for length of viral shedding at your fingertips, let me know. Otherwise I can find.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 6:36 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>
Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,

Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 6:30 PM

To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.

Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Tuesday, August 3, 2021 4:45 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen

tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 2:25 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:18 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date: 8/3/2021

Forecasted Completion: 8/16/2021

Intended Use: Publication: MMWR: Recommendations & Reports

Path: /EOC/_eClearance Folders and Files/2021/MMWR-COVID-19

Audience:

vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Topics:

Public health, medical professionals, and general public

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: actual numbers, please? -DRAFT response
Date: Wednesday, August 11, 2021 8:39:46 AM
Attachments: [actual numbers_response.docx](#)

Good morning,

This is a message received in regards to MMWR. Attached is drafted response. Please let me know if you think any additional changes to the drafted response are needed.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Matt Birchmeier <mjbirchmeier@hotmail.com>
Sent: Saturday, August 7, 2021 8:30 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: actual numbers, please?

Dr. Cavanaugh,

I read with interest your article here. However, as one PhD scientist to another, I found that the text you presented was completely lacking in a very important detail: what was the actual odds of someone who has previously been infected, of becoming re-infected during the study? You cite the 2.3X higher risk, but it matters greatly whether the risk of reinfection is 0.1% or 1% or 10% or 90%. Certainly, those numbers were generated during your study. You should present them. The Missouri study that I linked below found a <1% rate of reinfection among those who had significant illnesses. Furthermore, particularly hard hit areas like Detroit, Michigan, still seem to be benefiting from a strong degree of natural immunity, 1+ year after the worst of the pandemic, in spite of a low vaccination rate.

There is a very good argument that the benefits of vaccinating previously infected people in


the US are less than the benefit of vaccinating naive populations elsewhere in the world. That question may be an ethical debate for another day. But hopefully you can see that the absolute numbers around reinfection are important in that debate! If the risk of reinfection is 90%, then certainly that vaccination in Kentucky is important, both from an ethical and policy perspective. If the risk of reinfection is 0.7%, then perhaps someone in Vietnam should receive that dose.

Please update your publication at the earliest opportunity, to better inform the American public of what the true risks around COVID are. Most media outlets seem content to scare people rather than truly inform them; I would hope for much better from the CDC. We CAN handle the truth, if only you would tell the whole truth.

Best regards,

Matthew J. Birchmeier, Ph.D.

https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w




[Reduced Risk of
Reinfection with SARS-
CoV-2 After COVID-19
Vaccination — Kentucky,
May–June 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w)

Although laboratory evidence suggests that antibody responses following COVID-19 vaccination provide better neutralization of some circulating variants than does natural infection (1,2), few real-world epidemiologic studies

www.cdc.gov

<https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness>

[Study Finds COVID-19
Reinfection Rate Less Than
1% for Those with Severe](https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness)



[Illness - MU School of Medicine](#)

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from medicine.missouri.edu

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 8:33:15 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy.docx](#)

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this

afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Comments on report no. 1464
Date: Tuesday, July 27, 2021 6:23:44 PM
Attachments: [Cavanaugh_1464_JG.docx](#)
[FIGURE_JG.docx](#)
[TABLE 1_JG.docx](#)
[TABLE 2_JG.docx](#)
[TABLE 3_JG.docx](#)

Hi all,

Here are comments from MMWR from pre-review. In general, I agree with most edits.

- I agree with suggestion to use Figure 1 in supplemental and include the three tables in the MMWR.
- The one section I am unsure of is Page 5. This paragraph on single dose was added per comments from vaccine task force. Any suggestions for shortening would be appreciated, but I think some talk on the topic is needed.
- For the actual manuscript, if you have suggestions/edits/comments, please use the link: https://kymsoffice-my.sharepoint.com/:w/g/personal/alyson_cavanaugh_ky_gov/EZYxVWqbJ1pFnaIdyX75zHYBBd3cJK1e16C3m-hZ0jUkPQ

I plan to resubmit early morning (6am ish) on 7/29/21. The next submission step is higher levels of CDC clearance (CHEO/JIC). This is nearing the end of the process for clearance.

FYI – they edited the tables without track changes, so I will need to make some adjustments. Table 3 is confusing as laid out. I need to check these in more detail since track changes weren't used. If you have changes on tables, let me know. There is not a sharedrive link for tables.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Sent: Tuesday, July 27, 2021 4:19 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cck3@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>

Subject: Comments on report no. 1464

Dear Dr. Cavanaugh,

I appreciated the opportunity to review your draft manuscript (**Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021**) on behalf of *MMWR* before it undergoes further COVID-19 Response pre-clearance and JIC clearance.

I've made a number of edits to your manuscript in track changes in the attached files to enhance clarity and to further align with *MMWR* author guidelines, and have also included some comments and questions. You do not need to accept any edits that may have inadvertently introduced inaccuracies or deviated from the original intent of the narrative. However, please accept all other edits and make a concerted effort to address the comments and questions before sending a clean version to the next stage of pre-clearance. This will ultimately help facilitate more timely processing of the manuscript once it is eventually submitted to *MMWR* for official consideration of publication.

Please pay attention to the following:

1. *MMWR* reports are allowed to have a maximum of 3 tables and/or figures in any combination; you have submitted 3 tables and 1 figure; I suggest that you make the figure a supplementary figure; it will be archived in CDC Stacks, and there will be a clickable link within the report to access it.
2. I formatted your tables for *MMWR*; in the future, please be aware that table cells cannot have any hard returns nor can there be any empty cells.

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the *MMWR* functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance. Once cleared by JIC, you will then be directed to submit the manuscript to *MMWR* via ScholarOne (<https://mc.manuscriptcentral.com/mmwr>); at that time, please remember to include an ICMJE conflict of interest form for each co-author with your submission. If there is a group author on the byline, then the persons listed in the group will be indexed in PubMed as contributors rather than authors, and no ICMJE form is necessary for those persons.

As your manuscript continues through clearance, please remember that *MMWR* allows up to 1,650 words for COVID-19 reports and up to 10 references. You and your coauthors will likely receive requests for additional narrative to be added from the next several reviewers; but please ensure that the final submission to *MMWR* is less than 1,650 words with no more than 10 references or it will require another round of editorial review, which could delay processing of the report.

Please let me know if you have any questions.

With kind regards,

Jacqueline Gindler, MD
Editor, *MMWR Weekly*
404-639-8829
jgindler@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Friday, July 30, 2021 7:26:41 PM
Attachments: [image001.png](#)
[COVID-19 MMWR Comms Package Reinfection and Vaccination Status DRAFT for Clearance Review](#)
[kou4 AC.docx](#)

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>
Sent: Friday, July 30, 2021 6:57 PM
To: Bartley, Shelton (CDC/DDPHSS/CELS/OD) <vks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eoevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CELS/OD) (CTR) <pwf7@cdc.gov>

Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>

Sent: Friday, July 30, 2021 5:04 PM

To: Hardie, Ann (CDC/DDID/NCIRD/OD) <gpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <gmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>

Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>


Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMWR **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMWR Comms Package_ Reinfection and Vaccination Status_ DRAFT for Clearance Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333

404.808.4485 (cell)

vks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance Review
Date: Thursday, August 5, 2021 11:37:13 AM
Attachments: [COVID-19 MMWR Comms Package Reinfection and Vaccination Status_DRAFT for Clearance Review.docx](#)

This is still a draft and hasn't been approved. There still need to be some additional changes based on most recent version of manuscript.

I believe we will have final version today.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Thursday, August 5, 2021 11:15 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance Review

From: [Winter, Kathleen T.](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Fw: Data Science question on your paper "Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination- Kentucky, May June 2021"
Date: Sunday, August 15, 2021 8:40:19 PM
Attachments: [Reduced Risk of Reinfection KY.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Kathleen Winter, PhD, MPH
Assistant Professor
Department of Epidemiology
College of Public Health
University of Kentucky

From: Smith, Timothy A. <smitht1@erau.edu>
Sent: Friday, August 13, 2021 3:13 PM
To: Winter, Kathleen T. <kathleen.winter@uky.edu>
Subject: Data Science question on your paper "Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination- Kentucky, May June 2021"

CAUTION: External Sender

Hey Kathleen, my name is Tim and I'm a maths stats research professor & program coordinator of a MS in Data Science at a private university down here in Florida. First and foremost I would like to say thank you for your research and sharing such important work during these crucial times!!

Now, if you would be kind enough I had a question regarding this work and possibly a suggestion for further investigation that might be worthy to discuss. Namely, I reviewed the comments made in the discussion section near the end of page 2 "*The findings in this report are subject to at least five...*"

And, I was curious to ask if you'd be interested to perhaps use some machine learning type methods to train a model and then adjust the data set to adjust accordingly for things such as the issue noted in the third comment within that section of the paper regarding the likelihood of vaccinated people to get tested or not get tested when compared to the unvaccinated. I am confident that doing so would maintain your big picture conclusion of 2.34, but would remove that threat of validity.

I feel this work is showing us some extremely important information, and anything that could be done in the data analysis (e.g. my domain) to generalize would be worthy to consider as hopefully the methods behind this study will be picked up by other states or countries for larger data sets, hence generalization which would be so important for global vaccination challenges such as who to prioritize. Moreover, while I'm not a super big researcher – I did some work years back in financial modeling stock market stuff but recently I've been sucked into a somewhat administrative role which keeps me too busy to think - the idea I'm thinking about here should be somewhat routine to

do with some routine training & testing data methods. Also, here on campus we have an outstanding computer science department doing lots of research in the machine learning field lead by my friend who is an M.I.T. grad, and I am sure many of his faculty would be also eager to help if need be.

Please do let me know if you would like to possibly consider some discussions and/or possible collaborations. I am sure that some interesting results would come, perhaps a nice paper for some stats type journal or whatnot. Also, I fully understand we're all super busy so if this would need to be one of those "we'll get to it but on the backburner for now" that's completely understandable.

BTW and just FYI the reason I chose to email you from all of the listed authors was that you were the only one I could find associated with a University, and I felt that would be the appropriate forum as opposed to contacting someone working at a governmental type agency. And, last but not least please know that this is genuinely just a thought for research! I will admit as a covid survivor from last June that did catch my interest to the research, but this is honestly just my "math brain" going hmmm how could we apply some of these new learning data methods. Similarly I had a dialog with a student last March about how to predict the social distancing using learning models, and using some learning methods we did a nice study that yielded some interesting results. I've put the link to that published article below if you'd be interested – not a super high level journal but he was just an UG student so I wanted to get him a bullet on his resume - <https://www.ijmtjournal.org/archive/ijmtt-v66i11p504> Anyways, I guess what I'm trying to say is that this is honestly & genuinely a scientist reaching out to discuss some research idea :)

I look forward to hearing from you kind regards, Tim

Timothy A. Smith, PhD
Program Coordinator of Data Science
Department of Applied Mathematics

1 Aerospace Boulevard
Daytona Beach, FL 32114
386.226.6720

Smitht1@erau.edu <https://works.bepress.com/timothy-smith/>

Embry-Riddle Aeronautical University
Florida | Arizona | Worldwide

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 3:36:49 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF.pdf](#)
[mm7032e1 - Reinfection - vaccination status FINAL PROOF.docx](#)
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: First Proof of Your MMWR Early Release
Date: Wednesday, August 4, 2021 1:30:51 PM
Attachments: [Reinfection - vaccination status FIRST PROOF.docx](#)

First proof!

Please provide any edits prior to 9pm tonight (or e-mail/text me if you want to review but it will not be possible before 9).

I will likely submit first thing tomorrow morning.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Wednesday, August 4, 2021 1:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: First Proof of Your MMWR Early Release

Hi Alyson,

Please provide any edits by **8:00 Thursday** morning. Reviewers have been asked to provide any comments by that time as well. I'll consolidate the comments and get them to you by 9:00.

We'll then need to resolve any issues raised by the comments by midday to allow sufficient time to produce the final proof.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: For Review by 4 pm TODAY--Comms Pack for Reinfection Report
Date: Thursday, August 5, 2021 4:14:10 PM
Attachments: [image001.png](#)

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 4:13 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

The other titles are:

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

I'm working on finalizing the comms package now but it probably won't be completely final until tomorrow morning unless there are no last-minute updates.

Thanks.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 4:09 PM
To: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Cavanaugh, Alyson

(CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Ginger,

Do you have the titles of the other MMWRs for tomorrow?

What time do you think the final comms package will be approved?

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>

Sent: Thursday, August 5, 2021 3:51 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Thanks for the quick review! I am incorporating your edits/comments now.

I will be sending OADC's rollout plan for your review sometime later today (tomorrow morning at the latest).

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 3:39 PM

To: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Ginger,

I added quite a few comments. I hope that is okay.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 12:01 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Hi Alyson,

I forgot to attach a copy of the report. Here it is.

Thanks,
Ginger

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 11:56 AM
To: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Thank you so much! I will review and get it back by 4.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Redmon, Ginger (CDC/OD/OADC) <yco8@cdc.gov>

Sent: Thursday, August 5, 2021 11:40 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: For Review by 4 pm TODAY--Comms Pack for Reinfection Report

Hi all,

Linked below for final author review is the comms package for **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**:
[📎 COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review.docx](#)

A copy of the report is attached for your reference. If you could review by **4 pm TODAY**, it would be much appreciated.

Please note that in addition to this communications package, OADC is putting together a rollout plan that encompasses all three MMWR reports being released tomorrow. I will be sending that plan for all report authors to review later today.

Thanks,
Ginger

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 5:22:25 PM
Attachments: [MMWR Reinfection Rollout for 8_6_21.docx](#)

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 5:13 PM
To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>
Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>
Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:
Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021
Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021
Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: MMWR - Decision on Manuscript ID CDC-2021-0104 -
Date: Wednesday, August 4, 2021 7:36:19 AM
Attachments: [Guidelines-for-Author-Responses-to-External-Inquiries.pdf](#)
[CDC-2021-0104 ACCEPTED.docx](#)
[TABLE 1 ACCEPTED.docx](#)
[TABLE 2 ACCEPTED.docx](#)
[CDC-2021-0104 ACCEPTED tracked changes.docx](#)
[TABLE 1 ACCEPTED tracked changes.docx](#)
[CDC-2021-0104 ACCEPTED tracked changes AC.docx](#)

****CAUTION**** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov<<mailto:ServiceCorrespondence@ky.gov>> for any assistance.

Good morning,

FYI - MMWR editors already made some edits to have it align with MMWR format.

I added Kathleen's/Doug's changes here to submit. If you have additional suggestions, please work off the document with _AC.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

-----Original Message-----

From: Morbidity and Mortality Weekly Report <onbehalf@manuscriptcentral.com>
Sent: Wednesday, August 4, 2021 12:29 AM
To: qds1@cdc.gov
Cc: cgk3@cdc.gov; jsg5@cdc.gov; pzs1@cdc.gov; iyn3@cdc.gov; tfh5@cdc.gov; kya6@cdc.gov
Subject: MMWR - Decision on Manuscript ID CDC-2021-0104

****CAUTION**** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov<<mailto:ServiceCorrespondence@ky.gov>> for any assistance.

04-Aug-2021

Dear Dr. Cavanaugh:

It is a pleasure to provisionally accept your Prescheduled manuscript entitled, "Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021," for publication in MMWR. All reports undergo additional scientific and editorial review during the production process.

I made a few minor edits to the text and the tables; I am sending you tracked changes versions of the report and table 1 for your reference; the tracked changes version of table 2 were too hard to read, so I just accepted all those changes. Thanks for preparing such a nice manuscript.

Teresa Hood, Team Lead for the MMWR Weekly, will be in touch with you to schedule the publication of your manuscript. She also will describe the rapid, 7-day production process.

Once your manuscript is published, you might receive inquiries about it from persons outside of CDC. To assist with responding to non-media related inquiries, please use the attached guidelines for CDC authors.

Thank you for your contribution. On behalf of the Editors of MMWR, I look forward to your continued contributions to the Journal.

Sincerely,

Jacqueline Gindler, MD
Editor, MMWR Weekly

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
 To: [Alexander, Kelly A \(CHFS DPH\)](#)
 Cc: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winters, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
 Subject: FW: Questions, Concerns & Observations about CDC "study" used by "Safer" Federal Task Force "justify" "vaccination" mandates of federal employees who have COVID-19 antibodies from previous infection - end Pandemic & COVID-19 mandates & restrictions
 Date: Friday, October 15, 2021 9:54:53 AM
 Attachments: [safer federal work force task force members and qualifications.rtf](#)
 Importance: High

Kelly,

I am just sharing the below e-mail for your awareness.

Alyson M. Cavanaugh, DPT, MPH, PhD
 Lieutenant, U.S. Public Health Service Corps
 CDC Epidemic Intelligence Service Officer
 Assigned to Kentucky Department for Public Health
 275 East Main Street
 Frankfort, KY 40621
 E-mail: Alyson.cavanaugh@ky.gov
 Phone: 502-564-3261 x4231
 Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Paula Reitan <paula.reitan@outlook.com>
 Sent: Thursday, October 14, 2021 9:54 PM

To: qds1@cdc.gov; lzm6@cdc.gov; saferfederalworkforce@gsa.gov; lzm6@cdc.gov; afauci@niaid.nih.gov

Cc: nationalpresident@nteu.org; Pollard Calvin L [NTEU NON-IRS] [Contractor] <Calvin.L.Pollard@irs.gov>

Subject: Questions, Concerns & Observations about CDC "study" used by "Safer" Federal Task Force "justify" "vaccination" mandates of federal employees who have COVID-19 antibodies from previous infection - end Pandemic & COVID-19 mandates & restrictions

Importance: High

Greetings Erin, Arlyn, Anthony and "Safer" Federal Task Force Members,

In recent NTEU Townhall interview with Dr. Erin Tromble - YouTube (comments have been turned off - yesterday most the few comments were negative), Dr. Erin Tromble (EM/pediatrician) (lzm6@cdc.gov) referenced the following recent CDC study to "justify" MANDATORY vaccination of federal employees who have natural immunity to COVID-19 as a result of natural antibodies from a previous infection.

Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1081-1083.
 DOI: <http://dx.doi.org/10.15585/mmwr.mm7032a1>

Return

TABLE 2. Association of SARS-CoV-2 reinfection* with COVID-19 vaccination status — Kentucky, May–June 2021

Vaccination status	No. (%)		OR (95% CI) [†]
	Case-patients	Control participants	
Not vaccinated	179 (72.8)	284 (57.7)	2.34 (1.58–3.47)
Partially vaccinated [‡]	17 (6.9)	39 (7.9)	1.56 (0.81–3.01)
Fully vaccinated [§]	50 (20.3)	169 (34.3)	Ref
Total	246 (100)	492 (100)	—

Abbreviations: CI = confidence interval; NAAT = nucleic acid amplification test; OR = odds ratio; Ref = referent group.

*All case-patients (reinfectees) and control participants (not reinfectees) had previous SARS-CoV-2 infection documented by positive NAAT or antigen test results during March–December 2020. Reinfection was defined as receipt of positive NAAT or antigen test results during May 1–June 30, 2021.



† Estimated based on conditional logistic regression.


‡ Case-patients were considered partially vaccinated if ≥1 dose of vaccine was received, but the vaccination series was either not completed or the final dose was received <14 days before their reinfection date. For control participants, the same criteria were applied, using the matched case-patient's reinfection date.

§ Case-patients and control participants were considered fully vaccinated if a complete COVID-19 vaccine series was received ≥14 days before the case-patient's reinfection date.

I reviewed the article and have the following questions, concerns & observations:

- Has this article been peer reviewed?
- Has this article been published in a journal outside of the CDC?
- Could you please briefly describe the NAAT and antigen tests?
- What is the reliability of the NAAT and antigen tests? What is the false positive and false negative rates for the NAAT and antigen tests? Were the same thresholds and test conditions used for all test samples?
- If there is a substantial disparity between the reliability of the NAAT and antigen tests, why did you publish a study with results which contain disparate accuracy rates?
- Could someone with natural antibodies from a previous infection in March to December 2020 test positive (due to the naturally acquired antibodies) using the NAAT or antigen test without actually being reinfectees?
- Were the unvaccinated tested for antibodies after their initial infection? How certain are you that the unvaccinated had true initial COVID-19 infection and built natural antibodies?
- Serious issues with study & results – please comment/explain/justify.
 - All cases from Kentucky – should not necessarily be used to make policy for an entire nation. KY has one of the lower fully "vaccination" rates. Wonder how different the results from a similar study would be in a state with a higher vaccination rate.
 - Short time frame for reinfection is 2 months.
 - Small sample size 682. Fully vaccinated sample size 219 is substantially smaller than unvaccinated sample size 463. According to [CDC COVID Data Tracker](#) - thousands of COVID-19 cases were reported daily in KY in 2020 – why were so few selected for the study? Did you cherry pick the samples selected for this study to achieve your narrative? [Larger & different samples of data could well likely show substantially different results!](#) While the number of cases reported by CDC increased dramatically in July, August and early September, there has been a steep decline since late September. Also, note the inversion in the number of cases by age – early in the pandemic there were substantially more cases among the 75+ age, but in the recent surge there were more younger people reported with COVID-19. This could be simply because there was more testing among the younger people as they went back to school in person – speculation. Note that there were still substantially more deaths among the 75+ age, but that the numbers of deaths in the recent surge were substantially less than the 2020 pandemic. [Assert the pandemic is over – we have achieved herd immunity through "vaccinations" and natural immunity.](#) For much of the population, risk of COVID-19 is extremely low – and some doctors assert the risk of "vaccination" exceeds the benefits of "vaccination" for this population. COVID-19 cannot be eradicated. We need to follow the lead of other countries like Denmark, the Netherlands and Sweden and states like Texas, Florida, Arizona and South Dakota. We need to learn to live with COVID-19, end the pandemic/emergency, revoke all COVID-19 mandates and restrictions, return to common-sense and recommendations (not draconian, arbitrary and capricious mandates) and allow legal US citizens (including hardworking federal employees) the same rights afforded to illegal immigrants to make their own decisions with regard to COVID-19 "vaccines" and as we have with flu shots for decades.





- d. No distinction was made in how much time had elapsed from infection to re-infection and "vaccination" – could have been any where from between 15 months to 6 months. Given effectiveness of vaccination (and possibly natural immunity) is known to wane over time, if the 219 vaccinated cases were primarily selected from latter part of 2020 and the 463 unvaccinated cases were primarily selected from early part of 2020, then the results would be heavily skewed in toward "vaccinated" reinfection.
- e. Other ways to view your data – the disparity between the "unvaccinated" and "vaccinated" is due to the large disparity if sample sizes between "vaccinated" and "unvaccinated". Randomly selecting a unvaccinated sample size closer the same size as the vaccinated (219) could change statistics substantially.
- Unvaccinated % reinfected: $179 / (179 + 284) = 38.66\%$
 - Vaccinated % reinfected: $50 / (50 + 169) = 22.83\%$
 - Total % unvaccinated reinfected: $179 / (179 + 284 + 50 + 169) = 26.25\%$
 - Total % vaccinated reinfected: $50 / (179 + 284 + 50 + 169) = 7.33\%$
 - Total % unvaccinated: $(179 + 284) / (179 + 284 + 50 + 169) = 67.89\%$
 - Total % vaccinated: $(50 + 169) / (179 + 284 + 50 + 169) = 32.11\%$

I have a strong background in data science – this study seems highly flawed, deceptive and inaccurate to me.

Furthermore, why were reference such as the following regarding natural immunity ignored/disregarded by CDC and in "Safer" Work Force Task Forces's decision as to demand employees with natural immunity to get a COVID-19 "vaccine"? **In my opinion, this policy wastes, frauds and** The COVID-19 "vaccines" are not free and taxpayer funds are being wasted on citizens who have antibodies and/or strong/robust immune systems who have chosen not to get the "vaccine", but have been bullied (or currently are being bullied) into getting COVID-19 "vaccine" (many college students, professional athletes, health care professionals, airline employees, federal employees, armed forces personnel) in order to maintain their career or attend a university.

- [Senator Paul Asserts: Natural Immunity is As Good As COVID-19 Vaccine | C-SPAN.org](#)
- [Courier Journal Op-Ed: Rand Paul: "The science proves people with natural immunity should skip COVID vaccines" | Senator Rand Paul \(senate.gov\)](#)
- [Rand Paul accuses Dr. Fauci of lying about natural immunity because it foils his vaccination plans | Fox Business](#)
- [People who have already had COVID-19 could be less likely to catch Delta than the vaccinated | Gavi, the Vaccine Alliance](#)
- [Project Veritas captures Pfizer scientists giving thumbs up to COVID-19 natural immunity - Washington Times](#)
- [Pfizer scientists say their vaccine provides a weaker defence against Covid as compared to natural antibodies - Project Veritas \(opindia.com\)](#)
- [Natural Immunity and the Covid Vaccines - WSJ](#)

A timely response would be greatly appreciated. As you know, per [Vaccinations | Safer Federal Workforce](#) agencies have been authorized to initiate enforcement/disciplinary actions against some federal employees who do not "comply" with COVID-19 "vaccine" mandates for some federal employees (judicial branch, USPS, legislative branch excluded) on November 9, 2021. Also, please reply to my request sent yesterday regarding the composition/qualification of the Safer Federal Workforce Task Force (see attached).

- [Foley v. Biden \(4:21-cv-01098\) Texas Northern District Court \(nacermonitor.com\)](#)
- [COSTIN et al v. BIDEN et al 1:2021cv02484 | US District Court for the District of Columbia | Justia](#)
- [Browich v. Biden et al 2:2012cv01568 | US District Court for the District of Arizona | Justia](#)
- [Out-of-tough Biden threatens private sector companies as polls nose-dive | TheHill](#)

- [Axios-Ipsos poll: Biden is losing trust on COVID - Axios](#)
- [Poll: Americans Are More Pessimistic About Life Returning to Normal, Losing Trust in Biden | National News | US News](#)

Paula

I am a Federal employee with more than 30 years of federal government and military service. I have worked from home for the past decade at least 4 days a week. The projects I have been assigned to at the IRS have members disbursed across the United States and I teleconference when at the office the same as I teleconference the days I work from my home office. Team member who work from the same location are not collocated in the building, nor are in-office days coordinated. Most IT specialist telework 3-4 days a week and share a cube with others who are in the office on opposite days, thus saving the agency real estate expenses. Since the COVID-19 evacuation, I have worked from home 5 days a week with the exception of 4 days I went into office to get a finger printed for new id card, pick up new id card, laptop memory upgrade and laptop replacement. To the best of my recollection, I have never once met with anyone from the public in my work capacity in the nearly 11 years I have worked as an IT specialist at the IRS. The "safer" federal workforces demand I be vaccinated or be terminated is completely illogical.

Paula J. Reitan
 e Paula.Reitan@outlook.com
 t 301.464.4212
 c 240.675.7321
 1709 Mayfair Place
 Crofton, MD 21114-2624

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Monday, August 2, 2021 4:55:58 PM
Attachments: [image002.png](#)
[Cavanaugh_08.02_track.docx](#)
[Cavanaugh_08.02_clean.docx](#)
[TABLE 1_08.02.21_track.docx](#)
[TABLE 1_08.02.21_clean.docx](#)
[TABLE 2_08.02.21_clean.docx](#)
[TABLE 3_08.2.21_clean.docx](#)
[TABLE 3_08.2.21_track.docx](#)
[TABLE 2_08.02.21_track.docx](#)

For your records – and in case anyone wants to re-look at this prior to next round of revisions.

(Also – remind me of this day if I ever think about an MMWR concept proposal again).

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Monday, August 2, 2021 4:51 PM
To: 'CDC IMS 2019 NCOV Response EPI Clearance' <eocevent210@cdc.gov>
Subject: RE: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good afternoon,

I am attaching track changes for manuscript and three tables, as well as clean copies of all. We will not be including the supplementary figure in submission.

Please let me know if anything else is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, August 2, 2021 11:42 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Fw: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi Alyson,

JIC is returning your MMWR with comments. Please note these remarks:

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
-

Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.

- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Please address their comments and submit clean copies for OS review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Monday, August 2, 2021 11:39 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi,

Please revise and submit clean copies for OS Review.

Please see below from IM/PDIM,

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Thank you,

Kaliyah Hunter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

From: King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <iyn3@cdc.gov>

Sent: Monday, August 2, 2021 11:35 AM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsln2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: Re: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").

- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Brian

Brian A. King, PhD, MPH

Lead, *Strategic Science Unit, CDC COVID-19 Response*

Guest Science Editor, *Morbidity and Mortality Weekly Report Series*

E-mail: baking@cdc.gov

Phone: 770.488.5107 / 770.570.6330

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:43 PM

To: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsino2@cdc.gov>; Christie, Athalia (CDC/DDPHSS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

IM/PDIM,

We are requesting your review of the attached MMWR (ID# 1464). Please return your comments by 6pm on 8/2.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>

Sent: Sunday, August 1, 2021 9:57 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Cleared with no additional comments

Paul Mead, MD, MPH
Deputy Incident Manager (Epi, Lab, Data Visualization Task Forces)
CDC COVID-19 Response
Cell: 970-567-5024

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 4:57 PM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi DIMs,

This is a Tier 1 report and we provided the wrong deadline. Please return your comments by 6pm on 8/2, if possible. This one is expected to publish at the end of the week.

Apologies for the inconvenience.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:28 AM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For DIM Review by 10:30am on 8/3/21: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

DIM Review,

Attached is the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review.

Comments are due by 10:30am on 8/3/21.

Thank you,

Jeanita Porter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>

Sent: Saturday, July 31, 2021 5:06 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Cassell, Cynthia H. (CDC/DDPHSS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPHP/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSS/CPR/OD) <sxs8@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPHP/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>

Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

This MMWR has been reviewed by 2 rADS, Mary D. Ari and Harrell Chesson, and is cleared with the understanding that comments will be addressed and considered as noted.

Thanks for the opportunity to review.

Best regards,
Harrell

Harrell Chesson, PhD
COVID-19 Response ADS Team Reviewer
404-639-8182
404-551-7377

Division of STD Prevention
Centers for Disease Control and Prevention
CDC Mail-Stop US12-3
1600 Clifton Road
Atlanta, GA 30319

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:56 PM

To: Cassell, Cynthia H. (CDC/DDPHSS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPPH/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSS/CPR/OD) <sxs8@cdc.gov>; Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPPH/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

ADS Team...

Attached you will find the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review. Comments are due by 6:00p on 8/2/21.

HEADS-UP: They have requested expedited review and are seeking DIM approval so this deadline may change.

Regards,

Lisa Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 30, 2021 7:35 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Request for Review: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

JIC,

Epi TF is submitting Alyson Cavanaugh's **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky" for **expedited** review. Attached includes tracked changes and clean copies of the Article, Tables 1-3 a Supplementary figure and the clearance request form. This document has been cross-cleared by VTF, HSWS, SSU, and CHEO TFs.

Thank you,
Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 30, 2021 7:16 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

I have track changes that address the minor comments from SSU. I know CHEO cleared with comments, but I am unsure where to find additional comments from CHEO. I have e-mailed for further clarification.

The supplementary figure was edited in terms of placement of arrows/boxes and track changes weren't used for formatting, per comments.

Clean copies of manuscript, three tables, and supplementary figure are attached.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Thursday, July 29, 2021 7:29 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Thank you for clarifying!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Yes – it’s an odd step in the current protocol – but currently you are required to handle this review with SSU and CHEO. We recommend cc’ing the Epi Clearance mailbox (eocevent210@cdc.gov) so that we can keep an eye on how it’s moving, and help you follow up as needed.

I think they may be revisiting this procedure soon; I’m sorry this part is so complicated/unusual. But yes, please proceed with SSU and CHEO clearance.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:21 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I did not sent this to CHEO and SSU. Should I?

In the past, the clearance coordinator sent my manuscript to them. However, the instructions from MMWR pre-review said:

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance.

I wanted to check with you to see if I should send to SSU and CHEO or should clearance coordinator be managing this part?

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:18 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

To clarify, *did* you already send this to SSU and CHEO for pre-clearance? If so, please update your clearance request form to reflect this, and then we can proceed with JIC clearance. If not, you will need to complete that step independently before we (epi clearance) take it from you and go on to JIC.

Thanks!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:09 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I received feedback from MMWR pre-review. I am attaching the clean copies of the manuscript, tables and figure for MMWR 1464. I was told to e-mail to CHEO and SSU. However, I believe you will pass this on? Please let me know if I should be sending this anywhere else at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 12:44 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I think that "4289" in the subject line was used by VTF when they re-reviewed it, and we can disregard that entirely.

Actually, the next step is for you to submit this to MMWR pre-clearance. We do not handle that step in the process. Epi TF clearance coordinators should be looped back in after you receive clearance from Brian King and his group.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 25, 2021 12:33 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached clean and track versions.

I believe this is MMWR 1464. Is that correct? I added 1464 on the clearance request form, but this may need to be edited (The subject heading says 4289).

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Sunday, July 25, 2021 11:25 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF has cleared your MMWR. Please address the comments in the link below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Your next step is to send clean and tracked versions, along with an updated clearance request form, to MMWR pre-clearance.

Once you have been cleared by MMWR pre-clearance, please return the latest clean and tracked copies, and an updated clearance request form, to this mailbox for submission to SSU and CHEO.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Sunday, July 25, 2021 11:04 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced

risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

Please see following from JIC:

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: gij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Saturday, July 24, 2021 4:06 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is cleared by VTF ADS with comments that should be addressed.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Friday, July 23, 2021 2:04 PM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
Kimberly
Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov
Dany Hall: qij7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday
11am-1pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 23, 2021 1:11 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>
Subject: RE-REVIEW due 7/24 at 1:30PM - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

VTF,

Alyson Cavanaugh is submitting this **Tier 1 MMWR article** for your re-review. Attached is a clean copy and tracked changes copy with comments addressed. The requested deadline for your re-review is **7/24 at 1:30PM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov
Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays
Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 23, 2021 12:58 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>
Subject: RE: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached track and clean copies of revised paper. We believe the changes in analysis are appropriate to address concerns. However, if additional changes are suggested, please let us know.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Wednesday, July 21, 2021 3:45 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson,

VTF did not clear your MMWR article. Please see their comments in the attached Word doc. Additional notes from reviewers below:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

Please address comments and resubmit a clean copy and tracked changes copy for re-review with VTF.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Wednesday, July 21, 2021 3:27 PM
To: Bunting, Hannah (CDC/DDID/NCIRD/OD) (CTR) <rou3@cdc.gov>
Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

The below document is **not cleared** by VTF. Please address comments in the below link and return clean and tracked changes copies for re-review. Additionally, please note the following:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov
Dany Hall: qij7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

**Hours of Operation: 8:30am-5:30pm EST Monday-Friday
2-5pm EST Saturday & 12-3pm EST Sunday**

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Wednesday, July 21, 2021 2:45 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is not cleared by VTF ADS. Please see comment below and submit a revised version.

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Wednesday, July 21, 2021 9:26 AM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday-Friday

2-5pm EST Saturday & 12-3pm EST Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Wednesday, July 21, 2021 7:20 AM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good Morning VTF,

The author has made changes and we are requesting a re review. Please find clean and tracked copies attached.

Deadline for review is **7/22 by 8 AM**

Best Regards,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Tuesday, July 20, 2021 9:05 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please find attached the clean and track changes of MMWR on reinfections and vaccination. Please let me know if anything further is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Saturday, July 17, 2021 1:22 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF did not clear your MMWR. Please address the comments in the attached file and return clean and tracked copies for re-review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Saturday, July 17, 2021 1:08 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination

after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Epi,

The below document is **not cleared** by VTF. Please return clean and tracked changes copies for re-review.

[Reinfection and vaccination status_07.14.21_clean.docx](#)
[Clearance Request Form_July 14_reinfection.docx](#)

Thanks,

Dany

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8am-8pm EST Monday-Friday

12pm-5pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Saturday, July 17, 2021 12:41 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lkg6@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Please advise the status of the requested cross-clearance review of the MMWR titled "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky." The review was due **Friday, 7/16, at 10 a.m.**

[Reinfection and vaccination status_07.14.21_clean.docx](#)

We request the courtesy of a response with a status update.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 16, 2021 2:29 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Epi TF still requests your comments on this Tier 1 MMWR. As a reminder, here is the link:

[Reinfection and vaccination status_07.14.21_clean.docx](#)

Comments were due at 10 a.m., so please return your comments as soon as possible so that we can proceed with the clearance process.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 16, 2021 11:28 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear HSWS and VTF,

This is a gentle reminder that your cross-clearance of this MMWR was due today at 10 a.m.

 [Reinfection and vaccination status_07.14.21_clean.docx](#)

This is a Tier 1 MMWR. Please return your review as quickly as possible.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 15, 2021 10:04 AM

To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response CICP ADS/Clearance <eocdgmqsitrep@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF, HSWS, and CICP TFs,

Epi TF requests cross-clearance of the **Tier 1 MMWR**, "*COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky.*"

Please use the SharePoint link below during your review. Please indicate whether you clear the manuscript with major/minor comments, with no comments, or do not clear.

The deadline for your review is **7/16 at 10:00 a.m.**

-  [Reinfection and vaccination status_07.14.21_clean.docx](#)

CICP clearance coordinators: please forward this MMWR for review to your new POC ASAP, as we are aware your ADS/TF are no longer accepting submissions. Thank you.

Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, July 14, 2021 6:13 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please see attached track and clean changes where all comments were addressed.

I am also attaching the clearance form. I deleted the section about cross task force review. I apologize for the confusion. That was filled in with the template that was sent me and I didn't see it. Therefore I hadn't deleted that section before submitting the form for this MMWR.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Tuesday, July 13, 2021 12:24 PM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Epi ADS re-reviewed and cleared your MMWR with comments in the attached document. Please address comments and resubmit both a **clean copy** and a **tracked changes copy** to proceed with cross-clearance.

Also, your clearance request form originally stated that this MMWR article has been cleared by STLT, HSWS, and CICP. You and STLT have confirmed that Epi TF is the only TF to have reviewed it yet. When you resubmit, please update your clearance request form to reflect that only Epi TF has cleared it thus far.

Thank you!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Tuesday, July 13, 2021 11:42 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Clearance Team—this review is complete.

Reviewer: Lisa Grohskopf (ADS), Ruth Link-Gelles (SME)
Decision: Cleared with comments, some mandatory
Comments: please see attached
Please send to Lab TF as informational (not for cross clearance).

Thank,
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, July 12, 2021 7:20 AM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lkg6@cdc.gov>
Subject: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning Epi ADS,

Lisa -- Alyson Cavanaugh is submitting her **Tier 1 MMWR** for re-review: "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky". Attached includes a clean copy and a tracked changes copy. See your initial decision record below:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

The deadline for your re-review of this expedited article is **7/13 at 7:30AM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>
Sent: Sunday, July 11, 2021 9:56 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Thank you very much for the review. Please see attached clean and track changes of edits based on the suggestions. All comments have been addressed.

This paper has only been reviewed by epi TF to date. Am I supposed to send to the other task forces for cross-clearance? No other task forces have yet reviewed this.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department of Public Health
275 E. Main St.
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 11, 2021 8:00 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Subject: Fwd: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <>
Subject: Fw: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

Epi TF has reviewed and **does not clear** this MMWR. Please see the following comments:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Please address the comments in the attached document and submit clean and tracked copies for re-review. Additionally, please provide documentation of cross-clearance by STLT, CICIP, and HSWs.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Saturday, July 10, 2021 12:22 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Clearance Team! This review is complete.

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Thanks!
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 12:32 PM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Team,

The attached Tier 1 MMWR, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky," is submitted for review. The deadline for review is **Saturday, 7/10, at 12:30 p.m.**

The clearance request form notes that CICP, STLT, and HSWS have already cleared this.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 12:24 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Please see attached clearance form for MMWR 1464.

Let me know if I need to do anything additionally at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 9:18 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Thank you, Anna!

Alyson,

I see you attached the manuscript but mention that it still needs co-author feedback, is that correct? When you are ready to submit for JIC clearance please send the manuscript and the completed request form I have attached. I have also attached the SOP for moving MMWRs through clearance to help with any questions on the process going forward.

Best Regards,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Sent: Friday, July 9, 2021 9:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Hi Katie,

Epi TF has "adopted" this manuscript for COVID-19 Clearance and Alyson has submitted to begin the clearance process with Epi TF. Let me know if you have any questions.

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 8:28 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Alyson,

Is this an FYI that this MMWR is coming for review? Are you asking for any action from the Epi TF at this time?

Best,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 7:06 AM
To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Good morning,

Attached is the manuscript for MMWR 1464 regarding reinfections and vaccination status.

I am making some edits based on co-authors' feedback for 1459, but hope to have the paper ready tomorrow.

I believe both will be "adopted" by the vaccine task force because they involve vaccine effectiveness. Please let me know any next steps for this submission.

V/R,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Thursday, July 8, 2021 2:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Dear Alyson,

Following up on your VE/VB MMWR manuscripts, the COVID-19 Response Incident Manager would like to have both 1459 and 1464 published in about a month (see email below). I have copied the Epi Clearance Coordinators (eocevent210@cdc.gov) and Epi ADS (eocevent496@cdc.gov), who are ready to help you begin the COVID-19 Clearance Process. When do you anticipate submitting these manuscripts?

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Thursday, July 8, 2021 10:07 AM

To: Anderson, Mark (CDC/DDPHSIS/CGH/DGHP) <mea6@cdc.gov>

Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <iyn3@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>

Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Mark, as mentioned yesterday, Peggy would really like to have these published by end of month-early August. They are top response priorities. Is there anything I can do to facilitate process?

1464	Reinfection associated with vaccination status - Kentucky, May-June 2021 (Alyson Cavanaugh)	Concept approved 6/30
1459	Low county-level vaccination coverage increases the risk of breakthrough infections among fully vaccinated Kentucky residents – Kentucky, May 2021 (Alyson Cavanaugh)	Concept approved 6/30

Apologies for not sending this note yesterday.

Best,
Charlotte

Charlotte Kent, PhD, MPH

Editor-in-Chief, *Morbidity and Mortality Weekly Report (MMWR)* Series
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Monday, August 2, 2021 12:05:06 PM
Attachments: [image002.png](#)
[Cavanaugh_07.30_clean_copy_HC_MDA_IMPDIIM.docx](#)
[TABLE 2_07.29.21_SSU1_HC_MDA.docx](#)
[TABLE 1_07.29.21_SSU1_HC_MDA.docx](#)
[FIGURE Supplementary_07.30.21_HC_MDA.docx](#)
[TABLE 3_07.29.21_SSU1_HC_MDA.docx](#)

Good afternoon,

Here are comments on manuscript, tables, and figure.

I will begin working on manuscript at this time. Here is the link for any suggestions for manuscript:

https://kymsoffice-my.sharepoint.com/:w/g/person/alyson_cavanaugh_ky_gov/EbaQ3GcEvbFMrf6LgxPVKQBjqoEJUtGGb8xSoAqnjB2Gw

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, August 2, 2021 11:42 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Fw: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi Alyson,

JIC is returning your MMWR with comments. Please note these remarks:

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The

authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.

- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Please address their comments and submit clean copies for OS review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Monday, August 2, 2021 11:39 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi,

Please revise and submit clean copies for OS Review.

Please see below from IM/PDIM,

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Thank you,

Kaliyah Hunter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <lyn3@cdc.gov>

Sent: Monday, August 2, 2021 11:35 AM

To: CDC IMS JIC Emergency Clearance-3 <eojjcclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eo cdhslno2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: Re: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained

free from reinfection" could more simply be stated as "persons who were not reinfected".

Brian

Brian A. King, PhD, MPH

Lead, *Strategic Science Unit, CDC COVID-19 Response*

Guest Science Editor, *Morbidity and Mortality Weekly Report Series*

E-mail: baking@cdc.gov

Phone: 770.488.5107 / 770.570.6330

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:43 PM

To: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsln2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

IM/PDIM,

We are requesting your review of the attached MMWR (ID# 1464). Please return your comments by 6pm on 8/2.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>

Sent: Sunday, August 1, 2021 9:57 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Cleared with no additional comments

Paul Mead, MD, MPH
Deputy Incident Manager (Epi, Lab, Data Visualization Task Forces)
CDC COVID-19 Response
Cell: 970-567-5024

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Sunday, August 1, 2021 4:57 PM
To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi DIMs,

This is a Tier 1 report and we provided the wrong deadline. Please return your comments by 6pm on 8/2, if possible. This one is expected to publish at the end of the week.

Apologies for the inconvenience.

Thank you,

Brian Panasuk
JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Sunday, August 1, 2021 10:28 AM
To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>
Subject: For DIM Review by 10:30am on 8/3/21: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

DIM Review,

Attached is the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review.

Comments are due by 10:30am on 8/3/21.

Thank you,

Jeanita Porter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>

Sent: Saturday, July 31, 2021 5:06 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPPH/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPPH/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rs14@cdc.gov>

Cc: CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

This MMWR has been reviewed by 2 rADS, Mary D. Ari and Harrell Chesson, and is cleared with the understanding that comments will be addressed and considered as noted.

Thanks for the opportunity to review.

Best regards,
Harrell

Harrell Chesson, PhD
COVID-19 Response ADS Team Reviewer
404-639-8182
404-551-7377

Division of STD Prevention

Centers for Disease Control and Prevention
CDC Mail-Stop US12-3
1600 Clifton Road
Atlanta, GA 30319

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:56 PM

To: Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <jv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPPH/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPPH/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

ADS Team...

Attached you will find the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review. Comments are due by 6:00p on 8/2/21.

HEADS-UP: They have requested expedited review and are seeking DIM approval so this deadline may chance.

Regards,

Lisa Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 30, 2021 7:35 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Request for Review: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

JIC,

Epi TF is submitting Alyson Cavanaugh's **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky" for **expedited** review. Attached includes tracked changes and clean copies of the Article, Tables 1-3 a Supplementary figure and the clearance request form. This document has been cross-cleared by VTF, HSWS, SSU, and CHEO TFs.

Thank you,
Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 30, 2021 7:16 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

I have track changes that address the minor comments from SSU. I know CHEO cleared with comments, but I am unsure where to find additional comments from CHEO. I have e-mailed for further clarification.

The supplementary figure was edited in terms of placement of arrows/boxes and track changes weren't used for formatting, per comments.

Clean copies of manuscript, three tables, and supplementary figure are attached.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Thursday, July 29, 2021 7:29 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Thank you for clarifying!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Thursday, July 29, 2021 7:27 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Yes – it’s an odd step in the current protocol – but currently you are required to handle this review with SSU and CHEO. We recommend cc’ing the Epi Clearance mailbox (eocevent210@cdc.gov) so that we can keep an eye on how it’s moving, and help you follow up as needed.

I think they may be revisiting this procedure soon; I’m sorry this part is so complicated/unusual. But yes, please proceed with SSU and CHEO clearance.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance

COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:21 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I did not sent this to CHEO and SSU. Should I?

In the past, the clearance coordinator sent my manuscript to them. However, the instructions from MMWR pre-review said:

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance.

I wanted to check with you to see if I should send to SSU and CHEO or should clearance coordinator be managing this part?

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:18 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance

<eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

To clarify, *did* you already send this to SSU and CHEO for pre-clearance? If so, please update your clearance request form to reflect this, and then we can proceed with JIC clearance. If not, you will need to complete that step independently before we (epi clearance) take it from you and go on to JIC.

Thanks!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I received feedback from MMWR pre-review. I am attaching the clean copies of the manuscript, tables and figure for MMWR 1464. I was told to e-mail to CHEO and SSU. However, I believe you will pass this on? Please let me know if I should be sending this anywhere else at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If

the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 12:44 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I think that "4289" in the subject line was used by VTF when they re-reviewed it, and we can disregard that entirely.

Actually, the next step is for you to submit this to MMWR pre-clearance. We do not handle that step in the process. Epi TF clearance coordinators should be looped back in after you receive clearance from Brian King and his group.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 25, 2021 12:33 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached clean and track versions.

I believe this is MMWR 1464. Is that correct? I added 1464 on the clearance request form, but this may need to be edited (The subject heading says 4289).

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 11:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF has cleared your MMWR. Please address the comments in the link below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Your next step is to send clean and tracked versions, along with an updated clearance request form, to MMWR pre-clearance.

Once you have been cleared by MMWR pre-clearance, please return the latest clean and tracked copies, and an updated clearance request form, to this mailbox for submission to SSU and CHEO.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Sunday, July 25, 2021 11:04 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

Please see following from JIC:

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Saturday, July 24, 2021 4:06 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is cleared by VTF ADS with comments that should be addressed.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Friday, July 23, 2021 2:04 PM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSSELS/OD) <pzs1@cdc.gov>

Subject: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,

Kimberly
Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov
Dany Hall: qjj7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday
11am-1pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 23, 2021 1:11 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE-REVIEW due 7/24 at 1:30PM - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

VTF,

Alyson Cavanaugh is submitting this **Tier 1 MMWR article** for your re-review. Attached is a clean copy and tracked changes copy with comments addressed. The requested deadline for your re-review is **7/24 at 1:30PM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov
Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays
Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 23, 2021 12:58 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached track and clean copies of revised paper. We believe the changes in analysis are appropriate to address concerns. However, if additional changes are suggested, please let us know.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Wednesday, July 21, 2021 3:45 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson,

VTF did not clear your MMWR article. Please see their comments in the attached Word doc. Additional notes from reviewers below:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.
For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).
For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).
We are happy to discuss further with authors if they have any questions or concerns.

Please address comments and resubmit a clean copy and tracked changes copy for re-review with VTF.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Wednesday, July 21, 2021 3:27 PM
To: Bunting, Hannah (CDC/DDID/NCIRD/OD) (CTR) <rou3@cdc.gov>
Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

The below document is **not cleared** by VTF. Please address comments in the below link and return clean and tracked changes copies for re-review. Additionally, please note the following:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

**Hours of Operation: 8:30am-5:30pm EST Monday-Friday
2-5pm EST Saturday & 12-3pm EST Sunday**

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>
Sent: Wednesday, July 21, 2021 2:45 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>
Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>
Subject: RE: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is not cleared by VTF ADS. Please see comment below and submit a revised version.

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Wednesday, July 21, 2021 9:26 AM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday-Friday

2-5pm EST Saturday & 12-3pm EST Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Wednesday, July 21, 2021 7:20 AM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good Morning VTF,

The author has made changes and we are requesting a re review. Please find clean and tracked copies attached.

Deadline for review is **7/22 by 8 AM**

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, July 20, 2021 9:05 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please find attached the clean and track changes of MMWR on reinfections and vaccination. Please let me know if anything further is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Saturday, July 17, 2021 1:22 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF did not clear your MMWR. Please address the comments in the attached file and return clean and tracked copies for re-review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Saturday, July 17, 2021 1:08 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Epi,

The below document is **not cleared** by VTF. Please return clean and tracked changes copies for re-review.

[Reinfection and vaccination status_07.14.21_clean.docx](#)
[Clearance Request Form_July 14_reinfection.docx](#)

Thanks,
Dany

Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8am-8pm EST Monday-Friday
12pm-5pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Saturday, July 17, 2021 12:41 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lk6@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Please advise the status of the requested cross-clearance review of the MMWR titled "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky." The review was due **Friday, 7/16, at 10 a.m.**

[Reinfection and vaccination status_07.14.21_clean.docx](#)

We request the courtesy of a response with a status update.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

**Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov**

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 16, 2021 2:29 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Epi TF still requests your comments on this Tier 1 MMWR. As a reminder, here is the link:

[Reinfection and vaccination status_07.14.21_clean.docx](#)

Comments were due at 10 a.m., so please return your comments as soon as possible so that we can proceed with the clearance process.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE**

eoevent210@cdc.gov

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Sent: Friday, July 16, 2021 11:28 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eoevent229@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eoevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Subject: Fw: Reminder - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear HSWS and VTF,

This is a gentle reminder that your cross-clearance of this MMWR was due today at 10 a.m.

 [Reinfection and vaccination status_07.14.21_clean.docx](#)

This is a Tier 1 MMWR. Please return your review as quickly as possible.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eoevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Sent: Thursday, July 15, 2021 10:04 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eoevent229@cdc.gov>; CDC IMS 2019 NCOV Response CICP ADS/Clearance <ocdgmqsitrep@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eoevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Subject: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF, HSWS, and CICP TFs,

Epi TF requests cross-clearance of the **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky."

Please use the SharePoint link below during your review. Please indicate whether you clear the manuscript with major/minor comments, with no comments, or do not clear.

The deadline for your review is 7/16 at 10:00 a.m.

- [Reinfection and vaccination status_07.14.21_clean.docx](#)

CICP clearance coordinators: please forward this MMWR for review to your new POC ASAP, as we are aware your ADS/TF are no longer accepting submissions. Thank you.

Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qgz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, July 14, 2021 6:13 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please see attached track and clean changes where all comments were addressed.

I am also attaching the clearance form. I deleted the section about cross task force review. I apologize for the confusion. That was filled in with the template that was sent me and I didn't see it. Therefore I hadn't deleted that section before submitting the form for this MMWR.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, July 13, 2021 12:24 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Epi ADS re-reviewed and cleared your MMWR with comments in the attached document. Please address comments and resubmit both a **clean copy** and a **tracked changes copy** to proceed with cross-clearance.

Also, your clearance request form originally stated that this MMWR article has been cleared by STLT, HSWS, and CICP. You and STLT have confirmed that Epi TF is the only TF to have reviewed it yet. When you resubmit, please update your clearance request form to reflect that only Epi TF has cleared it thus far.

Thank you!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Tuesday, July 13, 2021 11:42 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Clearance Team—this review is complete.

Reviewer: Lisa Grohskopf (ADS), Ruth Link-Gelles (SME)
Decision: Cleared with comments, some mandatory
Comments: please see attached
Please send to Lab TF as informational (not for cross clearance).

Thank,
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, July 12, 2021 7:20 AM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lg6@cdc.gov>
Subject: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning Epi ADS,

Lisa -- Alyson Cavanaugh is submitting her **Tier 1 MMWR** for re-review: "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky". Attached includes a clean copy and a tracked changes copy. See your initial decision record below:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

The deadline for your re-review of this expedited article is **7/13 at 7:30AM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Sunday, July 11, 2021 9:56 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Thank you very much for the review. Please see attached clean and track changes of edits based on the suggestions. All comments have been addressed.

This paper has only been reviewed by epi TF to date. Am I supposed to send to the other task forces for cross-clearance? No other task forces have yet reviewed this.

Thank you,
Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department of Public Health
275 E. Main St.
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 11, 2021 8:00 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: Fwd: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <>
Subject: Fw: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

Epi TF has reviewed and **does not clear** this MMWR. Please see the following comments:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Please address the comments in the attached document and submit clean and tracked copies for re-review. Additionally, please provide documentation of cross-clearance by STLT, CICP, and HSWS.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Saturday, July 10, 2021 12:22 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Clearance Team! This review is complete.

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Thanks!
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 12:32 PM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Team,

The attached Tier 1 MMWR, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk

of reinfection – May through June, 2021 - Kentucky," is submitted for review. The deadline for review is Saturday, 7/10, at 12:30 p.m.

The clearance request form notes that CICP, STLT, and HSWS have already cleared this.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 12:24 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Please see attached clearance form for MMWR 1464.

Let me know if I need to do anything additionally at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 9:18 AM
To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Thank you, Anna!

Alyson,

I see you attached the manuscript but mention that it still needs co-author feedback, is that correct? When you are ready to submit for JIC clearance please send the manuscript and the completed request form I have attached. I have also attached the SOP for moving MMWRs through clearance to help with any questions on the process going forward.

Best Regards,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin ggz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Sent: Friday, July 9, 2021 9:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Hi Katie,

Epi TF has "adopted" this manuscript for COVID-19 Clearance and Alyson has submitted to begin the clearance process with Epi TF. Let me know if you have any questions.

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 8:28 AM

To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Alyson,

Is this an FYI that this MMWR is coming for review? Are you asking for any action from the Epi TF at this time?

Best,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 9, 2021 7:06 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Good morning,

Attached is the manuscript for MMWR 1464 regarding reinfections and vaccination status.

I am making some edits based on co-authors' feedback for 1459, but hope to have the paper ready tomorrow.

I believe both will be "adopted" by the vaccine task force because they involve vaccine effectiveness. Please let me know any next steps for this submission.

V/R,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and

destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Thursday, July 8, 2021 2:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Dear Alyson,

Following up on your VE/VB MMWR manuscripts, the COVID-19 Response Incident Manager would like to have both 1459 and 1464 published in about a month (see email below). I have copied the Epi Clearance Coordinators (eocevent210@cdc.gov) and Epi ADS (eocevent496@cdc.gov), who are ready to help you begin the COVID-19 Clearance Process. When do you anticipate submitting these manuscripts?

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Thursday, July 8, 2021 10:07 AM
To: Anderson, Mark (CDC/DDPHSS/CGH/DGHP) <mea6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <jyn3@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Mark, as mentioned yesterday, Peggy would really like to have these published by end of month-early August. They are top response priorities. Is there anything I can do to facilitate process?

1464	Reinfection associated with vaccination status - Kentucky, May-June 2021 (Alyson Cavanaugh)	Concept approved 6/30
1459	Low county-level vaccination coverage increases the risk of breakthrough infections among fully vaccinated Kentucky residents – Kentucky, May 2021 (Alyson Cavanaugh)	Concept approved 6/30

Apologies for not sending this note yesterday.

Best,
Charlotte

Charlotte Kent, PhD, MPH

Editor-in-Chief, *Morbidity and Mortality Weekly Report (MMWR)* Series
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Friday, July 30, 2021 5:12:37 PM
Attachments: [Cavanaugh_07.29_clean_SSU1.docx](#)
[TABLE 1_07.29.21_SSU1.docx](#)
[TABLE 2_07.29.21_SSU1.docx](#)
[TABLE 3_07.29.21_SSU1.docx](#)
[FIGURE_Supplementary_SSU1.docx](#)

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today 😊) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

***NOTICE OF CONFIDENTIALITY:** This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eoevent172@cdc.gov>; CDC IMS

2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>

Sent: Thursday, July 29, 2021 9:55 AM

To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>

Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

CDC IMS 2019 NCOV Response Strategic Scientific Unit

Email: eocevent538@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: [Parry, Carolyn \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#); [Berryman, Misty](#); [Gaither, Melanie L \(CHFS DPH DEHP\)](#); [Gillion, Grant T \(CHFS DPH DPHPS\)](#); [Gillis, Rebecca L \(CHFS DPH EPB\)](#); [Herrington, Amy \(CHFS DPH DEHP\)](#); [Higgins, Sue](#); [Hume, Robbie \(CHFS DPH DPHPS\)](#); [Johnson, Rick D \(CHFS DPH DPHPS\)](#); [Kik, Angela M \(CHFS DPH DPHPS\)](#); [Miracle, Julie \(CHFS DPH\)](#); [Michele Pinkston](#); [Robeson, Sara \(CHFS DPH\)](#); [Sanders, Kimberly \(CHFS DPH DEHP\)](#); [Taylor, Ida \(CHFS DPH\)](#); [White, Connie \(CHFS DPH\)](#); [Wible, Sarah C \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: Weekly Reader 8/9/21: Highlights from VDAPS
Date: Monday, August 9, 2021 7:56:04 PM
Attachments: [image003.png](#)

From: NCIRD Immunization Grantee Mailbox (CDC) <nipgrant@cdc.gov>
Sent: Monday, August 9, 2021 5:46 PM
To: NCIRD Immunization Grantee Mailbox (CDC) <nipgrant@cdc.gov>
Subject: Weekly Reader 8/9/21: Highlights from VDAPS



Key highlights for this week include:

- **We Have a New Name!**
- **MMWR Launches a New Site Focusing on COVID-19 Vaccine Effectiveness and Safety**
- **A Message From the Desk of Chris Duggar**
- **New Guidance on Coadministration of COVID-19 Vaccine With Other Vaccines**
- **Be Sure to Screen for Previous COVID-19 Vaccination**
- **School-based Immunization Programs FAQs**
- **Topline Messages for the Week**

GOOD NEWS!

Congratulations! Due in part to the hard work, long hours, and dedication you have shown in fighting COVID-19, the United States has now met the administration's goal of vaccinating 70% of US adults vaccinated against COVID-19. Sixty percent of people over 18 years old in the U.S. are now fully vaccinated!


This is a truly unprecedented success. The highest coverage rate for influenza vaccination recently achieved was 48.4% in 2019–2020, and that was only a single dose instead of a series. Well done! Here is some additional information to put this tremendous achievement into context:

- As of August 9, 2021, it's been 238 days since the first delivery of COVID vaccines in the USA
 - 405 million doses delivered
 - 400 million doses distributed is the equivalent to 5 years of distribution under the CDC Vaccines for Children Program
 - 165 million Americans are fully vaccinated
 - 70% of adults age 18+ have received at least 1 dose
 - 90% of adults age 65+ have received at least 1 dose
 - 70% & 90% coverage with an adult vaccine equivalent (read: seasonal influenza) has never been achieved before
 - In the past 5 years, adult seasonal flu vaccine coverage has averaged <48%. Sometimes coverage in adults 65+ has approached 69%. This number has been eclipsed by the current rate of 90% of 65+ year-olds having received 1 dose!
- Most of this work is done by CDC and State personnel...we recognize and appreciate you!

We Have a New Name!

On August 2, 2021, two changes were introduced to the Vaccine Task Force organizational chart. First, the Distribution & Federal

Partners (DFP) section was renamed Vaccine Distribution, Awardee and Partner Support section (VDAPS). Second, to achieve organizational efficiencies, the Vaccine Jurisdiction Support (VJS) section (which includes the Vaccine Coordination Cell) was relocated under the newly renamed VDAPS section. This reduces Vaccine Task Force footprint and improves communication and coordination within the CDC in support of the critical jurisdictional activities of the VCC.



DID YOU KNOW?

MMWR Launches a New Site Focusing on COVID-19 Vaccine Effectiveness and Safety

CDC’s primary publication for disseminating the science it produces is the *Morbidity and Mortality Weekly Report*, better known as MMWR. The staff at MMWR has just launched a new landing page to help people find the latest information on COVID-19 vaccine effectiveness and safety at https://www.cdc.gov/mmwr/covid19_vaccine_safety.html



[Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant – Mesa County, Colorado, April-June 2021](#)

[Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021](#)

[Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – COVID-NET, 13 States, February-April 2021](#)

Eleven years ago this week, the World Health Organization declared an end to the last global pandemic—the 2009 H1N1 influenza pandemic. The decision was based on epidemiological and virological data and the correct prediction by public health authorities that H1N1 would continue circulating as an annual strain.

Gratitude Corner

The past 34 weeks have shown the importance and effectiveness of on-the-ground public health workers like you. There is no way

that we could have come together as a nation to administer 350 million vaccines without your commitment, dedication, and hard work. We are so grateful to YOU!

A Message From the Desk of Chris Duggar

As we return from summer, the COVID-19 immunization efforts will begin to look different. The United States has achieved incredible vaccine coverage in 35 weeks of mass vaccination. While this has dramatically reduced morbidity and mortality, the need for vaccine administration continues.

If I had to capture the nuances of the COVID vaccination program (from ancillaries & allocations, EUAs, the J&J/Janssen “pause,” and finally waste) it is understandable that we have needed to operate a highly focused program within the national response—often due to those very nuances. However, as we begin day 240 of COVID-19 vaccine administration, the shift to normalization and integration with other vaccine programs begins.

Many clinics, pharmacies, and partners will be offering flu shots, back to school immunizations, and shaking the dust off the regular immunization schedules. Public health has begun assessing COVID-19 vaccine inventory to determine where doses exist in the field and reducing inventory in transition to a normalized vaccine program.

Moving forward, co-administration of COVID-19 vaccine with other available vaccines will be one of the greatest tools in our arsenal as immunization programs begin to look and act like their former selves. As we begin to integrate with other vaccine programs, we believe the lessons learned from the COVID-19 vaccination efforts will help to make all of our vaccine programs stronger.

Thank you for all of your hard-earned achievements.

Distribution

DISTRIBUTION OFFICE HOURS

AUGUST 10, 5PM–6PM ET

[Click here to join the meeting](#)

New Guidance on Coadministration of COVID-19 Vaccine With Other Vaccines

COVID-19 vaccines and other vaccines may now be coadministered without regard to timing. Until recently, COVID-19 vaccines were recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines. New data shows that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.

Find more additional information and best practice tips at [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)

Reminder: Communication and Education Resources

We want to remind you that the CDC COVID-19 Vaccine Task Force maintains a Communication and Education Product Inventory on the Awardee SharePoint portal in the “COVID-19 > Communication Content” folder. Check out the “New Content” tab with the latest webpages.

The product inventory is an index of key content compiled to support awardee needs, organized by product category and by stakeholder. It is updated at least once a week. Recent updates to the Communication and Education Product Inventory include:

[COVID-19 Vaccine FAQs for Healthcare Professionals](#)
[Janssen COVID-19 Vaccine \(Johnson & Johnson\) Questions](#)
[Moderna COVID-19 Vaccine Questions](#)
[Pfizer-BioNTech COVID-19 Vaccine Questions](#)
[Resources for Jurisdictions, Clinics, and Organizations](#)
[Inventory Manager User Manual](#)
[Open Registration](#)

Back to School Resources

Though lots of us are still enduring 90° F+ temperatures, school is already starting in many of our communities. New resources are available to help public health and school workers reach out to students and staff as they return to in-person learning.

The [Back to School Toolkit](#) from the federal We Can Do This COVID-19 Public Education Campaign has resources for school district leaders, teachers, parent leaders, and school supporters that want to help increase confidence in and uptake of COVID-19 vaccines in their school communities, answer questions, and outline school guidance about COVID-19.

The [Guide to On-Site Vaccination Clinic for Schools](#) has specific suggestions and tips for how schools can host pop-up vaccine clinics for students returning to in-person learning, as well as a list of resources available to make school-located clinics happen. For detailed step-by-step instructions for how to facilitate school-based vaccination clinics, you can use the resources at [Considerations for Planning School-Located Vaccination Clinics](#) and [On-Site Vaccination Clinic Toolkit](#).

Data

Coming Soon: Flu Vaccine Data on Vaccines.gov (New!)

As the flu season approaches, and in coordination with CDC's flu vaccination campaign, jurisdictions, providers, and pharmacies will be able to publicly display flu vaccine availability through Vaccines.gov. Providers and jurisdictions will not be asked to report flu vaccine inventory quantities daily (as is needed for COVID-19 vaccine).

In the coming weeks, the Vaccines.gov team will provide more information, including guides and training materials, on how to add flu vaccine data to the system so that locations administering flu vaccine can be displayed on Vaccines.gov.

If your jurisdiction reports on behalf of your providers and you are interested in onboarding providers to report flu vaccine data, please send an email to CARS_HelpDesk@cdc.gov with your request.

Pharmacy

Be Sure to Screen for Previous COVID-19 Vaccination

Public concern over new COVID-19 variants is growing, and federal authorities are analyzing data to determine if a 3rd dose of vaccine might be needed at some point in the future among specific populations. A number of pharmacists and jurisdictions have reported encountering patients who do not report their previous vaccine doses in order to get an additional 3rd dose.

Please diligently screen patients and check patients' vaccination history in the appropriate local Immunization Information System (IIS) registry prior to administering the vaccine when possible. Should the pharmacy discover a 3rd dose was inadvertently administered, CDC advises the following:

- Review <https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-errors-deviations.pdf>
- Contact the patient and provide the clinical guidance, and explain to patient to monitor and report any side effects that occur to the pharmacy and through the v-safe application.
 - Ensure the patient has received information on the v-safe application.
 - Complete a VAERS report for the patients and keep a copy on file in the pharmacy for a minimum of 3 years.
 - Amend the VAERS report as needed if the patient reports any further issues.
- Contact the patient's physician or primary health care provider to report the incident and document the issue and keep a copy in the pharmacy files for a minimum of 3 years.
 - If the patient does not have a physician or primary health care provider, document this and maintain a copy in the pharmacy files for a minimum of 3 years.
- Review the actions and processes that led to the administration error and take steps to correct and prevent this from occurring again.
 - Amend workflow to check with your state's IIS before administering the vaccine to catch these types of issues.
- If administration fees were billed to the patient's insurance plans, consider reversing the claims to avoid potential audits related to fraudulent claims.

One way to avoid administration errors is to encourage all staff to complete the CDC online training available at [Vaccine Webinars \(cdc.gov\)](#).

State Immunization Manager Inventory Redistribution Assistance

Data on field inventory indicates that efforts to redistribute vaccine across jurisdictions has been very successful. Still, some providers are struggling to find locations willing to accept excess inventory. In these instances, CDC recommends you contact your State Immunization Manager for assistance locating providers in your jurisdiction that may be able to accept redistributed vaccine. Likewise, you can check with your State Immunization Manager for assistance locating vaccine inventory in your area prior to ordering new vaccine. You can help reduce field inventory and reduce vaccine wastage. Let's use every dose!

A list of State Immunization Program Managers is available at:

<https://www.immunizationmanagers.org/page/MemPage>

School-based Immunization Programs FAQs

In follow-up to the [President's announcement last week](#), and your questions to CDC, we are providing the following FAQs regarding school-based vaccination clinics.

School-Based Vaccination Clinics

- **Q: How are federal retail pharmacy partners assisting?**
 - On July 29th, in an effort to get more kids 12 and older vaccinated, President Biden called on school districts nationwide to host at least one pop-up vaccination clinic over the coming weeks. As part of that effort, the Administration is encouraging Federal Retail Pharmacy Program partners to work with school districts to host on-site vaccination clinics. Federal pharmacy partners have already conducted around 2,500 school-based clinics; we are asking partners to build on that progress with a renewed push to host these clinics in the coming weeks ahead of back-to-school and as students return. As needed, pharmacy pop-up clinics will give a second dose at a second school-based clinic or at a nearby pharmacy store.

- **Q: How should federal pharmacy partners report on progress?**
 - The Administration asks that pharmacy partners continue to report metrics on completed school-based clinics to CDC on a biweekly basis. Please work with your teams to ensure that reporting is as complete as possible. This reporting will assist the Administration in tracking progress. We also encourage you to share success stories so that the Administration can highlight this important work.

- **Q: How can I contact school districts to offer clinics?**
 - We ask pharmacy partners to proactively reach out to local school districts. The Department of Education will be sharing the On-Site Vaccination Clinic Toolkit with school districts who may reach out to pharmacy partners through their established points of contact. You are encouraged to reach out to schools and districts you have worked with before, or any other nearby schools or districts, whom you are willing to host. Your proactive outreach to school districts will be very helpful in setting up these clinics.

- **Q: Can pharmacy partners choose to co-administer the influenza vaccine at the school-based clinics?**
 - Yes, pharmacies can choose to co-administer the COVID-19 vaccine and influenza vaccine.

- **Q: What more can I be doing to help in this effort?**
 - We welcome additional steps by pharmacy partners to work with schools in setting up dedicated vaccination clinics for their staff and students, and to promote vaccination to adolescents and their parents as part of your pharmacy's regular outreach. This may include additional signage in store on vaccination geared towards students and families of nearby high schools and middle schools; sending push notifications, texts, and emails to customers reminding them to get vaccinated as part of back to school; and featuring vaccination prominently in any of your public health outreach materials for back to school.

Technical Key Points

TOPLINE MESSAGES FOR THE WEEK

- COVID-19 vaccines are widely available. Getting a COVID-19 vaccine is fast, easy, and free. CDC recommends everyone 12 years and

older get vaccinated.

- Getting vaccinated helps prevent severe illness, hospitalization, and death; it also helps reduce the spread of COVID-19 in communities.
- Over 70% of the U.S. adult population has already received at least one dose, and 60% of adults are fully vaccinated (67.7% of the population age 12 and older have been vaccinated with at least one dose, and 58% have been fully vaccinated).
- Vaccination is more urgent than ever, as the Delta variant causes an increased number of cases in areas across the United States. The highest number of cases and severe outcomes are happening in places with low vaccination rates.
- To help prevent the spread of Delta and protect others, CDC recommends that everyone (including fully vaccinated people) wear a mask in public indoor settings in areas with substantial or high spread of COVID-19.
- In addition, CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K–12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.
- A recent MMWR reviewed vaccine safety data in adolescents and concluded that some adolescents experience mild reactions after receiving the Pfizer-BioNTech COVID-19 Vaccine, but serious adverse events are rare.
 - MMWR Study: [COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021 | MMWR \(cdc.gov\)](#)
- The U.S. Food and Drug Administration [authorized an extension](#) of the shelf life for Johnson & Johnson’s Janssen COVID-19 Vaccine from 4.5 months to 6 months (an additional 45 days).

Contact Information

Whitelist Email Addresses

Whitelist Email Addresses	
Pfizer Customer Service	cvgovernment@pfizer.com
For confirmation of the ancillary kit shipment	donotreply@pfizer.com
For communication from Controlant, including: <ul style="list-style-type: none"> • Notice at time of vaccine shipment with tracking information • Exceptions for either shipment delay or cancellation • Delivery Quality Report 	Pfizer_logistics@controlant.com
24/7 support inbox and line. Contact this address for issues or call 1-701-540-4039 or 1-855-442-668765 to reach the Controlant 24/7 hotline.	support@controlant.com
All temperature notifications and alerts will come from this email address. This address must be unblocked to receive temperature notifications.	onsitemonitoring@controlant.com
Inbox for government relations (state & federal) and USG dashboard only. Hospitals/clinics should not contact this address.	usgov.projects@controlant.com
Moderna Customer Service	1-866-MOD-ERNA or 1-866-663-3762 Email: excursions@modernatx.com
Janssen Customer Service	Phone: 800-565-4008 (or) 1-908-455-9922 Email: JSCCOVIDTEMPEXCURSION@its.inj.com
For communications from McKesson regarding Moderna/Janssen vaccine order shipments	CDCCustomerService@McKesson.com CDcnotifications@McKesson.com
For communication from McKesson about ancillary kits	SNSSupport@McKesson.com
VaccineFinder onboarding email to set up an account (no-reply)	vaccinefinder@auth.castlighthealth.com
COVID-19 DCH new user registration details and Two-Factor Authentication via email	covdch-no-reply@cdc.gov
Help desk for Provider Enrollment and Data Lake questions	IZDLhelpdesk@cdc.gov
VAMS help desk	VAMSHelp@cdc.gov
<ul style="list-style-type: none"> • Registration for Clinic, Employer, and Jurisdiction Portals • Confirmation of bulk upload files for 3-Party recipients, organization, and employee bulk imports 	VAMS@CDC.gov

System notifications (e.g., system downtime, trainings)	
One-time passwords during login, recipient registration Recipient email communications related to appointments	no-reply@mail.vams.cdc.gov
VTrckS Provider Order Portal (VPoP) new user registration details and Two-Factor Authentication via email (Federal and Pharmacy Partners ONLY)	yvop-no-reply@cdc.gov
Data Clearinghouse (DCH) emails	covdch-no-reply@cdc.gov
NEW To receive auto-generated email updates for COVID-19 Lot Number Expiration Date Reporting registration	No-reply@emailupdates.cdc.gov

For additional assistance:

I need help with...	Contact...
Pfizer vaccine shipment has a problem	Pfizer Customer Service Phone # (800) 666-7248 Email: cvgovernment@pfizer.com
Pfizer ancillary kit has a problem	Contact McKesson MedSurg to report SNSSupport@McKesson.com
Moderna/Janssen vaccine shipment has a problem	<p>Vaccine Viability – Temperature Excursions during shipment for McKesson Specialty Distributed COVID Vaccine</p> <p>Supports calls/emails from provider/admin sites and awardee or federal/pharmacy ordering points of contact. Questions/concerns about vaccine viability issues during shipment must be reported on the <u>same day as delivery</u>.</p> <p>Phone: (833) 272-6635 Mon-Fri, 8 a.m. - 8 p.m.ET Email: COVIDVaccineSupport@McKesson.com (only send email if after hours)</p> <p>Shipment issues/questions other than vaccine viability concerns Supports call/emails from awardee or federal/pharmacy ordering points of contact only. Providers/admin sites must work through their jurisdiction or program.</p> <p>Phone: (833) 343-2703 Mon-Fri, 8 a.m. - 8 p.m. ET Email: COVIDVaccineSupport@McKesson.com</p>
J&J/Janssen vaccine shipment has a problem	Phone: 800-565-4008 (or) 1-908-455-9922 Email: JSCCOVIDTEMPEXCURSION@its.inj.com
Moderna/Janssen ancillary kit has a problem	McKesson Specialty Phone #: (833) 343-2703 Email: COVIDVaccineSupport@McKesson.com
Temperature excursions within the Clinic/Site	<p>Call the Manufacturer</p> <p>Moderna: 1-866-MOD-ERNA or 1-866-663-3762 Email: excursions@modernatx.com</p> <p>Pfizer: Phone # (800) 666-7248 Email: cvgovernment@pfizer.com</p> <p>Janssen: Phone: 800-565-4008 (or) 908-455-9922 Email: JSCCOVIDTEMPEXCURSION@its.inj.com</p>
General IIS Inquiries	IIS Support: IISInfo@cdc.gov

Provider Enrollment Data	IZ Data Lake Support: IZDLhelpdesk@cdc.gov
VTrckS Ordering, Provider Master Data, Returns & Wastage Extracts	VTrckS ExIS Support: VTrckSExIS@cdc.gov VPoP (Federal Partners): VTrckSExIS@cdc.gov
VTrckS Allocations, Tracking and Shipment	Vaccine Order Management Contact Center: Vaccineordermgmt@cdc.gov
Vaccines.gov/VaccineFinder Support	Available M-F, 8am – 8pm ET Email: CARS_HelpDesk@cdc.gov Phone: 1-833-748-1979
Reporting Administration Data via CVRS Data Extract	CVRS Support: IZGateway@cdc.gov Data Clearinghouse: DCHInfo@cdc.gov Pharmacy Liaison: eocevent481@cdc.gov
VAMS	These help options are only for jurisdictions and providers using VAMS: VAMS Help Desk: 1-833-957-1100 **preferred contact method** VAMS Help: VAMSHelp@cdc.gov
V-safe	eocevent523@cdc.gov
HHS Protect/Tiberius	Log-in: Protect-ServiceDesk@hhs.gov Platform: ows-support@palantir.com Microplanning: ows-support-microplanning@palantir.com

PLEASE DO NOT RESPOND OR REPLY DIRECTLY TO THIS E-MAIL

This message has been sent to program managers and field staff. Please review the individual announcements for contact information. If you do not see any contact information and need additional information, please contact your program manager. If you need access to the ISD Awardee SharePoint site, please contact your supervisor or your CDC project officer for more information.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Cc: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Fwd: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR
Date: Sunday, August 8, 2021 6:15:13 PM

Kelly,

As an FYI - there was a media request for radio interview with Dr. Marc Siegel for Monday morning.

I will connect with Melissa at CDC because I am not available at proposed time.

V/R,
Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Sunday, August 8, 2021 5:40 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP)
Subject: Fwd: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

What's your schedule like in the morning? Up for doing this around 10:30? We could have another brief prep call at 10 if you like to talk through some tips for radio interviews. Just let me know if other times would work better. Thanks!!

Sent from my Verizon, Samsung Galaxy smartphone
Get [Outlook for Android](#)

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Saturday, August 7, 2021 7:03:31 AM

To: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Cc: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tws3@cdc.gov>
Subject: Re: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Sure. I am looking to discuss on the radio
Available to discuss today or Monday

[REDACTED]

Sent from my iPhone

On Aug 7, 2021, at 12:08 AM, Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov> wrote:

[EXTERNAL]

Happy to help. Dr. Siegel, what's your availability for a call on Monday?

Best,

Melissa

Melissa Brower, MMC
Public Affairs Specialist
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention
Office: 404-639-4718
Cell: 404-903-0241
mbrower@cdc.gov

From: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tws3@cdc.gov>
Sent: Friday, August 6, 2021 9:22 PM
To: Siegel, Marc <Marc.Siegel@nyulangone.org>; Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Subject: Re: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Including Melissa here who can put you in touch with the author. Thanks

Tom Skinner

Senior Public Affairs Officer, CDC

[REDACTED]

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Friday, August 6, 2021 9:15:09 PM
To: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tw3@cdc.gov>
Subject: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Very important study.

Would love to discuss with Dr Brooks

<https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm>

Sent from my iPhone

This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain information that is proprietary, confidential, and exempt from disclosure under applicable law. Any unauthorized review, use, disclosure, or distribution is prohibited. If you have received this email in error please notify the sender by return email and delete the original message. Please note, the recipient should check this email and any attachments for the presence of viruses. The organization accepts no liability for any damage caused by any virus transmitted by this email.
=====

From:
To:

CDC IMS 2019 NCOV Response STLT TF HDS Comms Section

Harris, Scott (CDC adph.state.al.us); Davidson, Sherri (CDC adph.state.al.us); Massingale, Sharon (CDC adph.state.al.us); jamev.durham@adph.state.al.us; McLaughlin, Joseph (CDC alaska.gov); Zink, Anne (CDC alaska.gov); coleman.cutchins@alaska.gov; Porter, Kimberly (CDC alaska.gov); kelsey.pistotnik@alaska.gov; matthew.bobo@alaska.gov; Nua, Motusa Tuileama (CDC doh.as); Ttufa, A (CDC doh.as); Sili, Benjamin (CDC doh.as); Christ, Cara (CDC azdhs.gov); Komatsu, Kenneth (CDC azdhs.gov); Brady, Shane (CDC azdhs.gov); Goode, Dana (CDC azdhs.gov); Venkat, Heather (CDC azdhs.gov); Dillaha, Jennifer (CDC arkansas.gov); jose.romero@arkansas.gov; James, Allison (CDC arkansas.gov); Chai, Shua (CDC cdph.ca.gov); Watt, James (CDC cdph.ca.gov); Blocher, Tricia (CDC cdph.ca.gov); Arwady, Allison AA (CDC cityofchicago.org); Pacilli, Massimo (CDC cityofchicago.org); maribel.chavez-torres@cityofchicago.org; Ghinai, Isaac (CDC cityofchicago.org); Jill.ryan@state.co.us; Stasinios, Greg (CDC state.co.us); Herlihy, Rachel (CDC state.co.us); Travanty, Emily (CDC state.co.us); Sosa, Lynn (CDC ct.gov); Provenzano, Francesca (CDC ct.gov); Razeq, Jafar (CDC ct.gov); Gifford, Deldre (CDC ct.gov); William.Gerrish@ct.gov; Cartter, Matthew (CDC ct.gov); Leung, Vivian (CDC ct.gov); Benjamin.Bechtolsheim@ct.gov; Bart, Stephen (CDC ct.gov); Rattay, Karyl (CDC state.de.us); Hong, Rick (CDC delaware.gov); Pleasanton, Christina (CDC delaware.gov); Steven.Blessing@delaware.gov; Offutt-Powell, Tabatha (CDC state.de.us); Offutt-Powell, Tabatha (CDC delaware.gov); Smith, Erica (CDC delaware.gov); paul.hess@delaware.gov; Davies-Cole, John (CDC dc.gov); Iyengar, Preetha (CDC dc.gov); Samo, Marcus (CDC fsmhealth.fm); Johnson, Eliaser (CDC fsmhealth.fm); Barrow, Lisa (CDC fsmhealth.fm); Pongliyab, Ruotpong (CDC fsmhealth.fm); Blackmore, Carina (CDC flhealth.gov); marie-claire.rowlinson@flhealth.gov; Edison, Laura (CDC dph.ga.gov); Gettings, Jenna (CDC dph.ga.gov); Drenzek, Cherie (CDC dph.ga.gov); Ghuman, Harjinder (CDC dph.ga.gov); Minarcine, Scott (CDC dph.ga.gov); Bell, Charlisa (CDC dph.ga.gov); david.newton@dph.ga.gov; arthur.sanagustin@dphss.guam.gov; Pobutsky, Ann (CDC dphss.guam.gov); Santos, Annemarie (CDC dphss.guam.gov); libby.char@doh.hawaii.gov; Kemble, Sarah (CDC doh.hawaii.gov); Gose, Remedios (CDC doh.hawaii.gov); Kern, Judy (CDC doh.hawaii.gov); Carter, Kris (CDC dhw.idaho.gov); Shaw-Tulloch, Elke (CDC dhw.idaho.gov); Hahn, Christine (CDC dhw.idaho.gov); Patrick, Sarah (CDC illinois.gov); Kauerauf, Judy (CDC illinois.gov); heidi.clark@illinois.gov; charles.williams@illinois.gov; ngozi.ezike@illinois.org; Pontones, Pamela (CDC isdh.in.gov); Hawkins, Eric (CDC isdh.in.gov); Norman, Lee (CDC ks.gov); Ahmed, Farah (CDC kdheks.gov); Gunsalov, Myron (CDC ks.gov); Pedati, Caitlin (CDC idph.iowa.gov); Kintigh, Bethany (CDC idph.iowa.gov); dex.walker@idph.iowa.gov; michael-pentella@uiowa.edu; Garcia, Kelly (CDC dhs.state.ia.us); Winter, Kathleen T (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Stack, Steven J (CHFS DPH); Balter, Sharon (CDC ph.lacounty.gov); Terashita, Dawn (CDC ph.lacounty.gov); Fogleman, Stella (CDC ph.lacounty.gov); Sokol, Theresa (CDC la.gov); joseph.kanter@la.gov; sean.simonson@la.gov; kimberly.hood@la.gov; Winder, Sundee (CDC la.gov); Krueger, Anna (CDC maine.gov); Farmer, Ann (CDC maine.gov); Robinson, Sara (CDC maine.gov); kristen.coaty@maine.gov; Shah, Nirav (CDC maine.gov); Pote, Ken (CDC maine.gov); Blythe, David (CDC maryland.gov); Dennis.Schrader@Maryland.gov; Acharya, Jessica (CDC maryland.gov); jinlene.chan1@maryland.gov; Feldman, Katherine (CDC maryland.gov); Pearlowitz, Marcia (CDC maryland.gov); Myers, Robert (CDC maryland.gov); Adams, Sherry (CDC maryland.gov); amalloy@CDCFoundation.org; Vongchan, Patrick (OS/ASPR/EMMO); Bastedo, Shelsy (OS/ASPR/EMMO); Woolslayer, Christine (HHS/OASH); Duwell, Monique MD (CDC maryland.gov); Manning, Susan (CDC state.ma.us); larry.madoff@mass.gov; Bharel, Monica (CDC state.ma.us); Smole, Sandra (CDC state.ma.us); Milesly, Kerin (CDC state.ma.us); Brown, Catherine (CDC mass.gov); OlsenC2@michigan.gov; Lyoncallo, Sarah (CDC michigan.gov); Collins, Jim (CDC michigan.gov); McFadden, Jevon (CDC michigan.gov); scott112@michigan.gov; Lynfield, Ruth (CDC state.mn.us); Dobbbs, Thomas (CDC msdh.ms.gov); Byers, Paul (CDC msdh.ms.gov); Craig, Jim (CDC msdh.ms.gov); Ware, Daphne (CDC msdh.ms.gov); Vaughn, Wayne (CDC msdh.ms.gov); Turabelidze, George (CDC health.mo.gov); Robert.knodell@health.mo.gov; Adam.Crumbliss@health.mo.gov; Cool-Shimanek, Maggie (CDC mt.gov); Williamson, Laura (CDC mt.gov); Gibson, Deborah (CDC mt.gov); O'Loughlin, Kevin (CDC mt.gov); Smith, Dannette (CDC nebraska.gov); Anthone, Gary (CDC nebraska.gov); Donahue, Matthew (CDC nebraska.gov); Buss, Bryan (CDC nebraska.gov); Ling, Angela (CDC nebraska.gov); Sherych, L (CDC health.nv.gov); Peek, Julia (CDC health.nv.gov); Peek-Bullock, Melissa (CDC health.nv.gov); Bennett, Shannon (CDC health.nv.gov); Chan, Benjamin (CDC dhhs.nh.gov); Lindsay.J.Pierce@dhhs.nh.gov; Hull, Torane (CDC dhhs.nh.gov); Patricia.Tilley@dhhs.nh.gov; Bean, Christine (CDC dhhs.nh.gov); Leigh.cheney@dhhs.nh.gov; R01-RRCC-PlanningSection@fema.dhs.gov; Persichilli, Judith (CDC doh.nj.gov); Tan, Christina CT (CDC doh.nj.gov); Anschuetz, Greta (CDC doh.nj.gov); Johnson, Dana (CDC doh.nj.gov); Cervantes, Kim (CDC doh.nj.gov); Thomas, Deepam (CDC doh.nj.gov); Lifshitz, Edward (CDC doh.nj.gov); Kirn, Thomas (CDC doh.nj.gov); Carothers, Barbara (CDC doh.nj.gov); David.Adinaro@doh.nj.gov; Diana.Bauer@doh.nj.gov; Denise.Anderson@doh.nj.gov; Katharine.McGreevy@doh.nj.gov; Greeley, Rebecca (CDC doh.nj.gov); kelly.anderson-thomas@doh.nj.gov; bhavani.sathya1@doh.nj.gov; Sirjue, Thalia (CDC doh.nj.gov); Martinez-Mejia, Andrea (CDC doh.nj.gov); Theresa.Lewis@doh.nj.gov; Satyam.Patel@doh.nj.gov; Dana.Woell@doh.nj.gov; Hannah.Hergert@doh.nj.gov; raissa.sanchez@doh.nj.gov; Richard.siderits@doh.nj.gov; Reed.Magleby@doh.nj.gov; Ross, Christine (CDC state.nm.us); Sosin, Daniel (CDC state.nm.us); Hicks, Joseph (CDC state.nm.us); traciec.collins@state.nm.us; laura.parajon@state.nm.us; Hughes, Scott SH (CDC health.nyc.gov); Maldin, Beth (CDC health.nyc.gov); Quinn, Celia (CDC health.nyc.gov); ICS-LNO-Chief@health.nyc.gov; ICS-LNO-DOfficer@health.nyc.gov; Weiss, Don (CDC health.nyc.gov); mpersaud@health.nyc.gov; Reddy, Sudha (CDC health.nyc.gov); Layton, Marci (CDC health.nyc.gov); Metroka, Amy (CDC health.nyc.gov); Ackelsberg, Joel (CDC health.nyc.gov); Blaney, Kathleen (CDC health.nyc.gov); Saad, Eduardo (CDC health.nyc.gov); Istalvey@health.nyc.gov; Zielinski, Lindsay (CDC health.nyc.gov); McGibbon, Emily (CDC health.nyc.gov); bbadenhop@health.nyc.gov; Eiras, Daniel (CDC health.nyc.gov); Ahuja, Shama (CDC health.nyc.gov); jsulliv2@health.nyc.gov; JVarma@cityhall.nyc.gov; dchokshi@health.nyc.gov; nafshar@health.nyc.gov; Madad, Syra (CDC nychhc.org); Fine, Annie (CDC health.nyc.gov); guerrall1@nychhc.org; smckenney@health.nyc.gov; dlee8@health.nyc.gov; atesfayerogoz@health.nyc.gov; pryland@health.nyc.gov; csantos2@health.nyc.gov; mmickle@health.nyc.gov; aramautar@health.nyc.gov; Crouch, Bindy (CDC health.nyc.gov); guerrall1@nychhc.org; smckenney@health.nyc.gov; Santiago, Celina (CDC health.nyc.gov); ejeffrey1@health.nyc.gov; ecabato@health.nyc.gov; gcovault@health.nyc.gov; Schilling, Julia (CDC health.nyc.gov); tstylesmd@health.nyc.gov; Harper, Scott (CDC health.nyc.gov); Zucker, Howard (CDC health.nyc.gov); Lutterloh, Emily (CDC health.nyc.gov); Belinda.Ostrowsky@health.nyc.gov;

roger.sokol@health.ny.gov; Daniel.Lang@health.ny.gov; DKuhles@saratogacountyny.gov; stephanie.ostrowski@health.ny.gov; Abigail.Gallucci@health.ny.gov; [Primeau, Michael \(CDC health.ny.gov\)](mailto:Primeau, Michael (CDC health.ny.gov)); loretta.santilli@health.ny.gov; jill.dunkel@health.ny.gov; dina.hoefer@health.ny.gov; elizabeth.rausch-phung@health.ny.gov; bryon.backenson@health.ny.gov; victoria.derbyshire@health.ny.gov; michael.ryan@health.ny.gov; johanne.morne@health.ny.gov; carlene.vanpatten@health.ny.gov; [Benton, Mark \(CDC dhhs.nc.gov\)](mailto:Benton, Mark (CDC dhhs.nc.gov)); [Moore, Zackary \(CDC dhhs.nc.gov\)](mailto:Moore, Zackary (CDC dhhs.nc.gov)); scott.shone@dhhs.nc.gov; amanda.fuller@dhhs.nc.gov; [Combs, Brian \(CDC dhhs.nc.gov\)](mailto:Combs, Brian (CDC dhhs.nc.gov)); [Fleischauer, Aaron \(CDC dhhs.nc.gov\)](mailto:Fleischauer, Aaron (CDC dhhs.nc.gov)); catherine.donovan@dhhs.nc.gov; nwehbi@nd.gov; [Miller, Tracy \(CDC nd.gov\)](mailto:Miller, Tracy (CDC nd.gov)); [Massen, Christie \(CDC nd.gov\)](mailto:Massen, Christie (CDC nd.gov)); jsickler@nd.gov; [Muña, Esther \(CDC dph.gov.mp\)](mailto:Muña, Esther (CDC dph.gov.mp)); emily.haanschoten@chcc.gov.mp; drp_dauterman@yahoo.com; [Villagomez, Warren \(CDC dph.gov.mp\)](mailto:Villagomez, Warren (CDC dph.gov.mp)); richard.gary@odh.ohio.gov; [Dewart, Courtney \(CDC odh.ohio.gov\)](mailto:Dewart, Courtney (CDC odh.ohio.gov)); Kara.Tarter@odh.ohio.gov; Kristen.Dickerson@odh.ohio.gov; [Stone, Jolianne \(CDC health.ok.gov\)](mailto:Stone, Jolianne (CDC health.ok.gov)); keithr@health.ok.gov; travisk@health.ok.gov; jackies@health.ok.gov; jennifer.lepard@health.ok.gov; [Bonner, Kimberly \(CDC dshsoa.state.or.us\)](mailto:Bonner, Kimberly (CDC dshsoa.state.or.us)); [Town, Cecile \(CDC dshsoa.state.or.us\)](mailto:Town, Cecile (CDC dshsoa.state.or.us)); [Kaisner, Heather \(CDC dshsoa.state.or.us\)](mailto:Kaisner, Heather (CDC dshsoa.state.or.us)); [Powell, Melissa \(CDC dshsoa.state.or.us\)](mailto:Powell, Melissa (CDC dshsoa.state.or.us)); [E.Sidelinger, Dean \(CDC dshsoa.state.or.us\)](mailto:E.Sidelinger, Dean (CDC dshsoa.state.or.us)); Akiko.SAITO@dshsoa.state.or.us; abeam@pa.gov; Denisejohn@pa.gov; [Watkins, Sharon \(CDC pa.gov\)](mailto:Watkins, Sharon (CDC pa.gov)); wbraund@pa.gov; [Xia, Dongxiang \(CDC pa.gov\)](mailto:Xia, Dongxiang (CDC pa.gov)); [Pickett, Andrew \(CDC pa.gov\)](mailto:Pickett, Andrew (CDC pa.gov)); [Harduar-Morano, Laurel \(CDC pa.gov\)](mailto:Harduar-Morano, Laurel (CDC pa.gov)); [Bettigole, Cheryl \(CDC phila.gov\)](mailto:Bettigole, Cheryl (CDC phila.gov)); [Toro, Mayra \(CDC salud.pr.gov\)](mailto:Toro, Mayra (CDC salud.pr.gov)); felix.schmidt@salud.pr.gov; sesquilin@salud.pr.gov; jesirizarry@salud.pr.gov; raserrano@salud.pr.gov; encijar.hassan@salud.pr.gov; irisr.cardona@salud.pr.gov; [Zavala Mendoza, Eduardo \(CDC salud.pr.gov\)](mailto:Zavala Mendoza, Eduardo (CDC salud.pr.gov)); zaira.kianes@salud.pr.gov; ismael.a.rodriguez@salud.pr.gov; milton.martinezgamez@salud.pr.gov; jose.becerra@salud.pr.gov; anrivera@salud.pr.gov; [Roberts, Emais \(CDC palauhealth.org\)](mailto:Roberts, Emais (CDC palauhealth.org)); [Termeteet, Francis \(CDC palauhealth.org\)](mailto:Termeteet, Francis (CDC palauhealth.org)); [Udui, Ritter \(CDC palauhealth.org\)](mailto:Udui, Ritter (CDC palauhealth.org)); bbilimon@rmihealth.org; jillmccready@yahoo.com; [Lalita, Paul \(CDC gmail.com\)](mailto:Lalita, Paul (CDC gmail.com)); [Wase, Francyne \(CDC gmail.com\)](mailto:Wase, Francyne (CDC gmail.com)); [Huard, Richard \(CDC health.ri.gov\)](mailto:Huard, Richard (CDC health.ri.gov)); [Bandy, Utpala \(CDC health.ri.gov\)](mailto:Bandy, Utpala (CDC health.ri.gov)); [Mihalakos, Alysia \(CDC health.ri.gov\)](mailto:Mihalakos, Alysia (CDC health.ri.gov)); [Alexanderscott, Nicole \(CDC health.ri.gov\)](mailto:Alexanderscott, Nicole (CDC health.ri.gov)); [Dixit, Seema \(CDC health.ri.gov\)](mailto:Dixit, Seema (CDC health.ri.gov)); Philip.Chan@health.ri.gov; [Novais, Ana \(CDC health.ri.gov\)](mailto:Novais, Ana (CDC health.ri.gov)); Ewa.King@health.ri.gov; Jaclyn.Porfilio@health.ri.gov; Jasper.Frank@ohhs.ri.gov; Kurt.Hinck.CTR@health.ri.gov; [Comella, Jaime \(CDC health.ri.gov\)](mailto:Comella, Jaime (CDC health.ri.gov)); Kristine.Campagna@health.ri.gov; [Quilliam, Daniela \(CDC health.ri.gov\)](mailto:Quilliam, Daniela (CDC health.ri.gov)); Thomas.McCarthy@health.ri.gov; Jennifer.Clarke@health.ri.gov; [Clyne, Ailis \(CDC health.ri.gov\)](mailto:Clyne, Ailis (CDC health.ri.gov)); [bornschein, suzanne \(CDC health.ri.gov\)](mailto:bornschein, suzanne (CDC health.ri.gov)); [Marak, Theodore \(CDC health.ri.gov\)](mailto:Marak, Theodore (CDC health.ri.gov)); edward.simmer@dhec.sc.gov; [Bell, Linda \(CDC dhec.sc.gov\)](mailto:Bell, Linda (CDC dhec.sc.gov)); kellyjm1@dhec.sc.gov; [Traxler, Brannon \(CDC dhec.sc.gov\)](mailto:Traxler, Brannon (CDC dhec.sc.gov)); davidsne@dhec.sc.gov; [Drociuk, Dan \(CDC dhec.sc.gov\)](mailto:Drociuk, Dan (CDC dhec.sc.gov)); [Diedhiou, Abdoulaye \(CDC dhec.sc.gov\)](mailto:Diedhiou, Abdoulaye (CDC dhec.sc.gov)); frostrk@dhec.sc.gov; brittwd@dhec.sc.gov; kackamj@dhec.sc.gov; [Blair, Jamie \(CDC dhec.sc.gov\)](mailto:Blair, Jamie (CDC dhec.sc.gov)); [White, Stephen \(CDC dhec.sc.gov\)](mailto:White, Stephen (CDC dhec.sc.gov)); [Malsam-Rysdon, Kim \(CDC state.sd.us\)](mailto:Malsam-Rysdon, Kim (CDC state.sd.us)); [Clayton, Joshua \(CDC state.sd.us\)](mailto:Clayton, Joshua (CDC state.sd.us)); [Southern, Tim \(CDC state.sd.us\)](mailto:Southern, Tim (CDC state.sd.us)); [Thomas, Kaitlin \(CDC state.sd.us\)](mailto:Thomas, Kaitlin (CDC state.sd.us)); [Shaffner, Julia \(CDC tn.gov\)](mailto:Shaffner, Julia (CDC tn.gov)); [Dunn, John \(CDC tn.gov\)](mailto:Dunn, John (CDC tn.gov)); [Piercey, Lisa \(CDC tn.gov\)](mailto:Piercey, Lisa (CDC tn.gov)); richard.steece@tn.gov; [Hellerstedt, John \(CDC dshs.texas.gov\)](mailto:Hellerstedt, John (CDC dshs.texas.gov)); [Pont, Stephen \(CDC dshs.texas.gov\)](mailto:Pont, Stephen (CDC dshs.texas.gov)); [Shuford, Jennifer \(CDC dshs.texas.gov\)](mailto:Shuford, Jennifer (CDC dshs.texas.gov)); [Martinez, Diana \(CDC dshs.texas.gov\)](mailto:Martinez, Diana (CDC dshs.texas.gov)); Kirk.Cole@shs.texas.gov; varun.shetty@dshs.texas.gov; [Encarnacion, Justa \(CDC doh.vi.gov\)](mailto:Encarnacion, Justa (CDC doh.vi.gov)); [Ellis, Esther \(CDC doh.vi.gov\)](mailto:Ellis, Esther (CDC doh.vi.gov)); donna.christensen@vi.gov; nicole.syms@doh.vi.gov; jahnesta.ritter@doh.vi.gov; monife.stout@doh.vi.gov; [Williams, Ovid \(CDC doh.vi.gov\)](mailto:Williams, Ovid (CDC doh.vi.gov)); tai.hunte@doh.vi.gov; Marlon.Lawrence@doh.vi.gov; Valerie.Mac@vi.gov; [Ellis, Brett \(CDC doh.vi.gov\)](mailto:Ellis, Brett (CDC doh.vi.gov)); Shanna.O'Reilly@vi.gov; [Hofmann, Michelle \(CDC utah.gov\)](mailto:Hofmann, Michelle (CDC utah.gov)); jbeckr@utah.gov; jessicapayne@utah.gov; [Borski, Heather \(CDC utah.gov\)](mailto:Borski, Heather (CDC utah.gov)); [Lakin, Rich \(CDC utah.gov\)](mailto:Lakin, Rich (CDC utah.gov)); kmcculley@utah.gov; kbabitz@utah.gov; blwcampos@utah.gov; rsaunders@utah.gov; jwagner@utah.gov; [Kelso, Patsy \(CDC vermont.gov\)](mailto:Kelso, Patsy (CDC vermont.gov)); [Pringle, Julia \(CDC partner.vermont.gov\)](mailto:Pringle, Julia (CDC partner.vermont.gov)); Helen.Reid@vermont.gov; Kayla.Donahue@partner.vermont.gov; Tracy.dolan@vermont.gov; [Levine, Mark \(CDC vermont.gov\)](mailto:Levine, Mark (CDC vermont.gov)); [Achilles, Cheryl \(CDC vermont.gov\)](mailto:Achilles, Cheryl (CDC vermont.gov)); [Read, Jennifer \(CDC vermont.gov\)](mailto:Read, Jennifer (CDC vermont.gov)); [Hammond, Jessie \(CDC vermont.gov\)](mailto:Hammond, Jessie (CDC vermont.gov)); amanda.lascale@vermont.gov; [Nicolai, Laura Ann \(CDC vermont.gov\)](mailto:Nicolai, Laura Ann (CDC vermont.gov)); Veronica.Fialkowski@vermont.gov; Amanda.Jones@vermont.gov; Julie.Corwin@vermont.gov; Gillian.Morgan@vermont.gov; [Fritch, William \(CDC vermont.gov\)](mailto:Fritch, William (CDC vermont.gov)); [Diskin, Elena \(CDC vdh.virginia.gov\)](mailto:Diskin, Elena (CDC vdh.virginia.gov)); [Falk, Jonathan \(CDC vdh.virginia.gov\)](mailto:Falk, Jonathan (CDC vdh.virginia.gov)); [McCombs, Katherine \(CDC vdh.virginia.gov\)](mailto:McCombs, Katherine (CDC vdh.virginia.gov)); [Forlano, Laurie \(CDC vdh.virginia.gov\)](mailto:Forlano, Laurie (CDC vdh.virginia.gov)); [Peake, Lilian \(CDC vdh.virginia.gov\)](mailto:Peake, Lilian (CDC vdh.virginia.gov)); rebecca.tomazin@vdh.virginia.gov; [Levine, Seth \(CDC vdh.virginia.gov\)](mailto:Levine, Seth (CDC vdh.virginia.gov)); [Stephens, Katie \(CDC vdh.virginia.gov\)](mailto:Stephens, Katie (CDC vdh.virginia.gov)); [Holsinger, Caroline \(CDC vdh.virginia.gov\)](mailto:Holsinger, Caroline (CDC vdh.virginia.gov)); [Saady, Dawn \(CDC vdh.virginia.gov\)](mailto:Saady, Dawn (CDC vdh.virginia.gov)); [Kurkjian, Katie \(CDC vdh.virginia.gov\)](mailto:Kurkjian, Katie (CDC vdh.virginia.gov)); [Young, Laura \(CDC vdh.virginia.gov\)](mailto:Young, Laura (CDC vdh.virginia.gov)); kfroeb@cdcfoundation.org; bdoyle@cdcfoundation.org; [Mayer, Harry \(OS/ASPR/EMMO\)](mailto:Mayer, Harry (OS/ASPR/EMMO)); [Paxman, Dalton G \(HHS/OASH\)](mailto:Paxman, Dalton G (HHS/OASH)); [Falone, Emily \(OS/ASPR/EMMO\)](mailto:Falone, Emily (OS/ASPR/EMMO)); [Lalvani, Mahak \(OS/OASH\)](mailto:Lalvani, Mahak (OS/OASH)); cynthia.harry@doh.wa.gov; [Holshue, Michelle \(CDC doh.wa.gov\)](mailto:Holshue, Michelle (CDC doh.wa.gov)); Jay.miller@doh.wa.gov; [Goldoft, Marcia MG \(CDC doh.wa.gov\)](mailto:Goldoft, Marcia MG (CDC doh.wa.gov)); [Lindquist, Scott SL \(CDC doh.wa.gov\)](mailto:Lindquist, Scott SL (CDC doh.wa.gov)); Ayne.Amjad@wv.gov; [W.Haynes, Donnie \(CDC wv.gov\)](mailto:W.Haynes, Donnie (CDC wv.gov)); [Cibrik, Sharon \(CDC wv.gov\)](mailto:Cibrik, Sharon (CDC wv.gov)); [D.Clark, Christi \(CDC wv.gov\)](mailto:D.Clark, Christi (CDC wv.gov)); [Del.Rosario, Maria \(CDC wv.gov\)](mailto:Del.Rosario, Maria (CDC wv.gov)); [Atkins, Amy \(CDC wv.gov\)](mailto:Atkins, Amy (CDC wv.gov)); Shawn.O.Farley@wv.gov; [McBee, Shannon \(CDC wv.gov\)](mailto:McBee, Shannon (CDC wv.gov)); Christina.R.Mullins@wv.gov; [Thomasson, Erica \(CDC wv.gov\)](mailto:Thomasson, Erica (CDC wv.gov)); [Westergaard, Ryan \(CDC dhs.wisconsin.gov\)](mailto:Westergaard, Ryan (CDC dhs.wisconsin.gov)); [Gibbons-Burgener, Suzanne \(CDC dhs.wisconsin.gov\)](mailto:Gibbons-Burgener, Suzanne (CDC dhs.wisconsin.gov)); [Segaloff, Hannah \(CDC dhs.wisconsin.gov\)](mailto:Segaloff, Hannah (CDC dhs.wisconsin.gov)); cari.sloma@wyo.gov; [Harrist, Alexia \(CDC wyo.gov\)](mailto:Harrist, Alexia (CDC wyo.gov)); sheryl.roub@wyo.gov; buck.mcveigh@wyo.gov; renny.mackay@wyo.gov; [Dijkstal1, Dirk \(CDC wyo.gov\)](mailto:Dijkstal1, Dirk (CDC wyo.gov)); joseph.reed@wyo.gov; keith.harris1@wyo.gov; [Sparkle Mischer, Virginia Dargan; Strickland, Colten \(CDC delaware.gov\); Ramirez, Judith M \(DHSS](mailto:Sparkle Mischer, Virginia Dargan; Strickland, Colten (CDC delaware.gov); Ramirez, Judith M (DHSS)

Cc:

[Bensyl, Diana M. \(CDC/DDPHSIS/CGH/DGHP\)](mailto:Bensyl, Diana M. (CDC/DDPHSIS/CGH/DGHP)); [Acharya, Jessica \(CDC/DDPHSIS/CPDR/DSLRL\)](mailto:Acharya, Jessica (CDC/DDPHSIS/CPDR/DSLRL)); [IR#0588 - KT DPH - Production_000176](mailto:Busacker, Ashley (CDC/DDNID/NCCDPHP/DRH); CDC IMS 2019 NCOV Response HDTF 1-3 Regional Support TM; CDC IMS 2019 NCOV Response HDTF 4/6 Regional Support TM; CDC IMS 2019 NCOV Response HDTF 5/10 Regional Support TM; CDC IMS 2019 NCOV Response HDTF 7-9 Regional Support TM; CDC IMS 2019 NCOV Response HDTF Deputies; Bair-Brake, Heather (ATSDR/OCOM); Fehrenbach, Nicole (CDC/DDNID/NCBDDD/DBDID); Byrne, Jennifer (CDC/DDID/NCEZID/DPEI); Byrkit, Ramona (CDC/DDID/NCEZID/DPEI); Pullani, Anita (CDC/DDID/NCEZID/DPEI); Brown, Vance R. (CDC/DDID/NCEZID/DPEI); Ewetola, Raimi (CDC/DDID/NCEZID/DPEI); Chadd, Phillippa (CDC/DDID/NCEZID/DPEI); CDC Health Dept Section; CDC IMS 2019 NCOV Response STLT TF HDS Comms Section; Gooch, James D. (ATSDR/OAD/OD); Roth, Joseph N. Jr. (CDC/DDPHSIS/CPDR/DSLRL); Shetty, Varun (CDC/DDID/NCEZID/DPEI); Steinberg, Jonathan (CDC/DDID/NCEZID/DPEI); Bafford, Nastocia (CDC/DDPHSIS/CSTLTS/DPIFS); Concepcion Acevedo, Jeniffer (CDC/DDPHSIS/CSTLTS/OD); O'Neill, Eduardo (CDC/DDPHSIS/CSTLTS/OD); Paz-Bailey, Gabriela</p></div><div data-bbox=)

(CDC/DDID/NCEZID/DVBD); Dewart, Courtney (CDC/DDPHSIS/CPR/DSLRL); Reid, Cathony (CDC/DDPHSIS/CSTLTS/DPIFS); Anaele, Beverly (CDC/DDPHSIS/CSTLTS/DPIFS); Klena, John D. (CDC/DDID/NCEZID/DHCPP); Hull, Torane (CDC/DDID/NCIRD/ISD); Jefferson, Randy (CDC/DDID/NCHHSTP/DSTDP); Manning, Susan (CDC/DDNID/NCCDPPH/DRH); Werner, Lora S. (ATSDR/OAD/OCHHA); Coaty, Kristen (CDC/DDID/NCIRD/ISD); Hewett, Rafe (CDC/DDID/NCIRD/ISD); Bushman, Dena (CDC/DDID/NCEZID/DPEI); Morrison, Melissa (CDC/DDPHSIS/CPR/DSLRL); James, Allison (CDC/DDID/NCEZID/DGMO); Furness, Bruce W. (CDC/DDID/NCHHSTP/DSTDP); Doyle, Tim (CDC/DDPHSIS/CPR/DSLRL); Marianni, Lisa (CDC/DDPHSS/OS/OTI); Rose, Tasleem (CDC/DDID/NCIRD/OD) (CTR); Roehl, Sheryl (CDC/DDID/NCIRD/OD) (CTR); Wisham, Dianne (CDC/DDNID/NCBDDD/DBDID) (CTR)

Subject: Health Department Weekly 08.06.21
Date: Friday, August 6, 2021 6:25:25 PM
Attachments: [image002.png](#)
[Festivals Toolkit 080421.pdf.pdf](#)
[RaceToEndCovid.pdf.pdf](#)
[Incentives with Immunization Funding.pdf.pdf](#)
[Incentives FAQs.pdf.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Health Department Weekly Email

August 6, 2021

Dear Health Department Colleagues,

Please see this week's news and noteworthy items below. Topics range widely and include eviction moratorium status, updated school guidance, a new festivals COVID-19 planning toolkit, vaccination incentives, and more.

Is there anything specific that you would like to see featured? Please do not hesitate to email any questions and suggestions to our Health Department Section Communications Team:

eoevent501@cdc.gov.

Thank you all for your continuing dedication to your communities,
STLT Support Task Force, Health Department Section

Breaking News

CDC Issues Eviction Moratorium Order in Areas of Substantial and High Transmission

CDC Director Dr. Rochelle Walensky signed on August 3, 2021 an order determining the evictions of tenants for failure to make rent or housing payments could be detrimental to public health control measures to slow the spread of SARS-CoV-2, the virus that causes COVID-19. This order will expire on October 3, 2021 and applies in United States counties experiencing substantial and high levels of community transmission levels of SARS-CoV-2.

For more detailed information, please see the [full media statement](#) and [link to order](#).

New + Notable

New Festivals and Other Multi-Day Large Gatherings: COVID-19 Planning

Toolkit

CDC has developed a new toolkit to help health departments prevent the spread of COVID-19 at multi-day events that are expected to draw large numbers of people. It includes checklists, resources, and a case study that state and local health departments, event planners, vendors, and other partners can use to anticipate and plan for some of the challenges they could encounter. Of particular concern now are numerous events with at least 20,000 attendees planned for this summer and fall in U.S. areas with substantial and high [levels](#) of COVID-19 transmission. Please review the attached document named **Festivals Toolkit 080421.pdf**.

CDC Updates K-12 School Guidance

CDC updated the *Guidance for COVID-19 Prevention in K-12 Schools* to align with CDC's existing [guidance for fully vaccinated people](#) and assist K-12 schools in opening for in-person instruction and remaining open. Additionally, the [Considerations for Case Investigation and Contact Tracing in K-12 Schools and Institutions of Higher Education \(IHEs\)](#) has been updated to align with new CDC guidance.

[CDC's Guidance for COVID-19 Prevention in K-12 Schools](#) includes recommendations for:

- Promoting vaccination among teachers, staff, families, and eligible students
- Universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status
- Implementation of layered prevention strategies to reduce the spread of COVID-19 in schools

[CDC's Considerations for Case Investigation and Contact Tracing in K-12 Schools and Institutions of Higher Education \(IHEs\)](#) highlights include:

- How case investigation and contact tracing--in combination with testing, isolation, and quarantine--are effective strategies to help prevent transmission of COVID-19 in K-12 schools
- How collaboration between schools and STLT health departments on reporting COVID-19 cases can facilitate timely case investigation and contact tracing in school settings
- Recommendations for students, staff, and educators, regardless of vaccination status, who have come into close contact with a person diagnosed with COVID-19

CDC has also updated the exception to the [close contact definition](#) for students in K-12 indoor classroom settings.

Given the importance of key services that schools offer and the benefits of in-person learning for students, it is critical for K-12 schools to open for in-person instruction and stay open. Working together, school leaders, local health departments and community members can take actions to keep schools open for in-person learning by protecting students, teachers, and school staff where they live, work, learn, and play.

New Set of 15 Priority Public Health Science Questions

The CDC's [Public Health Science Agenda for COVID-19](#) articulates key areas of scientific inquiry and opportunities to guide the development of actionable, evidence-based public health guidance to limit the spread and impact of SARS-CoV-2 and ultimately end the COVID-19 pandemic.

On August 4, 2021, CDC released a second update to the *Priority Public Health Science Questions* to help achieve objectives. The latest set of 15 priority public health questions span six major topic areas:

- Vaccines
- Variants
- Natural History, Reinfection, and Health Impact
- Prevention Strategies and Non-Pharmaceutical Interventions
- Testing
- Transmission Risk and Dynamics

Vaccine Updates

Secretary Becerra Extends PREP Act Coverage

With the flu season around the corner and understanding that health risks may increase for people who contract seasonal influenza at the same time as COVID-19, vaccination is the best way for most people to protect themselves against COVID-19 and seasonal flu. To ensure that the most people can get vaccinated as easily and conveniently as possible, HHS Secretary Becerra has taken action to extend PREP Act coverage to pharmacy techs and interns with proper training to administer seasonal flu vaccines to adults.

Expanding the scope of authorized vaccinators for seasonal influenza vaccine lessens the harm otherwise caused by COVID-19. This declaration anticipates the need for the adult population to receive COVID-19 and seasonal influenza vaccines throughout the 2021-2022 influenza season. We expect this action to help pharmacies meet the demand for both flu and COVID-19 vaccines this fall.

You can find more information about the PREP Act at [PHE.gov](https://www.phe.gov).

Update to COVID-19 Vaccination Incentive Policy

In alignment with newly announced White House initiatives to get more Americans vaccinated against COVID-19 and slow the spread of the Delta variant, we have updated our policy regarding the use of COVID-19 supplemental funding to purchase incentives for vaccine recipients. The new per person incentive cap is \$100. This is an increase over the previously established cap of \$25 per person.

Want to learn more? Please review the attached documents, **Incentives FAQs.pdf** and **Incentives with Immunization Funding.pdf**. Any further questions about incentives or the approval process can be directed to your CDC Program Operations Branch Project Officer.

Find a COVID-19 Vaccine Near You Via Text Message

[Vaccines.gov](https://vaccines.gov) is live, available in English and Spanish, and helping make it easier for individuals to access COVID-19 vaccines by connecting Americans with locations offering vaccines near them.

Individuals in the U.S. can now utilize a text messaging service to locate vaccine locations, available in both English and Spanish. Individuals can text their ZIP code to 438829 (GETVAX) and 822862 (VACUNA) to find three locations nearby that have vaccines available.

Website Updates

CDC COVID-19 New Information

[What's New & Updated | CDC](#)

School Considerations and Guidance

[Considerations for Case Investigation and Contact Tracing in K-12 Schools and Institutions of Higher Education \(IHEs\)](#)

[CDC's Guidance for COVID-19 Prevention in K-12 Schools](#)

[Know What to Expect at Your Child's K- 12 School or Child Care Program | CDC](#)

[How Schools Can Support COVID-19 Vaccination](#)

[CDC Launches New STEM Website](#)

Critical Populations Webpages

[A Guide for Community Partners Increasing COVID-19 Vaccine Uptake Among Members of Racial and Ethnic Minority Communities](#)

[COVID-19 Vaccine Monitoring Systems for Pregnant People](#)

NEW Vaccine Webpages

[What to Consider When Planning to Operate a COVID-19 Vaccine Clinic](#)

[Ways Health Departments Can Help Increase COVID-19 Vaccinations](#)

[Document Vaccinations at Standard and Mobile Clinics in VAMS](#)

[Scheduling Appointments for Recipients](#)

[How to Address COVID-19 Vaccine Misinformation | CDC](#)

[How to Tailor COVID-19 Information to Your Specific Audience](#)

COVID-19 Webpages

[CDC COVID Data Tracker](#)

[COVID-19 Mathematical Modeling | COVID-19 | CDC](#)

[CDC Public Health Science Agenda for COVID-19 | CDC](#)

[What to Know About HIV and COVID-19 | CDC](#)

[Health Departments: Information on COVID-19 | CDC](#)

Note: stay up to date with new and updated content on the COVID-19 website. Visit [What's New & Updated | CDC](#) for a comprehensive list of significant changes like new pages and guidance recommendations. You can search by topic and also sign up for email updates.

Notable Publications & Resources

New Race to End COVID Playbook

CDC has developed a *Race to End COVID* Playbook for planning and conducting community-based COVID-19 testing and vaccination events at racetracks. The events encourage participation by offering an incentive, namely the chance for participants to drive their own car around the track. These events, referred to as the *Race to End COVID*, are envisioned as partnerships between STLT health departments; NASCAR; and/or local racetracks, whether league-affiliated and/or

independently owned. An informational PDF named **RaceToEndCovid.pdf** is attached to this email and can be downloaded [here](#) for sharing with any interested partners. Additional info is posted on the following web pages:

- [Health Departments: Information on COVID-19 | CDC](#)
- [Communication Resources for Health Departments | CDC](#)
- [Print Resources | CDC](#)

MMWR Early Release

- [Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado, April–June 2021](#)
- [Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021](#)
- [Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021](#)

New Vaccine Equity Resources Available

Infographics containing information about the Delta Variant are available in both [English](#) and [Spanish](#).

As a part of the COVID-19 Vaccine Education Initiative, the Ad Council and COVID Collaborative created [video clips](#) to address making informed decisions about COVID vaccination in light of the building back trust from the Tuskegee Study.

Back to School Toolkit

This [toolkit](#) has resources for school district leaders, teachers, parent leaders, and school supporters that want to help increase confidence in and uptake of COVID-19 vaccines in their school communities, answer questions, and outline school guidance about COVID-19. It includes information from CDC and new, tailored materials from the HHS COVID-19 Public Education Campaign.

Please feel free to share these resources with appropriate partners.

Guide to On-Site Vaccination Clinics for School

Over the next 6 weeks, more than 50 million students will head back to school. For young people, getting vaccinated right away is the best way back to the things they love – like playing sports and spending time with friends and loved ones. However, as of the end of July, only 42% of Americans age 12-17 years had received at least one dose of a COVID-19 vaccination. Now is the time to make sure young Americans get vaccinated.

[Host Pop-Up COVID-19 Vaccine Clinics for Students Going Back to School!](#)

Get CDC's Science at Its Source!

Science Clips is produced weekly to enhance awareness of emerging scientific knowledge for the public health community. Check out [CDC Science Clips](#) and pass it on to colleagues!

Attachments

Incentives with Immunization Funding.pdf

Incentives FAQs.pdf

RaceToEndCovid.pdf

Festivals Toolkit 080421.pdf

[cdc.gov/coronavirus](https://www.cdc.gov/coronavirus)

From: [Morbidity and Mortality Weekly Report](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: MMWR - Account Created in ScholarOne Manuscripts
Date: Tuesday, August 3, 2021 9:56:16 PM

03-Aug-2021

Dear Dr. Winter:

A manuscript titled, "Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021 (CDC-2021-0104)," has been submitted by Dr. Alyson Cavanaugh to MMWR.

You are listed as a co-author for this manuscript. The online system, ScholarOne Manuscripts, automatically creates a user account for you. Your USER ID and PASSWORD for your account is as follows:

Site URL:

[https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfCOta8av\\$](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfCOta8av$)

USER ID: kathleen.winter@ky.gov

PASSWORD: For security reasons your password is not contained in this email. To set your password click the link below.

[https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?URL_MASK=621e59fdaaf94de8a0771f540c68a7b4___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfIQS3JHy$)

[URL_MASK=621e59fdaaf94de8a0771f540c68a7b4___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfIQS3JHy\\$](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?URL_MASK=621e59fdaaf94de8a0771f540c68a7b4___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfIQS3JHy$)

You can use the above USER ID and PASSWORD (once set) to log in to the site and check the status of papers you have authored/co-authored. Please log in to

[https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfCOta8av\\$](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfCOta8av$) to update your account information via the edit account tab at the top right.

Thank you for your participation.

Sincerely,

Editorial Office, MMWR

Log in to Remove This Account - [https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?URL_MASK=091a67f2e2b04a3f8b40f728dd5aaa14___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfBHDrylr$)
[URL_MASK=091a67f2e2b04a3f8b40f728dd5aaa14___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfBHDrylr\\$](https://urldefense.com/v3/___https://mc.manuscriptcentral.com/mmwr?URL_MASK=091a67f2e2b04a3f8b40f728dd5aaa14___!!Db6frn15oIvDD3UI!2UKvgCWPHWBWQNh--IEz5KXX4mXbj9Tj0bSsaulutitkBJCwfLo9H0obCkGfBHDrylr$)

From: [Centers for Disease Control and Prevention](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: News: Immunization MMWRs Update - 8/6/2021
Date: Friday, August 6, 2021 2:43:40 PM

Prevention of disease, disability, and death through immunization and by control of respiratory and related diseases.



[Subscribe now](#) to receive this distribution email.



You are subscribed to CDC News: Immunization-related MMWRs email subscription service.

This message serves to inform you that one or more MMWRs have recently been added to the MMWR page and are [now available](#).

Vaccine related articles:

- Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥ 65 Years — COVID-NET, 13 States, February–April 2021
- Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021
- Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

[View now](#)



Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

[Questions or Problems](#) | [Unsubscribe](#)

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Subject: NOT FOR DISTRIBUTION: EMBARGOED: CDC Science Brief SARS-COV-2 INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY
Date: Friday, October 29, 2021 7:35:40 PM
Attachments: [image.png](#)
[Outlook-dtyzt3vj.png](#)
[Infection and Vaccine Induced Immunity Science Brief v10292021 DRAFT.docx](#)
Importance: High



*****CLOSE HOLD: NOT FOR DISTRIBUTION ***** EMBARGOED *****

Sent to State Epidemiologists and the CSTE Executive Board,

Please find attached an **EMBARGOED** copy of the new CDC Science Brief: SARS-COV-2 INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY. **EMBARGOED: This document CANNOT be shared until it has been posted on the CDC website.** We *anticipate* the document will be posted tonight but we DO NOT have confirmation of the scheduled CDC go live or if it will happen today. THUS, I am asking you please **DO NOT SHARE** until you have confirmed the document is live on the CDC website.

The CSTE National Office is in contact with CDC and will work to notify you all once it has gone live.

Janet Hamilton, MPH (she, her)
Executive Director
CSTE

*****CLOSE HOLD: NOT FOR DISTRIBUTION ***** EMBARGOED *****

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
Business Hours Line: 770.458.3811
After-Hours Line: 678.256.3945

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: actual numbers, please? -DRAFT response
Date: Thursday, August 12, 2021 10:08:31 AM

I totally agree with Kevin – it’s not our battle to fight, we are just adding a nugget of data to the understanding of the overall situation. I think your answer is great. The only addition I would suggest *if you have it easily available* is to add references for some of those observational studies that you mentioned in the first sentence, “. . . several observational studies have shown significantly lower incidence of infection among those with prior SARS-CoV-2 infections compared to those without previous infections.”

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 12, 2021 9:56 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: actual numbers, please? -DRAFT response

Hi Alyson,

I realize you may have already responded, and I have nothing significant just some very minor edits.

I think it best to do what you have done, which is to keep the response brief and to the point. The inquiry I believe is trying to pull us into a larger policy and ethical debate.

Nicely done.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, August 11, 2021 8:40 AM

To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: FW: actual numbers, please? -DRAFT response

Good morning,

This is a message received in regards to MMWR. Attached is drafted response. Please let me know if you think any additional changes to the drafted response are needed.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Matt Birchmeier <mjbirchmeier@hotmail.com>

Sent: Saturday, August 7, 2021 8:30 AM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: actual numbers, please?

Dr. Cavanaugh,

I read with interest your article here. However, as one PhD scientist to another, I found that the text you presented was completely lacking in a very important detail: what was the actual odds of someone who has previously been infected, of becoming re-infected during the study? You cite the 2.3X higher risk, but it matters greatly whether the risk of reinfection is 0.1% or 1% or 10% or 90%. Certainly, those numbers were generated during your study. You should present them. The Missouri study that I linked below found a <1% rate of reinfection among those who had significant illnesses. Furthermore, particularly hard hit areas like Detroit, Michigan, still seem to be benefiting from a strong degree of natural immunity, 1+ year after the worst of the pandemic, in spite of a low vaccination rate.

There is a very good argument that the benefits of vaccinating previously infected people in


the US are less than the benefit of vaccinating naive populations elsewhere in the world. That question may be an ethical debate for another day. But hopefully you can see that the absolute numbers around reinfection are important in that debate! If the risk of reinfection is 90%, then certainly that vaccination in Kentucky is important, both from an ethical and policy perspective. If the risk of reinfection is 0.7%, then perhaps someone in Vietnam should receive that dose.

Please update your publication at the earliest opportunity, to better inform the American public of what the true risks around COVID are. Most media outlets seem content to scare people rather than truly inform them; I would hope for much better from the CDC. We CAN handle the truth, if only you would tell the whole truth.

Best regards,

Matthew J. Birchmeier, Ph.D.

https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w




[Reduced Risk of
Reinfection with SARS-
CoV-2 After COVID-19
Vaccination — Kentucky,
May–June 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w)

Although laboratory evidence suggests that antibody responses following COVID-19 vaccination provide better neutralization of some circulating variants than does natural infection (1,2), few real-world epidemiologic studies

www.cdc.gov

<https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness>

[Study Finds COVID-19
Reinfection Rate Less Than
1% for Those with Severe](https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness)



[Illness - MU School of Medicine](#)

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from medicine.missouri.edu

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: actual numbers, please? -DRAFT response
Date: Thursday, August 12, 2021 9:56:17 AM
Attachments: [actual numbers response ks.docx](#)

Hi Alyson,

I realize you may have already responded, and I have nothing significant just some very minor edits.

I think it best to do what you have done, which is to keep the response brief and to the point. The inquiry I believe is trying to pull us into a larger policy and ethical debate.

Nicely done.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 11, 2021 8:40 AM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: actual numbers, please? -DRAFT response

Good morning,

This is a message received in regards to MMWR. Attached is drafted response. Please let me know if you think any additional changes to the drafted response are needed.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Matt Birchmeier <mjbirchmeier@hotmail.com>

Sent: Saturday, August 7, 2021 8:30 AM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: actual numbers, please?

Dr. Cavanaugh,

I read with interest your article here. However, as one PhD scientist to another, I found that the text you presented was completely lacking in a very important detail: what was the actual odds of someone who has previously been infected, of becoming re-infected during the study? You cite the 2.3X higher risk, but it matters greatly whether the risk of reinfection is 0.1% or 1% or 10% or 90%. Certainly, those numbers were generated during your study. You should present them. The Missouri study that I linked below found a <1% rate of reinfection among those who had significant illnesses. Furthermore, particularly hard hit areas like Detroit, Michigan, still seem to be benefiting from a strong degree of natural immunity, 1+ year after the worst of the pandemic, in spite of a low vaccination rate.


There is a very good argument that the benefits of vaccinating previously infected people in the US are less than the benefit of vaccinating naive populations elsewhere in the world. That question may be an ethical debate for another day. But hopefully you can see that the absolute numbers around reinfection are important in that debate! If the risk of reinfection is 90%, then certainly that vaccination in Kentucky is important, both from an ethical and policy perspective. If the risk of reinfection is 0.7%, then perhaps someone in Vietnam should receive that dose.

Please update your publication at the earliest opportunity, to better inform the American public of what the true risks around COVID are. Most media outlets seem content to scare people rather than truly inform them; I would hope for much better from the CDC. We CAN handle the truth, if only you would tell the whole truth.

Best regards,

Matthew J. Birchmeier, Ph.D.

https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w




[Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR](#)

Although laboratory evidence suggests that antibody responses following

COVID-19 vaccination provide better neutralization of some circulating variants than does natural infection (1,2), few real-world epidemiologic studies

www.cdc.gov

<https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness>



[Study Finds COVID-19 Reinfection Rate Less Than 1% for Those with Severe Illness - MU School of Medicine](https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness)

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from

medicine.missouri.edu

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Wednesday, August 4, 2021 7:43:24 AM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw dat ks.docx](#)

Hello Alyson,

A few additional edits/comments for your consideration. Sorry to be late.

Best,

Kevin

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Wednesday, August 4, 2021 7:09 AM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

I think it looks great, and I do like the protective OR's now.

I only found an additional period, an additional space, and a missing comma worth revising. I think the rest was fine with Kathleen's revisions.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Tuesday, August 3, 2021 11:25 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick,

Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Tuesday, August 3, 2021 9:58 PM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Tuesday, August 3, 2021 9:46 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,

Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 12:17 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:09 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>
Sent: Monday, August 2, 2021 5:09 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review


My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review



Document Description

Filename:	MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Targeted Completion Date:	8/3/2021
Forecasted Completion:	8/16/2021
Intended Use:	Publication: MMWR: Recommendations & Reports
Path:	/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19

Audience:

vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Topics:

Public health, medical professionals, and general public

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Wednesday, August 4, 2021 7:09:03 AM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw dat.docx](#)

I think it looks great, and I do like the protective OR's now.

I only found an additional period, an additional space, and a missing comma worth revising. I think the rest was fine with Kathleen's revisions.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Tuesday, August 3, 2021 11:25 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, August 3, 2021 9:58 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,
Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 2:25 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 12:17 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>
Sent: Monday, August 2, 2021 5:09 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

**MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection
May through June, 2021 Kentucky**

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date:

8/3/2021

Forecasted Completion:

8/16/2021

Intended Use:

Publication: MMWR: Recommendations & Reports

Path:

/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Audience:

Public health, medical professionals, and general public

Topics:

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE
Date: Monday, August 2, 2021 10:23:18 AM

Good morning all,

Just to update – the report got stuck in JIC clearance but is now escalated for expedited review. I have not yet received any official feedback, but I received notification that it is still expected this report gets published Friday. I was told to expect feedback this afternoon and have revisions prepared/submitted by this evening. I will work to do that, if possible.

If you haven't already e-mailed COI form, please do so by close of business today.

In addition, please send me a separate email so that I can archive for records that statement:

"I, FULL NAME , agree to be included as an author on the manuscript, "**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**" and certify that I meet the qualifications for authorship for this article

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Saturday, July 31, 2021 8:30 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: COI_disclosure forms - due COB Monday

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 10:21:27 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC dat.docx](#)

I think I only had one or two comments to consider.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 10:00 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

One more change to be aware of. I changed the reference order. One of the lab studies focuses more on reduced neutralization for convalescent plasma on newer variants, but not specifically on vaccination. The order is more appropriate to the lines in the manuscript now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the

individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:51 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Thank you, Alyson. I think you have done an admirable job.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:42 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health

275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:42:07 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP)

<connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 8:33 AM

To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated ☺

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Thursday, August 5, 2021 8:25 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:59:32 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)

One more change to be aware of. I changed the reference order. One of the lab studies focuses more on reduced neutralization for convalescent plasma on newer variants, but not specifically on vaccination. The order is more appropriate to the lines in the manuscript now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:51 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Thank you, Alyson. I think you have done an admirable job.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:42 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior

reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 8:52:51 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy ks.docx](#)

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on report no. 1464
Date: Wednesday, July 28, 2021 6:58:53 PM

Thank you!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Wednesday, July 28, 2021 5:40 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Comments on report no. 1464

Thank you, Alyson. I made a couple of edits and comments in the sharepoint document.

I have no edits/comments on the tables.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, July 27, 2021 6:24 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Comments on report no. 1464

Hi all,

Here are comments from MMWR from pre-review. In general, I agree with most edits.

- I agree with suggestion to use Figure 1 in supplemental and include the three tables in the MMWR.
- The one section I am unsure of is Page 5. This paragraph on single dose was added per comments from vaccine task force. Any suggestions for shortening would be appreciated, but I think some talk on the topic

is needed.

- For the actual manuscript, if you have suggestions/edits/comments, please use the link: https://kymsoffice-my.sharepoint.com/:w:/g/personal/alyson_cavanaugh_ky_gov/EZYxVWqbJ1pFnaIdyX75zHYBBd3cJK1e16C3m-hZ0jUkPQ

I plan to resubmit early morning (6am ish) on 7/29/21. The next submission step is higher levels of CDC clearance (CHEO/JIC). This is nearing the end of the process for clearance.

FYI – they edited the tables without track changes, so I will need to make some adjustments. Table 3 is confusing as laid out. I need to check these in more detail since track changes weren't used. If you have changes on tables, let me know. There is not a sharedrive link for tables.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Sent: Tuesday, July 27, 2021 4:19 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <lyn3@cdc.gov>
Subject: Comments on report no. 1464

Dear Dr. Cavanaugh,

I appreciated the opportunity to review your draft manuscript (**Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021**) on behalf of *MMWR* before it undergoes further COVID-19 Response pre-clearance and JIC clearance.

I've made a number of edits to your manuscript in track changes in the attached files to enhance clarity and to further align with *MMWR* author guidelines, and have also included some comments and questions. You do not need to accept any edits that may have inadvertently introduced inaccuracies or deviated from the original intent of the narrative. However, please accept all other edits and make a concerted effort to address the comments and questions before sending a clean version to the next stage of pre-clearance. This will ultimately help facilitate more timely processing of the manuscript once it is eventually submitted to *MMWR* for official consideration of publication.

Please pay attention to the following:

1. MMWR reports are allowed to have a maximum of 3 tables and/or figures in any combination; you have submitted 3 tables and 1 figure; I suggest that you make the figure a supplementary figure; it will be archived in CDC Stacks, and there will be a clickable link within the report to access it.
2. I formatted your tables for MMWR; in the future, please be aware that table cells cannot have any hard returns nor can there be any empty cells.

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance. Once cleared by JIC, you will then be directed to submit the manuscript to MMWR via ScholarOne (<https://mc.manuscriptcentral.com/mmwr>); at that time, please remember to include an ICMJE conflict of interest form for each co-author with your submission. If there is a group author on the byline, then the persons listed in the group will be indexed in PubMed as contributors rather than authors, and no ICMJE form is necessary for those persons.

As your manuscript continues through clearance, please remember that MMWR allows up to 1,650 words for COVID-19 reports and up to 10 references. You and your coauthors will likely receive requests for additional narrative to be added from the next several reviewers; but please ensure that the final submission to MMWR is less than 1,650 words with no more than 10 references or it will require another round of editorial review, which could delay processing of the report.

Please let me know if you have any questions.

With kind regards,

Jacqueline Gindler, MD
Editor, MMWR Weekly
404-639-8829
jgindler@cdc.gov

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Friday, July 30, 2021 7:51:57 PM
Attachments: [image001.png](#)
[COVID-19 MMWR Comms Package Reinfection and Vaccination Status DRAFT for Clearance Review kou4 AC ks.docx](#)

Hi Alyson,

Couple of comments for the comms package.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 7:27 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>

Sent: Friday, July 30, 2021 6:57 PM

To: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <yks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eoevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>

Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <yks0@cdc.gov>

Sent: Friday, July 30, 2021 5:04 PM

To: Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eoevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>

Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMWR **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance](#)

[Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333

404.808.4485 (cell)

vks0@cdc.gov

From: [Alexander, Kelly N \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Stack, Steven J \(CHFS DPH\)](#)
Subject: Re: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Friday, July 30, 2021 8:49:40 PM
Attachments: [image001.png](#)

Thank you.

Kelly N. Alexander, J.D., M.A.
Chief of Staff
Kentucky Department for Public Health

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Friday, July 30, 2021 7:53 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Spicer, Kevin B (CHFS DPH DEHP); Alexander, Kelly N (CHFS DPH); Stack, Steven J (CHFS DPH)
Subject: Fwd: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Alyson,
Yes, Susan Dunlap and Kelly Alexander should be included for communications.

Congrats on another great paper. This is really important work and I am so grateful for your effort in pulling this together.

I cc-ed Kelly and Dr. Stack here.

Get [Outlook for iOS](#)

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 7:26 PM
To: Winter, Kathleen T (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Spicer, Kevin B (CHFS DPH DEHP)
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>
Sent: Friday, July 30, 2021 6:57 PM
To: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>
Sent: Friday, July 30, 2021 5:04 PM
To: Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR)

<gmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>


Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMWR **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
vks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:13:51 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks2.docx](#)

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH

DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>

Sent: Thursday, August 5, 2021 4:15 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:02:54 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks.docx](#)

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:55:05 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks3.docx](#)

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Sent: Thursday, August 5, 2021 9:03 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 7:48 PM

To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday’s eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I’ll request the same from reviewers.

If anything needs to be deconflicted, I’ll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Glick, Connor \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 11:05:16 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC CG.docx](#)

Only a minor suggestion or two. Thanks!

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:55 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and

exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS

Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Friday, August 6, 2021 5:52:20 AM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC CG2.docx](#)

I have to submit before 7. I am going to look at everything one or two more times but I believe this will be the version used.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Sent: Thursday, August 5, 2021 11:05 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Final Proof of Your Early Release

Only a minor suggestion or two. Thanks!

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:55 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

***NOTICE OF CONFIDENTIALITY:** This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Thursday, August 5, 2021 3:10 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Final Proof of Your Early Release

Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 7:48:08 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC.docx](#)

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C

Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Final Proof of Your Early Release

Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Alexander, Kelly N \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 7:33:38 PM

Thank you

Kelly N. Alexander, J.D., M.A.
Chief of Staff
Kentucky Department for Public Health
Cabinet for Health and Family Services
275 East Main Street
Frankfort, KY 40621
Phone: 502-564-3970
Email: Kelly.Alexander@ky.gov



CONFIDENTIALITY NOTICE: This e-mail message, including any attachment, is the sole use of the intended recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender, by e-mail, and destroy all copies of this message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Thursday, August 5, 2021 5:42 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>

Sent: Thursday, August 5, 2021 5:13 PM

To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>

Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ld0@cdc.gov>

Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Alexander, Kelly N \(CHFS DPH\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: RE: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 8:13:05 PM
Attachments: [MMWR Reinfection Rollout for 8 6 21 kw ks.docx](#)

Hi Alyson,

Some additional edits/comments for consideration.

Thanks.

Kevin

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Thursday, August 5, 2021 5:50 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

With my edits. Adding Kelly.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>

Sent: Thursday, August 5, 2021 5:13 PM

To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>

Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>

Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥ 65 Years — 13 states, COVID-NET, February–April 2021

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Alexander, Kelly N \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: RE: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 5:54:15 PM

Thank you so much – and I will need to clarify about spokesperson.

I am uninvolved with the other MMWRs in this rollout and shouldn't be listed as spokesperson for them.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Thursday, August 5, 2021 5:50 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

With my edits. Adding Kelly.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 5:13 PM
To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>
Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>
Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)
Morbidity and Mortality Weekly Report (MMWR)
Center for Surveillance, Epidemiology, and Laboratory Services
vco8@cdc.gov
(404) 639-6434

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Alexander, Kelly N \(CHFS DPH\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: Re: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 8:54:20 PM

Thank you

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:13:03 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Subject: RE: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi Alyson,

Some additional edits/comments for consideration.

Thanks.

Kevin

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Thursday, August 5, 2021 5:50 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>

Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

With my edits. Adding Kelly.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 5:22 PM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>

Sent: Thursday, August 5, 2021 5:13 PM

To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>

Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>

Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: Alexander, Kelly N (CHFS DPH)
 To: Cavanaugh, Alyson (CHFS DPH DEHP)
 Cc: Thoroughman, Douglas (CHFS DPH); Winter, Kathleen T (CHFS DPH DEHP); Spicer, Kevin B (CHFS DPH DEHP)
 Subject: RE: Questions, Concerns & Observations about CDC "study" used by "Safer" Federal Task Force "justify" "vaccination" mandates of federal employees who have COVID-19 antibodies from previous infection - end Pandemic & COVID-19 mandates & restrictions
 Date: Saturday, October 16, 2021 6:06:16 PM

Thank you

Kelly N. Alexander, J.D., M.A.
 Chief of Staff
 Kentucky Department for Public Health
 Cabinet for Health and Family Services
 275 East Main Street
 Frankfort, KY 40621
 Phone: 502-564-3970
 Email: Kelly.Alexander@ky.gov



Kentucky Public Health

CONFIDENTIALITY NOTICE: This e-mail message, including any attachment, is the sole use of the intended recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender, by e-mail, and destroy all copies of this message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
 Sent: Friday, October 15, 2021 9:55 AM
 To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>
 Cc: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
 Subject: FW: Questions, Concerns & Observations about CDC "study" used by "Safer" Federal Task Force "justify" "vaccination" mandates of federal employees who have COVID-19 antibodies from previous infection - end Pandemic & COVID-19 mandates & restrictions
 Importance: High

Kelly,

I am just sharing the below e-mail for your awareness.

Alyson M. Cavanaugh, DPT, MPH, PhD
 Lieutenant, U.S. Public Health Service Corps
 CDC Epidemic Intelligence Service Officer
 Assigned to Kentucky Department for Public Health
 275 East Main Street
 Frankfort, KY 40621
 E-mail: Alyson.cavanaugh@ky.gov
 Phone: 502-564-3261 x4231
 Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Paula Reitan <paula.reitan@outlook.com>

Sent: Thursday, October 14, 2021 9:54 PM

To: pds1@cdc.gov; lzn6@cdc.gov; saferfederalworkforce@gsa.gov; lzn6@cdc.gov; afauci@niaid.nih.gov

Cc: nationalir@nsa.gov; pollard@nteu.org; Pollard Calvin L [NTEU NON-IRS] [Contractor] <Calvin.L.Pollard@nteu.org>

Subject: Questions, Concerns & Observations about CDC "study" used by "Safer" Federal Task Force "justify" "vaccination" mandates of federal employees who have COVID-19 antibodies from previous infection - end Pandemic & COVID-19 mandates & restrictions

Importance: High

Greetings Alyson, Erin, Anthony and "Safer" Federal Task Force Members,

In recent NTEU Townhall Interview with Dr. Erin Tromble - YouTube (comments have been turned off - yesterday most the few comments were negative) , Dr. Erin Tromble (EM/pediatrician) (lzn6@cdc.gov) referenced the following recent CDC study to "justify" MANDATORY vaccination of federal employees who have natural immunity to COVID-19 as a result of natural antibodies from a previous infection.

Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1081-1083.

DOI: <https://dx.doi.org/10.15585/mmwr.mm7032e1>

Return

TABLE 2. Association of SARS-CoV-2 reinfection* with COVID-19 vaccination status — Kentucky, May–June 2021

Vaccination status	No. (%)		OR (95% CI) [†]
	Case-patients	Control participants	
Not vaccinated	179 (72.8)	284 (57.7)	2.34 (1.58–3.47)
Partially vaccinated [‡]	17 (6.9)	39 (7.9)	1.56 (0.81–3.01)
Fully vaccinated [§]	50 (20.3)	169 (34.3)	Ref
Total	246 (100)	492 (100)	—

Abbreviations: CI = confidence interval; NAAT = nucleic acid amplification test; OR = odds ratio; Ref = referent group.

*All case-patients (reinfecteds) and control participants (not reinfecteds) had previous SARS-CoV-2 infection documented by positive NAAT or antigen test results during March–December 2020. Reinfection was defined as receipt of positive NAAT or antigen test results during May 1–June 30, 2021.

[†] Estimated based on conditional logistic regression.


[‡] Case-patients were considered partially vaccinated if ≥ 1 dose of vaccine was received, but the vaccination series was either not completed or the final dose was received < 14 days before their reinfection date. For control participants, the same criteria were applied, using the matched case-patient's reinfection date.

[§] Case-patients and control participants were considered fully vaccinated if a complete COVID-19 vaccine series was received ≥ 14 days before the case-patient's reinfection date.

I reviewed the article and have the following questions, concerns & observations:


- Has this article been peer reviewed?
- Has this article been published in a journal outside of the CDC?
- Could you please briefly describe the NAAT and antigen test?
- What is the reliability of the NAAT and antigen tests? What is the false positive and false negative rates for the NAAT and antigen tests? Were the same thresholds and test conditions used for all test samples?
- If there is a substantial disparity between the reliability of the NAAT and antigen tests, why did you publish a study with results which contain disparate accuracy rates?
- Could someone with natural antibodies from a previous infection in March to December 2020 test positive (due to the naturally acquired antibodies) using the NAAT or antigen test without actually being reinfecteds?
- Were the unvaccinated tested for antibodies after their initial infection? How certain are you that the unvaccinated had true initial COVID-19 infection and built natural antibodies?
- Serious issues with study & results – please comment/explain/justify.
 - All cases from Kentucky – should not necessarily be used to make policy for an entire nation. KY has one of the lower fully "vaccination" rates. Wonder how different the results from a similar study would be in a state with a higher vaccination rate.
 - Short time frame for reinfection is 2 months.
 - Small sample size 682. Fully vaccinated sample size 219 is substantially smaller than unvaccinated sample size 463. According to CDC COVID Data Tracker - thousands of COVID-19 cases were reported daily in KY in 2020 – why were so few selected for the study? Did you cherry pick the samples selected for this study to achieve your narrative? **Insert a different sample of data could well likely show substantially different results!** While the number of cases reported by CDC increased dramatically in July, August and early September, there has been a steep decline since late September. Also, note the inversion in the number of cases by age – early in the pandemic there were substantially more cases among the 75+ age, but in the recent surge there were more younger people reported with COVID-19. This could be simply because there was more testing among the younger people as they went back to school in person – speculation. Note the there were still substantially more deaths among the 75+ age, but that the numbers of deaths in the recent surge were substantially less than the 2020 pandemic. **assert the pandemic is over – we have achieved herd immunity through "vaccinations" and natural immunity.** For much of the population, risk of COVID-19 is extremely low – and some doctors assert the risk of "vaccination" exceeds the benefits of "vaccination" for this population. COVID-19 cannot be eradicated. We need to follow the lead of other countries like Denmark, the Netherlands and Sweden and states like Texas, Florida, Arizona and South Dakota. We need to learn to live with COVID-19, end the pandemic/emergency, revoke all COVID-19 mandates and restrictions, return to common-sense and recommendations (not draconian, arbitrary and capricious mandates) and allow legal US citizens (including hardworking federal employees) the same rights afforded to illegal immigrants to make their own decisions with regard to COVID-19 "vaccines" and as we have with flu shots for decades.

Note the graphs for cases and deaths for KY look fairly similar to the rest of the county.




Trends in Number of COVID-19 Cases and Deaths in the US Reported to CDC, by State/Territory


Reported to the CDC by State or Territory; Maps, charts, and data provided by CDC, updates Mon-Sat by 8 pm ET¹
[View Footnotes and Download Data](#)



COVID-19 Weekly Cases and Deaths per 100,000 Population by Age, Race/Ethnicity, and Sex



COVID-19 Weekly Cases and Deaths per 100,000 Population by Age, Race/Ethnicity, and Sex



- d. No distinction made in how much time had elapsed from infection to re-infection and "vaccination" – could have been any where from between 15 months to 6 months. Given effectiveness of vaccination (and possibly natural immunity) is known to wane over time, if the 219 vaccinated cases were primarily selected from latter part of 2020 and the 463 unvaccinated cases were primarily selected from early part of 2020, then the results would be heavily skewed in toward "vaccinated" reinfection.
- e. Other ways to view your data – the disparity between the "unvaccinated" and "vaccinated" is due to the large disparity if sample sizes between "vaccinated" and "unvaccinated". Randomly selecting a unvaccinated sample size closer the same size as the vaccinated (219) could change statistics substantially.
- Unvaccinated % reinfected: $179 / (179 + 284) = 38.66\%$
 - Vaccinated % reinfected: $50 / (50 + 169) = 22.83\%$
 - Total % unvaccinated reinfected: $179 / (179 + 284 + 50 + 169) = 26.25\%$
 - Total % vaccinated reinfected: $50 / (179 + 284 + 50 + 169) = 7.33\%$
 - Total % unvaccinated: $(179 + 284) / (179 + 284 + 50 + 169) = 67.89\%$
 - Total % vaccinated: $(50 + 169) / (179 + 284 + 50 + 169) = 32.11\%$

I have a strong background in data science – this study seems highly flawed, deceptive and inaccurate to me.

Furthermore, why were reference such as the following regarding natural immunity ignored/disregarded by CDC and in "Safer" Work Force Task Forces's decision as to demand employees with natural immunity to get a COVID-19 "vaccine"? ***In my opinion, this policy yields waste, fraud and abuse.*** The COVID-19 "vaccines" are not free and taxpayer funds are being wasted on citizens who have antibodies and/or strong/robust immune systems who have chosen not to get the "vaccine", but have been bullied (or currently are being bullied) into getting COVID-19 "vaccine" (many college students, professional athletes, health care professionals, airline employees, federal employees, armed forces personnel) in order to maintain their career or attend a university.

- [Senator Paul Asserts Natural Immunity is As Good As COVID-19 Vaccine | C-SPAN.org](#)
- [Courier Journal Op-Ed: Rand Paul, "The science proves people with natural immunity should skip COVID vaccines" | Senator Rand Paul \(senate.gov\)](#)
- [Rand Paul accuses Dr. Fauci of lying about natural immunity because it foils his vaccination plans | Fox Business](#)
- [People who have already had COVID-19 could be less likely to catch Delta, than the vaccinated | CNN, the Vaccine Alliance](#)
- [Project Veritas captures Pfizer scientists giving thumbs up to COVID-19 natural immunity - Washington Times](#)
- [Pfizer scientists say their vaccine provides a weaker defence against Covid as compared to natural antibodies: Project Veritas \(projectveritas.com\)](#)
- [Natural Immunity and the Covid Vaccines - WSJ](#)

A timely response would be greatly appreciated. As you know, per [Vaccinations | Safer Federal Workforce](#), agencies have been authorized to initiate enforcement/disciplinary actions against some federal employees who do not "comply" with COVID-19 "vaccine" mandates for some federal employees (judicial branch, USPS, legislative branch excluded) on November 9, 2021. Also, please reply to my request sent yesterday regarding the composition/qualification of the Safer Federal Workforce Task Force (see attached).

- [Foley v. Biden \(4:21-cv-01098\) Texas Northern District Court \(jacecmonitor.com\)](#)
- [COSTIN et al v. BIDEN et al 1:2021cv02484 | US District Court for the District of Columbia | Justia](#)
- [Birnovich v. Biden et al 2:2021cv01568 | US District Court for the District of Arizona | Justia](#)
- [Out-of-touch Biden threatens private-sector companies as polls nose-dive | TheHill](#)

- [Axios-ipsos poll: Biden is losing trust on COVID - Axios](#)
- [Poll: Americans Are More Pessimistic About Life Returning to Normal, Losing Trust in Biden | US News](#)

Paula

I am a Federal employee with more than 30 years of federal government and military service. I have worked from home for the past decade at least 4 days a week. The projects I have been assigned to at the IRS have members disbursed across the United States and I teleconference when at the office the same as I teleconference the days I work from my home office. Team member who work from the same location are not collocated in the building, nor are in-office days coordinated. Most IT specialist telework 3-4 days a week and share a cube with others who are in the office on opposite days, thus saving the agency real estate expenses. Since the COVID-19 evacuation, I have worked from home 5 days a week with the exception of 4 days I went into office to get a finger printed for new id card, pick up new id card, laptop memory upgrade and laptop replacement. To the best of my recollection, I have never once met with anyone from the public in my work capacity in the nearly 11 years I have worked as an IT specialist at the IRS. The "safer" federal workforces demand I be vaccinated or be terminated is completely illogical.

Paula J. Reitan
 e Paula.Reitan@outlook.com
 t 301.464.4212
 c 240.675.7321
 1709 Mayfair Place
 Crofton, MD 21114-2624

From: [Alexander, Kelly N \(CHFS DPH\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Cc: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR
Date: Sunday, August 8, 2021 8:11:21 PM

Thank you

Kelly N. Alexander, J.D., M.A.
Chief of Staff
Kentucky Department for Public Health
Cabinet for Health and Family Services
275 East Main Street
Frankfort, KY 40621
Phone: 502-564-3970
Email: Kelly.Alexander@ky.gov



CONFIDENTIALITY NOTICE: This e-mail message, including any attachment, is the sole use of the intended recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender, by e-mail, and destroy all copies of this message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, August 8, 2021 6:15 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>
Cc: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: Fwd: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Kelly,

As an FYI - there was a media request for radio interview with Dr. Marc Siegel for Monday morning.

I will connect with Melissa at CDC because I am not available at proposed time.

V/R,
Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Sunday, August 8, 2021 5:40 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP)
Subject: Fwd: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

What's your schedule like in the morning? Up for doing this around 10:30? We could have another brief prep call at 10 if you like to talk through some tips for radio interviews. Just let me know if other times would work better. Thanks!!

Sent from my Verizon, Samsung Galaxy smartphone
Get [Outlook for Android](#)

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Saturday, August 7, 2021 7:03:31 AM
To: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Cc: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tws3@cdc.gov>
Subject: Re: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Sure. I am looking to discuss on the radio
Available to discuss today or Monday



Sent from my iPhone

On Aug 7, 2021, at 12:08 AM, Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov> wrote:

[EXTERNAL]


Happy to help. Dr. Siegel, what's your availability for a call on Monday?

Best,

Melissa

Melissa Brower, MMC
Public Affairs Specialist
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention
Office: 404-639-4718
Cell: 404-903-0241
mbrower@cdc.gov

From: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tw3@cdc.gov>
Sent: Friday, August 6, 2021 9:22 PM
To: Siegel, Marc <Marc.Siegel@nyulangone.org>; Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Subject: Re: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Including Melissa here who can put you in touch with the author. Thanks
Tom Skinner
Senior Public Affairs Officer, CDC


From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Friday, August 6, 2021 9:15:09 PM
To: Skinner, Thomas W. (CDC/DDID/NCEZID/OD) <tw3@cdc.gov>
Subject: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMWR

Very important study.
Would love to discuss with Dr Brooks
<https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm>

Sent from my iPhone

This email message, including any attachments, is for the sole use of the intended recipient(s) and may contain information that is proprietary, confidential, and exempt from disclosure under applicable law. Any unauthorized review, use, disclosure, or

distribution is prohibited. If you have received this email in error please notify the sender by return email and delete the original message. Please note, the recipient should check this email and any attachments for the presence of viruses. The organization accepts no liability for any damage caused by any virus transmitted by this email.

=====

From: [Glick, Connor \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:20:44 AM
Attachments: [Reinfection - vaccination status FIRST PROOF CG.docx](#)

Great work. Thank you, Alyson!

I just had one comment on the interpretation of the estimates, and I know I have brought this up before, but I could not find any previous feedback or comments that addressed this specifically so I figure I would bring this up again.

“2.34 times more likely” and “2.34 times as likely” imply probability, but we’re reporting an odds ratio so (from what I understand) it would only be correct to say “2.34 times the odds”.

If I missed something, though – please point me in the right direction!

Best,
CG

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 12:17 AM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 7:12:34 AM
Attachments: [Reinfection - vaccination status FIRST PROOF 8.5.21_clean.docx](#)
[Reinfection - vaccination status FIRST PROOF 8.5.21.docx](#)

THANK YOU ALL!

I think I used most suggestions except:

- I kept title the same for now – I think it is simple and we do discuss lower odds of reinfection in vaccinated. I can change if there are strong opinions on this.
- I used “odds” in abstract paragraph, results, and summary box. However, in discussion I continue to use terms like “twice as likely.” Reinfections are rare outcome in epi terms (If using the standard 10% cut-off). Therefore the OR should be a good estimate of RR. For public health messaging purposes, “odds” is a term that is hard for general public (outside gamblers) to understand.

Hopefully these changes meet everyone’s input. We will get reviewer feedback by 9 am and I need to resubmit by noon so they can create final proof.

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Sent: Thursday, August 5, 2021 12:21 AM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP)

<alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great work. Thank you, Alyson!

I just had one comment on the interpretation of the estimates, and I know I have brought this up before, but I could not find any previous feedback or comments that addressed this specifically so I figure I would bring this up again.

“2.34 times more likely” and “2.34 times as likely” imply probability, but we’re reporting an odds ratio so (from what I understand) it would only be correct to say “2.34 times the odds”.

If I missed something, though – please point me in the right direction!

Best,
CG

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>

Sent: Thursday, August 5, 2021 12:17 AM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:17:12 AM
Attachments: [Reinfection - vaccination status FIRST PROOF AC KW DAT.docx](#)

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.

- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 6:35:10 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC ks.docx](#)

Hi Alyson,

Nice work as always. Sorry, but I was $\frac{3}{4}$ way through when I saw Kathleen's email come through. Just a few edits/comments for consideration.

Best,

Kevin

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Friday, July 30, 2021 5:55:35 PM
Attachments: [Cavanaugh 07.29 clean SSU1 ks.docx](#)

Hi Alyson,

I took a (quick) look and think you have done a very nice job. I did make a couple of edits/comments for your consideration. No issues with the tables or figure.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 5:13 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today ☺) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Sent: Thursday, July 29, 2021 9:55 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

CDC IMS 2019 NCOV Response Strategic Scientific Unit

Email: eocevent538@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the*

individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 5:09:12 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC.docx](#)

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection
Date: Friday, August 6, 2021 12:23:00 PM
Attachments: [image002.png](#)
[EMBARGOED UNTIL 1PM Media Statement MMWR.pdf](#)
[MMWR ER - Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States - August 6, 2021.pdf](#)
[MMWR ER - Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado - August 6, 2021.pdf](#)
[MMWR ER - Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky - August 6, 2021.pdf](#)

Dr. Walensky's statement will be at 1pm

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Sorry for flooding e-mail but this went out to media and has more info than the previous message I forwarded.

I also heard from AP reporter that there is a JAMA article being released today that again finds higher antibody response after vaccination of previously-infected individuals.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Friday, August 6, 2021 12:20 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

This went out to CDC's media list while we were talking to Mike. Just FYI

From: Media@cdc.gov (CDC) <sohco@cdc.gov>
Sent: Friday, August 6, 2021 11:49 AM
To: Media@cdc.gov (CDC) <sohco@cdc.gov>
Subject: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection



The MMWR is Embargoed until Friday, August 6, 2021 at 1PM ET



know what matters.

August 6, 2021

Please see the attached E-books for:

“Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

“Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

“Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Thank you,

CDC News Media Branch
404-639-3286



CENTERS FOR DISEASE
CONTROL AND PREVENTION

The Media Statement is Embargoed until Friday, August 6, 2021 at 1PM ET

Media Statement

EMBARGOED FOR 1PM ET
Friday, August 6, 2021

Contact: [CDC Media Relations](#)
(404) 639-3286

New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

In today's MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.

"If you have had COVID-19 before, please still get vaccinated," said CDC Director Dr. Rochelle Walensky. "This study shows you are twice as likely to get infected again if you are unvaccinated. Getting the vaccine is the best way to protect yourself and others around you, especially as the more contagious Delta variant spreads around the country."

The study of hundreds of Kentucky residents with previous infections through June 2021 found that those who were unvaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated. The findings suggest that among people who have had COVID-19 previously, getting fully vaccinated provides additional protection against reinfection.

Additionally, a second publication from MMWR shows vaccines prevented COVID-19 related hospitalizations among the highest risk age groups. As cases, hospitalizations, and deaths rise, the data in today's MMWR reinforce that COVID-19 vaccines are the best way to prevent COVID-19.

COVID-19 vaccines remain safe and effective. They prevent severe illness, hospitalization, and death. Additionally, even among the uncommon cases of COVID-19 among the fully or partially vaccinated vaccines make people more likely to have a milder and shorter illness compared to those who are unvaccinated. CDC continues to recommend everyone 12 and older get vaccinated against COVID-19.

###

[U.S. Department of Health and Human Services](#)

CDC works 24/7 protecting America's health, safety, and security. Whether diseases start at home

or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [White, Connie \(CHFS DPH\)](#)
Subject: FW: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:44:00 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)

Here is the latest proof/working copy. Dr. Walensky is going to highlight this tomorrow in a press briefing/release.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:42 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the

original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are*

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Alford, James \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Robeson, Sara \(CHFS DPH\)](#); [Patel, Dimple \(CHFS DPH DEHP\)](#); [Rush, Carrell \(CHS DPH DEHP\)](#); [Messerli, Emily C \(CHFS DPH DEHP\)](#)
Subject: FW: CSTE COVID-19 Response | Digest for Aug. 26 (CSTE Position Statement, CDC Webinar Series, CDC ELC School Testing Toolkit, CSTE PH Law Webinar, and more)
Date: Thursday, August 26, 2021 5:09:00 PM
Attachments: [image001.png](#)
[image002.png](#)
[Jajosky 2021 State Epi Letter New 2021 COVID-19 Case Definition for NNDSS WebSite Cleared 08242021.pdf](#)
[COVID19 Vaccine Effectiveness Transmission Impact Studies - Summary Tables 20210819.pdf](#)
[COVID-19 Partner Updates August 25 2021.msg](#)
[CDC Health Alert Network \(HAN\) Health Advisory Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19.msg](#)

FYI

From: CSTE Emergency Response <Preparedness@cste.org>
Sent: Thursday, August 26, 2021 4:09 PM
To: CSTE Emergency Response <Preparedness@cste.org>
Cc: CSTE Novel Coronavirus 2019 <CSTEncov2019@cste.org>
Subject: CSTE COVID-19 Response | Digest for Aug. 26 (CSTE Position Statement, CDC Webinar Series, CDC ELC School Testing Toolkit, CSTE PH Law Webinar, and more)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**



Sent to State Epidemiologists, Deputy State Epidemiologists, CLUE, Infectious Disease Points of Contact, and the CSTE Executive Board

Good afternoon,

Please see below for a collection of Coronavirus Disease 2019 (COVID-19) information, gathered for your awareness:

New Information

- [CSTE COVID-19 Position Statement – State Epi Letter](#) [Attachment, [Link](#)]
 - Yesterday, **August 25**, CSTE shared a letter (attached) with State and Territorial Epidemiologists providing implementation information for the new 2021 COVID-19 case definition in the National Notifiable Diseases Surveillance System (NNDSS). For cases identified beginning September 1, 2021, jurisdictions should use the case definition approved by the Council on June 17, 2021 in 21-ID-01 ([linked here](#)).

Jurisdictions should **not** retroactively change the classification of cases reported prior to September 1, 2021.

- If you have any questions related to this letter, please send them to positionstatements@cste.org and we will triage them with CDC.
- Webinar Series: CDC Awardee COVID-19 Vaccine Response Planning [Link]
 - CDC hosts a weekly webinar series every Wednesday at 3:30 pm ET to provide key on-the-ground stakeholders with the latest information on COVID-19 vaccine planning and distribution. These calls are an opportunity for a focused discussion on vaccine logistics and other critical planning information. Call information is available below:
 - Weblink: [REDACTED]
[REDACTED]
 - Web Passcode: [REDACTED]
 - One-Tap Mobile: [REDACTED]
[REDACTED]
 - Telephone: [REDACTED]
[REDACTED]
 - Meeting ID: [REDACTED]
 - Phone Passcode: [REDACTED]
- IVAC/WHO Vaccine Effectiveness Weekly Literature Review [Attachment, Link]
 - John Hopkins University's International Vaccine Access Center (IVAC), in collaboration with the World Health Organization (WHO), have released an updated COVID-19 Vaccine Effectiveness (VE) literature review as of August 19 (attached and [linked here](#)).
 - Note a section has been added to highlight duration of protection data that is not calculating a VE estimate, but can inform the duration of protection of COVID-19 vaccines.
- Resource: CDC ELC School Testing Toolkit [Link]
 - CDC has developed a COVID-19 School Testing Toolkit ([linked here](#)) featuring a suite of free resources including flyers, posters and social media content highlighting the benefits of COVID-19 testing programs in schools. The toolkit also includes customizable letters and FAQs for teachers, parents, and guardians that address frequently asked questions about school COVID-19 testing programs.
 - If you have questions or have suggestions for additional toolkit materials, please contact CDC's School Support Section at eocevent335@cdc.gov.
- CDC Health Alert Network (HAN) 449: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19 [Attachment, Link]
 - This CDC HAN Update (attached and [linked here](#)) was issued today, **August 26**, 2021. It summarizes known information about the increased use of Ivermectin, a medication used to treat certain infections caused by internal and external parasites, during the COVID-19 pandemic. Adverse effects associated with Ivermectin misuse and overdose are increasing, as shown by a rise in calls to poison control centers reporting overdoses and more people experiencing adverse effects.
- CSTE Webinar: "Back to School" [Link]
 - The CSTE Public Health Law Subcommittee will host a webinar **tomorrow, Friday, August 27**, at 2:00 pm EDT. This call will be an open discussion on the issue of back-to-

school, quarantine and other school-related legal issues, including whether schools can require quarantine of infected students.

- Questions may be sent to Sunbal Virk at publichealthlaw@cste.org to have them asked anonymously. Call information is below:

- Weblink: [REDACTED]

Web Passcode: [REDACTED]

Telephone: [REDACTED]

Meeting ID: [REDACTED]

One-Tap Mobile: [REDACTED]

Standing Updates

- [CDC Partner Updates – August 25](#) [Attachment]
 - Please see attached for the latest updates from CDC’s State, Tribal, Local, and Territorial (STLT) Task Force.
- [Press Briefings: White House COVID-19 Response Team and Public Health Officials](#) [Link]
 - The White House COVID-19 Response Team holds regular press briefings during the week, typically on **Mondays, Wednesdays, and Fridays** at **11:00 am EDT**. *Please note:* Briefings sometimes begin after 11:00 am. Visit www.whitehouse.gov/live for the latest schedule and broadcast links. All COVID briefings are publicly available on the [White House YouTube channel](#); past briefings may appear in [this playlist link](#).
- [CSTE COVID-19 Response Resource Repository](#) [Link]
 - The CSTE COVID-19 Response Resource Repository and related discussion forums are available via Basecamp to encourage jurisdictional sharing of information, resources, best practices, and challenges. To sign-up and access the Basecamp, please visit [this link](#).
- [Request Form for CSTE COVID-19 Call Topics](#) [Link]
 - CSTE encourages members to suggest topics for future COVID-19 response-related calls with CSTE members, CDC, and/or partner organizations. To submit a request, please visit [this link](#).

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
preparedness.cste.org

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 5:49:00 PM
Attachments: [MMWR Reinfection Rollout for 8 6 21 kw.docx](#)

With my edits. Adding Kelly.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 5:13 PM
To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>
Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>
Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate

Director for Communication that encompasses all three COVID-19 reports being released tomorrow:
**Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years
— 13 states, COVID-NET, February–April 2021**

**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June
2021**

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan
Date: Thursday, August 5, 2021 5:42:00 PM
Attachments: [MMWR Reinfection Rollout for 8 6 21.docx](#)

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 5:22 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>
Sent: Thursday, August 5, 2021 5:13 PM
To: Herlihy, Rachel (CDC state.co.us) <rachel.herlihy@state.co.us>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Moline, Heidi (CDC/DDID/NCIRD/DBD) <ick6@cdc.gov>
Cc: Turner Hoffman, Katherine (Kat) (CDC/DDPHSS/CSELS/OD) <ltd0@cdc.gov>
Subject: For Review by 10:30 am Friday 8/6--MMWR Rollout Plan

Hi all,

Attached for your review is an MMWR rollout plan put together by our Office of the Associate Director for Communication that encompasses all three COVID-19 reports being released tomorrow:

**Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥ 65 Years
— 13 states, COVID-NET, February–April 2021**

**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June
2021**

Rapid Increase in SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021

If you could review the plan for accuracy by **10:30 am Friday, August 6**, it would be much appreciated.

Thanks so much,
Ginger

Ginger Redmon

Health Communication Specialist (on detail)

Morbidity and Mortality Weekly Report (MMWR)

Center for Surveillance, Epidemiology, and Laboratory Services

vco8@cdc.gov

(404) 639-6434

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: theonefixedpoint@gmail.com
Subject: Fwd: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection
Date: Friday, August 6, 2021 12:47:10 PM
Attachments: [image002.png](#)
[EMBARGOED UNTIL 1PM Media Statement MMWR.pdf](#)
[MMWR ER - Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States - August 6, 2021.pdf](#)
[MMWR ER - Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado - August 6, 2021.pdf](#)
[MMWR ER - Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky - August 6, 2021.pdf](#)

Get [Outlook for iOS](#)

From: Winter, Kathleen T (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:23:54 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

Dr. Walensky's statement will be at 1pm

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Sorry for flooding e-mail but this went out to media and has more info than the previous message I forwarded.

I also heard from AP reporter that there is a JAMA article being released today that again finds higher antibody response after vaccination of previously-infected individuals.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Friday, August 6, 2021 12:20 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

This went out to CDC's media list while we were talking to Mike. Just FYI

From: Media@cdc.gov (CDC) <sohco@cdc.gov>
Sent: Friday, August 6, 2021 11:49 AM
To: Media@cdc.gov (CDC) <sohco@cdc.gov>
Subject: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection



The MMWR is Embargoed until Friday, August 6, 2021 at 1PM ET



know what matters.

August 6, 2021

Please see the attached E-books for:

“Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

“Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

“Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Thank you,

CDC News Media Branch
404-639-3286



The Media Statement is Embargoed until Friday, August 6, 2021 at 1PM ET

Media Statement

EMBARGOED FOR 1PM ET
Friday, August 6, 2021

Contact: [CDC Media Relations](#)
(404) 639-3286

New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

In today’s MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.

“If you have had COVID-19 before, please still get vaccinated,” said CDC Director Dr. Rochelle Walensky. “This study shows you are twice as likely to get infected again if you are unvaccinated. Getting the vaccine is the best way to protect yourself and others around you, especially as the more contagious Delta variant spreads around the country.”

The study of hundreds of Kentucky residents with previous infections through June 2021 found that those who were unvaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated. The findings suggest that among people who have had COVID-19 previously, getting fully vaccinated provides additional protection against reinfection.

Additionally, a second publication from MMWR shows vaccines prevented COVID-19 related hospitalizations among the highest risk age groups. As cases, hospitalizations, and deaths rise, the data in today’s MMWR reinforce that COVID-19 vaccines are the best way to prevent COVID-19.

COVID-19 vaccines remain safe and effective. They prevent severe illness, hospitalization, and

death. Additionally, even among the uncommon cases of COVID-19 among the fully or partially vaccinated vaccines make people more likely to have a milder and shorter illness compared to those who are unvaccinated. CDC continues to recommend everyone 12 and older get vaccinated against COVID-19.

###

[U.S. Department of Health and Human Services](#)

CDC works 24/7 protecting America's health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Alexander, Kelly N \(CHFS DPH\)](#); [Stack, Steven J \(CHFS DPH\)](#)
Subject: Fwd: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Friday, July 30, 2021 7:53:46 PM
Attachments: [image001.png](#)
[COVID-19 MMWR Comms Package Reinfection and Vaccination Status DRAFT for Clearance Review kou4 AC.docx](#)

Alyson,

Yes, Susan Dunlap and Kelly Alexander should be included for communications.

Congrats on another great paper. This is really important work and I am so grateful for your effort in pulling this together.

I cc-ed Kelly and Dr. Stack here.

Get [Outlook for iOS](#)

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 7:26 PM
To: Winter, Kathleen T (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Spicer, Kevin B (CHFS DPH DEHP)
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the

original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>
Sent: Friday, July 30, 2021 6:57 PM
To: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>
Sent: Friday, July 30, 2021 5:04 PM
To: Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>
Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMWR **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333

404.808.4485 (cell)

vks0@cdc.gov

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#); [Stack, Steven J \(CHFS DPH\)](#); [White, Connie \(CHFS DPH\)](#); [Dunlap, Susan \(CHFS\)](#)
Cc: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Subject: MMWR to be released tomorrow
Date: Thursday, August 5, 2021 4:15:00 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF.pdf](#)
Importance: High

All,

Please see the attached proofs for the MMWR that is scheduled to be released tomorrow (stated to be the final, but there may still be minor edits). I or Alyson will send the next version of the communications package once it is received.

Key message:

Among Kentucky residents with a prior SARS-CoV-2 infection in 2020, those who were not vaccinated after their COVID-19 illness had a higher risk of being reinfected compared to those who received vaccination for COVID-19. All eligible individuals, including those who have previously had COVID-19, should get vaccinated to reduce their risk of infection or reinfection.

We have also heard that Dr. Walensky may be highlighting this paper tomorrow in some communication with the media.

Please let me or Alyson know if you have any questions.

Thanks,
Kathleen

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Subject: MMWR
Date: Monday, August 2, 2021 1:53:00 PM

“I, Kathleen Winter, agree to be included as an author on the manuscript, “**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**” and certify that I meet the qualifications for authorship for this article

Kathleen Winter, PhD, MPH
State Epidemiologist
Director, Division of Epidemiology and Health Planning
Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
Desk: 502-564-3418 ext. 4310
Cell: 502-892-9895

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Tuesday, August 3, 2021 11:24:00 PM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw.docx](#)

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, August 3, 2021 9:58 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Tuesday, August 3, 2021 6:47 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you

have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,
Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3

<eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date: 8/3/2021

Forecasted Completion: 8/16/2021

Intended Use:

Publication: MMWR: Recommendations & Reports

Path:

/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Audience:

Public health, medical professionals, and general public

Topics:

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Subject: RE: COI_disclosure forms - due COB Monday
Date: Sunday, August 1, 2021 7:45:00 AM
Attachments: [coi_disclosure kwinter.docx](#)

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Saturday, July 31, 2021 8:30 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: COI_disclosure forms - due COB Monday

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Sunday, August 1, 2021 7:42:00 AM
Attachments: [COVID-19 MMWR Comms Package Reinfection and Vaccination Status DRAFT for Clearance Review kou4 AC ks kw.docx](#)
[image001.png](#)

With some additional edits and comments

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, July 30, 2021 7:52 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi Alyson,

Couple of comments for the comms package.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 7:27 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>
Sent: Friday, July 30, 2021 6:57 PM
To: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD) <gpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <gmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>
Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>
Sent: Friday, July 30, 2021 5:04 PM
To: Hardie, Ann (CDC/DDID/NCIRD/OD) <gpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media -2 <eocjimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content <eocevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine (CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR) <gmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis (CDC/DDID/NCEZID/DHQP) (CTR) <gpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID) <nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR) <pwf7@cdc.gov>
Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMWR **Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Clearance Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333

404.808.4485 (cell)

vks0@cdc.gov

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review
Date: Thursday, August 5, 2021 2:36:00 PM
Attachments: [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review_kw.docx](#)

Lots of edits to the talking points – for your discretion.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 1:54 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

Hi all,

Here is the revised Comms package, not yet fully approved. If you think there needs to be additional edits, let me know before 4 pm.

Interestingly, a comment by the media team made me recognize an edit needed for final proof. December 31 to May 1 is (>4 months) not (>=5 months) as stated in discussion.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Thursday, August 5, 2021 1:28 PM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>

Subject: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 6:18:00 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC KW.docx](#)

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Sunday, August 1, 2021 8:06:00 AM
Attachments: [Cavanaugh 07.29 clean SSU1 ks kw.docx](#)

With a few additional edits and comments. No need to incorporate if you have already resubmitted. I added my UK affiliation also.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, July 30, 2021 5:56 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I took a (quick) look and think you have done a very nice job. I did make a couple of edits/comments for your consideration. No issues with the tables or figure.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 5:13 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today ☺) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Sent: Thursday, July 29, 2021 9:55 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

*CDC IMS 2019 NCOV Response Strategic Scientific Unit
Email: eocevent538@cdc.gov*

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:27 AM
To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Bcc: MMWR
Date: Monday, August 2, 2021 10:27:22 AM

"I, Kathleen Winter, agree to be included as an author on the manuscript, "**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**" and certify that I meet the qualifications for authorship for this article

Kathleen Winter, PhD, MPH
State Epidemiologist
Director, Division of Epidemiology and Health Planning
Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
Desk: 502-564-3418 ext. 4310
Cell: 502-892-9895

From: [CSTE Emergency Response](#)
To: [CSTE Emergency Response](#)
Subject: NOT FOR DISTRIBUTION: EMBARGOED: CDC Science Brief SARS-COV-2 INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY
Date: Friday, October 29, 2021 7:35:40 PM
Attachments: [image.png](#)
[Outlook-dtyzt3vj.png](#)
[Infection and Vaccine Induced Immunity Science Brief v10292021 DRAFT.docx](#)
Importance: High



*****CLOSE HOLD: NOT FOR DISTRIBUTION ***** EMBARGOED *****

Sent to State Epidemiologists and the CSTE Executive Board,

Please find attached an **EMBARGOED** copy of the new CDC Science Brief: SARS-COV-2 INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY. **EMBARGOED: This document CANNOT be shared until it has been posted on the CDC website.** We *anticipate* the document will be posted tonight but we DO NOT have confirmation of the scheduled CDC go live or if it will happen today. THUS, I am asking you please **DO NOT SHARE** until you have confirmed the document is live on the CDC website.

The CSTE National Office is in contact with CDC and will work to notify you all once it has gone live.

Janet Hamilton, MPH (she, her)
Executive Director
CSTE

*****CLOSE HOLD: NOT FOR DISTRIBUTION ***** EMBARGOED *****

--



Council of State and Territorial Epidemiologists
Emergency Preparedness & Response Mailbox
Business Hours Line: 770.458.3811
After-Hours Line: 678.256.3945

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: actual numbers, please? -DRAFT response
Date: Thursday, August 12, 2021 10:23:40 AM

Thank you for reviewing. I will send this later this afternoon.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 12, 2021 10:09 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: actual numbers, please? -DRAFT response

I totally agree with Kevin – it’s not our battle to fight, we are just adding a nugget of data to the understanding of the overall situation. I think your answer is great. The only addition I would suggest *if you have it easily available* is to add references for some of those observational studies that you mentioned in the first sentence, “. . . several observational studies have shown significantly lower incidence of infection among those with prior SARS-CoV-2 infections compared to those without previous infections.”

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621

Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 12, 2021 9:56 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: actual numbers, please? -DRAFT response

Hi Alyson,

I realize you may have already responded, and I have nothing significant just some very minor edits.

I think it best to do what you have done, which is to keep the response brief and to the point. The inquiry I believe is trying to pull us into a larger policy and ethical debate.

Nicely done.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 11, 2021 8:40 AM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: actual numbers, please? -DRAFT response

Good morning,

This is a message received in regards to MMWR. Attached is drafted response. Please let me know if you think any additional changes to the drafted response are needed.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Matt Birchmeier <mjbirchmeier@hotmail.com>
Sent: Saturday, August 7, 2021 8:30 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: actual numbers, please?

Dr. Cavanaugh,

I read with interest your article here. However, as one PhD scientist to another, I found that the text you presented was completely lacking in a very important detail: what was the actual odds of someone who has previously been infected, of becoming re-infected during the study? You cite the 2.3X higher risk, but it matters greatly whether the risk of reinfection is 0.1% or 1% or 10% or 90%. Certainly, those numbers were generated during your study. You should present them. The Missouri study that I linked below found a <1% rate of reinfection among those who had significant illnesses. Furthermore, particularly hard hit areas like Detroit, Michigan, still seem to be benefiting from a strong degree of natural immunity, 1+ year after the worst of the pandemic, in spite of a low vaccination rate.

There is a very good argument that the benefits of vaccinating previously infected people in the US are less than the benefit of vaccinating naive populations elsewhere in the world. That question may be an ethical debate for another day. But hopefully you can see that the absolute numbers around reinfection are important in that debate! If the risk of reinfection is 90%, then certainly that vaccination in Kentucky is important, both from an ethical and policy perspective. If the risk of reinfection is 0.7%, then perhaps someone in Vietnam should receive that dose.

Please update your publication at the earliest opportunity, to better inform the American public of what the true risks around COVID are. Most media outlets seem content to scare people rather than truly inform them; I would hope for much better from the CDC. We CAN handle the truth, if only you would tell the whole truth.

Best regards,

Matthew J. Birchmeier, Ph.D.

https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w



[Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021 | MMMWR](#)

Although laboratory evidence suggests that antibody responses following COVID-19 vaccination provide better neutralization of some circulating variants than does natural infection (1,2), few real-world epidemiologic studies

www.cdc.gov

<https://medicine.missouri.edu/news/study-finds-covid-19-reinfection-rate-less-1-those-severe-illness>



[Study Finds COVID-19 Reinfection Rate Less Than 1% for Those with Severe Illness - MU School of Medicine](#)

A review of more than 9,000 U.S. patients with severe COVID-19 infection showed less than 1% contracted the illness again, with an average reinfection time of 3.5 months after an initial positive test. Those are the findings from medicine.missouri.edu

From: Winter, Kathleen T (CHFS DPH DEHP)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Subject: Re: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection
Date: Friday, August 6, 2021 12:46:37 PM
Attachments: [image002.png](#)

Get [Outlook for iOS](#)

From: Winter, Kathleen T (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:23:54 PM
To: Alexander, Kelly N (CHFS DPH) <kelly.alexander@ky.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

Dr. Walensky's statement will be at 1pm

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Sorry for flooding e-mail but this went out to media and has more info than the previous message I forwarded.

I also heard from AP reporter that there is a JAMA article being released today that again finds higher antibody response after vaccination of previously-infected individuals.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any

review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Friday, August 6, 2021 12:20 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

This went out to CDC's media list while we were talking to Mike. Just FYI

From: Media@cdc.gov (CDC) <sohco@cdc.gov>
Sent: Friday, August 6, 2021 11:49 AM
To: Media@cdc.gov (CDC) <sohco@cdc.gov>
Subject: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection



The MMWR is Embargoed until Friday, August 6, 2021 at 1PM ET



know what matters.

August 6, 2021

Please see the attached E-books for:

“Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

“Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

“Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13

states, COVID-NET, February–April 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Thank you,

CDC News Media Branch
404-639-3286



The Media Statement is Embargoed until Friday, August 6, 2021 at 1PM ET

Media Statement

**EMBARGOED FOR 1PM ET
Friday, August 6, 2021**

Contact: [CDC Media Relations](#)
(404) 639-3286

New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

In today’s MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.

“If you have had COVID-19 before, please still get vaccinated,” said CDC Director Dr. Rochelle Walensky. “This study shows you are twice as likely to get infected again if you are unvaccinated. Getting the vaccine is the best way to protect yourself and others around you, especially as the more contagious Delta variant spreads around the country.”

The study of hundreds of Kentucky residents with previous infections through June 2021 found that those who were unvaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated. The findings suggest that among people who have had COVID-19 previously, getting fully vaccinated provides additional protection against reinfection.

Additionally, a second publication from MMWR shows vaccines prevented COVID-19 related hospitalizations among the highest risk age groups. As cases, hospitalizations, and deaths rise, the data in today’s MMWR reinforce that COVID-19 vaccines are the best way to prevent COVID-19.

COVID-19 vaccines remain safe and effective. They prevent severe illness, hospitalization, and death. Additionally, even among the uncommon cases of COVID-19 among the fully or partially vaccinated vaccines make people more likely to have a milder and shorter illness compared to those who are unvaccinated. CDC continues to recommend everyone 12 and older get vaccinated against

COVID-19.

###

[U.S. Department of Health and Human Services](#)

CDC works 24/7 protecting America's health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE
Date: Monday, August 2, 2021 10:36:45 AM

Thank you Connor!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Sent: Monday, August 2, 2021 10:36 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

I, Connor Glick, agree to be included as an author on the manuscript, "Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021" and certify that I meet the qualifications for authorship for this article.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Monday, August 2, 2021 10:23 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE

Good morning all,

Just to update – the report got stuck in JIC clearance but is now escalated for expedited review. I have not yet received any official feedback, but I received notification that it is still expected this report gets published Friday. I was told to expect feedback this afternoon and have revisions prepared/submitted by this evening. I will work to do that, if possible.

If you haven't already e-mailed COI form, please do so by close of business today.

In addition, please send me a separate email so that I can archive for records that statement:

"I, FULL NAME , agree to be included as an author on the manuscript, "**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**" and certify that I meet the qualifications for authorship for this article

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Saturday, July 31, 2021 8:30 AM

To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: COI_disclosure forms - due COB Monday

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am

attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: Re: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review
Date: Friday, July 30, 2021 7:50:03 PM
Attachments: [image001.png](#)

Yes

Get [Outlook for iOS](#)

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 7:26:38 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Kathleen,

The comms package is beginning to be circulated in preparation for the publication.

For the last comms package, I added Susan Dunlap as communications POC. Should I add her info as POC again?

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>
Sent: Friday, July 30, 2021 6:57 PM
To: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <vks0@cdc.gov>; Hardie, Ann (CDC/DDID/NCIRD/OD)

<qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC) <gnf0@cdc.gov>; CDC IMS JIC Media -2
<eojcimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content
<eoevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine
(CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR)
<qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis
(CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID)
<nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR)
<pwf7@cdc.gov>

Subject: RE: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hey Shelton—

The autosave feature did not work for me. Please find JIC Content's changes attached.

-Myron D.

From: Bartley, Shelton (CDC/DDPHSS/CSELS/OD) <yks0@cdc.gov>

Sent: Friday, July 30, 2021 5:04 PM

To: Hardie, Ann (CDC/DDID/NCIRD/OD) <qpe2@cdc.gov>; McDonald, Jason (CDC/OD/OADC)
<gnf0@cdc.gov>; Douglas, Myron (CDC/DDNID/NCEH/DEHSP) <kou4@cdc.gov>; CDC IMS JIC Media
-2 <eojcimedia2@cdc.gov>; CDC IMS 2019 NCOV Response Deputy JIC Lead for Content
<eoevent469@cdc.gov>; Pauley, Scott (CDC/OD/OADC) <pvq2@cdc.gov>; Reed, Jasmine
(CDC/OD/OADC) <pvz1@cdc.gov>; Kachinsky, Noelle (CDC/DDID/NCIRD/OD) (CTR)
<qmy8@cdc.gov>; Grusich, Katherina (Kate) (CDC/DDID/NCIRD/OD) <yhb3@cdc.gov>; Hauk, Alexis
(CDC/DDID/NCEZID/DHQP) (CTR) <qpu9@cdc.gov>; Choban, Ana (CDC/DDID/NCIRD/ID)
<nlf9@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Redmon, Ginger (CDC/OD/OADC) <vco8@cdc.gov>; Ray, Amanda (CDC/DDPHSS/CSELS/OD) (CTR)
<pwf7@cdc.gov>

Subject: COVID19 Comm Pack - Reinfection and Vaccination Status - For Clearance Review

Hi all,

Linked below is the comms package for the MMRW **Reduced Risk of Reinfection with SARS-CoV-2
After COVID-19 Vaccination — Kentucky, May–June 2021**

Will you please provide any edits/comments by **COB Monday, August 2?**

A copy of the report is attached for reference.

 [COVID-19 MMRW Comms Package_ Reinfection and Vaccination Status_DRAFT for Clearance Review.docx](#)

Thanks,

Shelton

Shelton Bartley, MPH

Health Communication Specialist

Morbidity and Mortality Weekly Report (MMWR)

Office of the Director

Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)

1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333

404.808.4485 (cell)

vks0@cdc.gov

To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Tuesday, December 14, 2021 3:00:10 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC CG.docx](#)

Only a minor suggestion or two. Thanks!

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:55 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the*

individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services

gdamon@cdc.gov

Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Re: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:29:31 PM

Its actually just a written statement that is in the other email I just sent. I just checked with Melissa and there will be no live messaging.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Glick, Connor (CHFS DPH DEHP); Winter, Kathleen T (CHFS DPH DEHP)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Delta variant case study

Rapid increase in Mesa County, CO, April-June 2021

Mesa County, CO

COVID-19 vaccination low: **36%***

Hospitalizations
ICU use
Deaths

TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places

*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
vks0@cdc.gov

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:23:05 PM

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health

275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>
Sent: Friday, August 6, 2021 11:08 AM
To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>
Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places



*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:08:52 PM

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release

MMWR
Morbidity and Mortality Weekly Report



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021


Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
vks0@cdc.gov

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:33:04 PM

Okay. Thanks.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:30 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: Re: MMWR Embargoed eBook for 8/6 Early Release

Its actually just a written statement that is in the other email I just sent. I just checked with Melissa and there will be no live messaging.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Glick, Connor (CHFS DPH DEHP); Winter, Kathleen T (CHFS DPH DEHP)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWRERBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places



*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:33:04 PM

Okay. Thanks.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:30 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: Re: MMWR Embargoed eBook for 8/6 Early Release

Its actually just a written statement that is in the other email I just sent. I just checked with Melissa and there will be no live messaging.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Glick, Connor (CHFS DPH DEHP); Winter, Kathleen T (CHFS DPH DEHP)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places



*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR
Date: Monday, August 2, 2021 1:54:23 PM

Thank you!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Monday, August 2, 2021 1:54 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: MMWR

"I, Kathleen Winter, agree to be included as an author on the manuscript, "**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**" and certify that I meet the qualifications for authorship for this article

Kathleen Winter, PhD, MPH
State Epidemiologist
Director, Division of Epidemiology and Health Planning
Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
Desk: 502-564-3418 ext. 4310
Cell: 502-892-9895

To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:21:07 AM
Attachments: [Reinfection - vaccination status FIRST PROOF_CG.docx](#)

Great work. Thank you, Alyson!
Apologies for just now getting around to this.

I know I have brought this up before, but I could not find any

Just one comment on the interpretation of the estimate(s).
"2.34 times more likely" and "2.34 times as likely" imply probability, but we're reporting an odds ratio so it would correct to say "2.34 times the odds".

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 7:24 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Thank you!

No problem with multiple copies. It helps me check and double check.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Sent: Wednesday, August 4, 2021 6:35:07 PM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Hi Alyson,

Nice work as always. Sorry, but I was ¾ way through when I saw Kathleen's email come through. Just a few edits/comments for consideration.

Best,

Kevin

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Sent: Wednesday, August 4, 2021 6:18 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, August 4, 2021 5:09 PM

To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:20:34 AM
Attachments: [Reinfection - vaccination status FIRST PROOF_CG.docx](#)

Great work. Thank you, Alyson!

I just had one comment on the interpretation of the estimates, and I know I have brought this up before, but I could not find any previous feedback or comments that addressed this specifically so I figure I would bring this up again.

“2.34 times more likely” and “2.34 times as likely” imply probability, but we’re reporting an odds ratio so (from what I understand) it would only be correct to say “2.34 times the odds”.

If I missed something, though – please point me in the right direction!

Best,
CG

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 12:17 AM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 6:18:06 PM
Attachments: [Reinfection - vaccination status FIRST PROOF_AC_KW.docx](#)

Great job. Here are my edits.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Mimi Huynh](#)
To: [Mimi Huynh](#)
Cc: [Charla Debolt](#); [Susan Lett](#)
Subject: Cancelled: CSTE Vaccine-Preventable Diseases Subcommittee Call | August 9, 2021
Date: Monday, August 9, 2021 10:16:02 AM
Attachments: [image001.png](#)
[image002.png](#)



Sent to the CSTE Vaccine-Preventable Diseases Subcommittee

Good morning,

Today's CSTE VPD Subcommittee call is **cancelled**. We will reconvene on September 13, 2021 at 3:00pm ET. Given the current surge in COVID-19 cases and unprecedented demands related to vaccine breakthrough infections, the CSTE VPD Subcommittee would like to acknowledge the complexity of your efforts and thank you for your continued commitment to public health. Your resiliency and hard work is much appreciated, and the subcommittee leadership is dedicated to supporting its members however possible. Please do not hesitate to reach out to Chas, Susan, or myself with any questions, comments, or suggestions on how we can address your needs.

In the meantime, please see below a few updates for your awareness.

- ACIP Meeting – August 13 @ 11am ET
 - The webcast link can be accessed here: <https://www.cdc.gov/vaccines/acip/index.html>. No registration is required.
- Recently released immunization MMWR articles
 - [Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021](#)
 - [Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021](#)
 - [Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado, April–June 2021](#)
 - [COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021](#)
 - [Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021](#)

Best regards,
Mimi

Mimi P. Huynh, MPH (she/her/hers)
Program Analyst



Council of State and Territorial Epidemiologists

"Using the power of epidemiology to improve the public's health"

[CSTE Website](#) · [Facebook](#) · [Twitter](#) · [Career Center](#) · [Join CSTE](#)

2635 Century Parkway NE, Suite 700, Atlanta, GA, 30345

Tel: 770.458.3811 | Fax: 770.458.8516

Documents with personal data and/or confidential information must be sent to CSTE's national office only through a secure ShareFile request and not through regular email.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Cavanaugh_08.02_track
Date: Monday, August 2, 2021 4:36:30 PM
Attachments: [Cavanaugh_08.02_track.docx](#)

Here are the track changes of manuscript. I sent revised table 3 earlier. I am not going to submit Supplementary Figure. Instead, I will submit manuscript and 3 tables unless anyone opposes that plan.

I am working to revise the tables and will send them off to OS review.

Thanks!
Alyson

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: COI_disclosure forms - due COB Monday
Date: Saturday, July 31, 2021 8:30:17 AM
Attachments: [coi_disclosure.docx](#)

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Final comments - revisions in analysis
Date: Tuesday, August 3, 2021 7:07:06 PM
Attachments: [COPY EOC Cavanaugh 08.02 clean for OS-OS-BPZ.docx](#)
[COPY EOC TABLE 1 08.02.21 clean For OS-BPZ.docx](#)
[COPY EOC TABLE 2 08.02.21 cleanFor OS-BPZ.docx](#)
[COPY EOC TABLE 3 08.2.21 clean For OS-BPZ.docx](#)
Importance: High

FYI - They have requested we flip the OR using essentially comparing cases to controls with no vaccination as reference group. It will place all of our OR below 1. I can do this, but find this harder to interpret.

Other comments are much easier to address.

Dr. Spicer – if you have any good resources for length of viral shedding at your fingertips, let me know. Otherwise I can find.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 6:36 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>
Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,

Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 6:30 PM

To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.

Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Tuesday, August 3, 2021 4:45 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen

tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 2:25 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:18 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date: 8/3/2021

Forecasted Completion: 8/16/2021

Intended Use: Publication: MMWR: Recommendations & Reports

Path: /EOC/_eClearance Folders and Files/2021/MMWR-COVID-19

Audience:

vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Topics:

Public health, medical professionals, and general public

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Tuesday, August 3, 2021 9:58:21 PM
Attachments: [COPY EOC Cavanaugh 08.03 clean.docx](#)
[COPY EOC Cavanaugh 08.03 track.docx](#)
[COPY EOC TABLE 2 08.3.21 clean.docx](#)
[COPY EOC TABLE 2 08.3.21 track.docx](#)
[COPY EOC TABLE 1 08.03.21 clean.docx](#)
[COPY EOC TABLE 1 08.03.21 track.docx](#)

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Tuesday, August 3, 2021 6:38 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,

Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 6:30 PM

To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.

Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Tuesday, August 3, 2021 4:45 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 2:27 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by

OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:	MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Targeted Completion Date:	8/3/2021
Forecasted Completion:	8/16/2021
Intended Use:	Publication: MMWR: Recommendations & Reports
Path:	/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Audience:	Public health, medical professionals, and general public
Topics:	
Description:	A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.
CDC ADS Notification Criteria:	Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Comments on report no. 1464
Date: Tuesday, July 27, 2021 6:23:44 PM
Attachments: [Cavanaugh_1464_JG.docx](#)
[FIGURE_JG.docx](#)
[TABLE 1_JG.docx](#)
[TABLE 2_JG.docx](#)
[TABLE 3_JG.docx](#)

Hi all,

Here are comments from MMWR from pre-review. In general, I agree with most edits.

- I agree with suggestion to use Figure 1 in supplemental and include the three tables in the MMWR.
- The one section I am unsure of is Page 5. This paragraph on single dose was added per comments from vaccine task force. Any suggestions for shortening would be appreciated, but I think some talk on the topic is needed.
- For the actual manuscript, if you have suggestions/edits/comments, please use the link: https://kymsoffice-my.sharepoint.com/:w/g/personal/alyson_cavanaugh_ky_gov/EZYxVWqbJ1pFnaIdyX75zHYBBd3cJK1e16C3m-hZ0jUkPQ

I plan to resubmit early morning (6am ish) on 7/29/21. The next submission step is higher levels of CDC clearance (CHEO/JIC). This is nearing the end of the process for clearance.

FYI – they edited the tables without track changes, so I will need to make some adjustments. Table 3 is confusing as laid out. I need to check these in more detail since track changes weren't used. If you have changes on tables, let me know. There is not a sharedrive link for tables.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsjg5@cdc.gov>
Sent: Tuesday, July 27, 2021 4:19 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>

Subject: Comments on report no. 1464

Dear Dr. Cavanaugh,

I appreciated the opportunity to review your draft manuscript (**Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021**) on behalf of *MMWR* before it undergoes further COVID-19 Response pre-clearance and JIC clearance.

I've made a number of edits to your manuscript in track changes in the attached files to enhance clarity and to further align with *MMWR* author guidelines, and have also included some comments and questions. You do not need to accept any edits that may have inadvertently introduced inaccuracies or deviated from the original intent of the narrative. However, please accept all other edits and make a concerted effort to address the comments and questions before sending a clean version to the next stage of pre-clearance. This will ultimately help facilitate more timely processing of the manuscript once it is eventually submitted to *MMWR* for official consideration of publication.

Please pay attention to the following:

1. *MMWR* reports are allowed to have a maximum of 3 tables and/or figures in any combination; you have submitted 3 tables and 1 figure; I suggest that you make the figure a supplementary figure; it will be archived in CDC Stacks, and there will be a clickable link within the report to access it.
2. I formatted your tables for *MMWR*; in the future, please be aware that table cells cannot have any hard returns nor can there be any empty cells.

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the *MMWR* functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance. Once cleared by JIC, you will then be directed to submit the manuscript to *MMWR* via ScholarOne (<https://mc.manuscriptcentral.com/mmwr>); at that time, please remember to include an ICMJE conflict of interest form for each co-author with your submission. If there is a group author on the byline, then the persons listed in the group will be indexed in PubMed as contributors rather than authors, and no ICMJE form is necessary for those persons.

As your manuscript continues through clearance, please remember that *MMWR* allows up to 1,650 words for COVID-19 reports and up to 10 references. You and your coauthors will likely receive requests for additional narrative to be added from the next several reviewers; but please ensure that the final submission to *MMWR* is less than 1,650 words with no more than 10 references or it will require another round of editorial review, which could delay processing of the report.

Please let me know if you have any questions.

With kind regards,

Jacqueline Gindler, MD
Editor, *MMWR Weekly*
404-639-8829
jgindler@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review
Date: Thursday, August 5, 2021 1:54:11 PM
Attachments: [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review.docx](#)
[Reinfection - vaccination status FINAL TO DTP.docx](#)

Hi all,

Here is the revised Comms package, not yet fully approved. If you think there needs to be additional edits, let me know before 4 pm.

Interestingly, a comment by the media team made me recognize an edit needed for final proof. December 31 to May 1 is (>4 months) not (>=5 months) as stated in discussion.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Thursday, August 5, 2021 1:28 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 3:36:49 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF.pdf](#)
[mm7032e1 - Reinfection - vaccination status FINAL PROOF.docx](#)
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: MMWR - Decision on Manuscript ID CDC-2021-0104 -
Date: Wednesday, August 4, 2021 7:36:19 AM
Attachments: [Guidelines-for-Author-Responses-to-External-Inquiries.pdf](#)
[CDC-2021-0104 ACCEPTED.docx](#)
[TABLE 1 ACCEPTED.docx](#)
[TABLE 2 ACCEPTED.docx](#)
[CDC-2021-0104 ACCEPTED tracked changes.docx](#)
[TABLE 1 ACCEPTED tracked changes.docx](#)
[CDC-2021-0104 ACCEPTED tracked changes AC.docx](#)

****CAUTION**** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov<<mailto:ServiceCorrespondence@ky.gov>> for any assistance.

Good morning,

FYI - MMWR editors already made some edits to have it align with MMWR format.

I added Kathleen's/Doug's changes here to submit. If you have additional suggestions, please work off the document with _AC.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

-----Original Message-----

From: Morbidity and Mortality Weekly Report <onbehalf@manuscriptcentral.com>
Sent: Wednesday, August 4, 2021 12:29 AM
To: qds1@cdc.gov
Cc: cgk3@cdc.gov; jsg5@cdc.gov; pzs1@cdc.gov; iyn3@cdc.gov; tfh5@cdc.gov; kya6@cdc.gov
Subject: MMWR - Decision on Manuscript ID CDC-2021-0104

****CAUTION**** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov<<mailto:ServiceCorrespondence@ky.gov>> for any assistance.

04-Aug-2021

Dear Dr. Cavanaugh:

It is a pleasure to provisionally accept your Prescheduled manuscript entitled, "Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021," for publication in MMWR. All reports undergo additional scientific and editorial review during the production process.

I made a few minor edits to the text and the tables; I am sending you tracked changes versions of the report and table 1 for your reference; the tracked changes version of table 2 were too hard to read, so I just accepted all those changes. Thanks for preparing such a nice manuscript.

Teresa Hood, Team Lead for the MMWR Weekly, will be in touch with you to schedule the publication of your manuscript. She also will describe the rapid, 7-day production process.

Once your manuscript is published, you might receive inquiries about it from persons outside of CDC. To assist with responding to non-media related inquiries, please use the attached guidelines for CDC authors.

Thank you for your contribution. On behalf of the Editors of MMWR, I look forward to your continued contributions to the Journal.

Sincerely,

Jacqueline Gindler, MD
Editor, MMWR Weekly

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Monday, August 2, 2021 2:23:23 PM
Attachments: [image002.png](#)
[Cavanaugh_07.30_clean_copy_HC_MDA_IMPDM.docx](#)
[TABLE 2_07.29.21_SSU1_HC_MDA.docx](#)
[TABLE 1_07.29.21_SSU1_HC_MDA.docx](#)
[FIGURE Supplementary_07.30.21_HC_MDA.docx](#)
[TABLE 3_07.29.21_SSU1_HC_MDA.docx](#)

Hi Connor,

Here are all comments. Any feedback you see would be greatly appreciated!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Monday, August 2, 2021 12:05 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good afternoon,

Here are comments on manuscript, tables, and figure.

I will begin working on manuscript at this time. Here is the link for any suggestions for manuscript:

https://kymsoffice-my.sharepoint.com/:w/g/personal/alyson_cavanaugh_ky_gov/EbaQ3GcEVBMrzf6LgXPVKQBjqoEJUtGGb8xSoAqniB2Gw

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Monday, August 2, 2021 11:42 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Fw: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi Alyson,

JIC is returning your MMWR with comments. Please note these remarks:

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a

sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").

- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Please address their comments and submit clean copies for OS review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Monday, August 2, 2021 11:39 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi,

Please revise and submit clean copies for OS Review.

Please see below from IM/PDIM,

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully

realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).

- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Thank you,

Kalayah Hunter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kalayah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>

Sent: Monday, August 2, 2021 11:35 AM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsln02@cdc.gov>; Christie, Athalia (CDC/DDPHSS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: Re: For IM/PDIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The

authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.

- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Brian

Brian A. King, PhD, MPH

Lead, *Strategic Science Unit, CDC COVID-19 Response*

Guest Science Editor, *Morbidity and Mortality Weekly Report Series*

E-mail: baking@cdc.gov

Phone: 770.488.5107 / 770.570.6330

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:43 PM

To: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2

<eocdhsln02@cdc.gov>; Christie, Athalia (CDC/DDPHSS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

IM/PDIM,

We are requesting your review of the attached MMWR (ID# 1464). Please return your comments by 6pm on 8/2.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>

Sent: Sunday, August 1, 2021 9:57 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Cleared with no additional comments

Paul Mead, MD, MPH
Deputy Incident Manager (Epi, Lab, Data Visualization Task Forces)
CDC COVID-19 Response
Cell: 970-567-5024

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 4:57 PM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi DIMs,

This is a Tier 1 report and we provided the wrong deadline. Please return your comments by 6pm on 8/2, if possible. This one is expected to publish at the end of the week.

Apologies for the inconvenience.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:28 AM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For DIM Review by 10:30am on 8/3/21: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

DIM Review,

Attached is the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review.

Comments are due by 10:30am on 8/3/21.

Thank you,

Jeanita Porter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>

Sent: Saturday, July 31, 2021 5:06 PM

To: CDC IMS JIC Emergency Clearance-3 <eocticclear3@cdc.gov>; Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPHP/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPHP/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

This MMWR has been reviewed by 2 rADS, Mary D. Ari and Harrell Chesson, and is cleared with the understanding that comments will be addressed and considered as noted.

Thanks for the opportunity to review.

Best regards,
Harrell

Harrell Chesson, PhD
COVID-19 Response ADS Team Reviewer
404-639-8182
404-551-7377

Division of STD Prevention
Centers for Disease Control and Prevention
CDC Mail-Stop US12-3
1600 Clifton Road
Atlanta, GA 30319

From: CDC IMS JIC Emergency Clearance-3 <eocticclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:56 PM

To: Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPHP/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPHP/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocticclear3@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

ADS Team...

Attached you will find the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review. Comments are due by 6:00p on 8/2/21.

HEADS-UP: They have requested expedited review and are seeking DIM approval so this deadline may change.

Regards,

Lisa Lynch

JIC Emergency Clearance: eocticclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS 2019 NCOV Response EPI Clearance <eocticclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:35 PM

To: CDC IMS JIC Emergency Clearance-3 <eocticclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocticclear3@cdc.gov>

Subject: Request for Review: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

JIC,

Epi TF is submitting Alyson Cavanaugh's **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky" for **expedited** review. Attached includes tracked changes and clean copies of the Article, Tables 1-3 a Supplementary figure and the clearance request form. This document has been cross-cleared by VTF, HSWS, SSU, and CHEO TFs.

Thank you,

Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocticclear3@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 30, 2021 7:16 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

I have track changes that address the minor comments from SSU. I know CHEO cleared with comments, but I am unsure where to find additional comments from CHEO. I have e-mailed for further clarification.

The supplementary figure was edited in terms of placement of arrows/boxes and track changes weren't used for formatting, per comments.

Clean copies of manuscript, three tables, and supplementary figure are attached.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Thursday, July 29, 2021 7:29 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Thank you for clarifying!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Thursday, July 29, 2021 7:27 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Yes – it's an odd step in the current protocol – but currently you are required to handle this review with SSU and CHEO. We recommend cc'ing the Epi Clearance mailbox (eocevent210@cdc.gov) so that we can keep an eye on how it's moving, and help you follow up as needed.

I think they may be revisiting this procedure soon; I'm sorry this part is so complicated/unusual. But yes, please proceed with SSU and CHEO clearance.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:21 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I did not sent this to CHEO and SSU. Should I?

In the past, the clearance coordinator sent my manuscript to them. However, the instructions from MMWR pre-review said:

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies

of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance.

I wanted to check with you to see if I should send to SSU and CHEO or should clearance coordinator be managing this part?

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:18 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

To clarify, *did* you already send this to SSU and CHEO for pre-clearance? If so, please update your clearance request form to reflect this, and then we can proceed with JIC clearance. If not, you will need to complete that step independently before we (epi clearance) take it from you and go on to JIC.

Thanks!

Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:09 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I received feedback from MMWR pre-review. I am attaching the clean copies of the manuscript, tables and figure for MMWR 1464. I was told to e-mail to CHEO and SSU. However, I believe you will pass this on? Please let me know if I should be sending this anywhere else at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 12:44 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I think that "4289" in the subject line was used by VTF when they re-reviewed it, and we can disregard that entirely.

Actually, the next step is for you to submit this to MMWR pre-clearance. We do not handle that step in the process. Epi TF clearance coordinators should be looped back in after you receive clearance from Brian King and his group.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 25, 2021 12:33 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached clean and track versions.

I believe this is MMWR 1464. Is that correct? I added 1464 on the clearance request form, but this may need to be edited (The subject heading says 4289).

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 11:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF has cleared your MMWR. Please address the comments in the link below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Your next step is to send clean and tracked versions, along with an updated clearance request form, to MMWR pre-clearance.

Once you have been cleared by MMWR pre-clearance, please return the latest clean and tracked copies, and an updated clearance request form, to this mailbox for submission to SSU and CHEO.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Sunday, July 25, 2021 11:04 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

Please see following from JIC:

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Saturday, July 24, 2021 4:06 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is cleared by VTF ADS with comments that should be addressed.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Friday, July 23, 2021 2:04 PM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,

Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 23, 2021 1:11 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE-REVIEW due 7/24 at 1:30PM - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

VTF,

Alyson Cavanaugh is submitting this **Tier 1 MMWR article** for your re-review. Attached is a clean copy and tracked

changes copy with comments addressed. The requested deadline for your re-review is **7/24 at 1:30PM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov
Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays
Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 23, 2021 12:58 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached track and clean copies of revised paper. We believe the changes in analysis are appropriate to address concerns. However, if additional changes are suggested, please let us know.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Wednesday, July 21, 2021 3:45 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with

reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson,

VTF did not clear your MMWR article. Please see their comments in the attached Word doc. Additional notes from reviewers below:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

Please address comments and resubmit a clean copy and tracked changes copy for re-review with VTF.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Wednesday, July 21, 2021 3:27 PM

To: Bunting, Hannah (CDC/DDID/NCIRD/OD) (CTR) <rou3@cdc.gov>

Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

The below document is **not cleared** by VTF. Please address comments in the below link and return clean and tracked changes copies for re-review. Additionally, please note the following:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov
Dany Hall: qij7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

**Hours of Operation: 8:30am-5:30pm EST Monday-Friday
2-5pm EST Saturday & 12-3pm EST Sunday**

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>
Sent: Wednesday, July 21, 2021 2:45 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>
Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>
Subject: RE: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is not cleared by VTF ADS. Please see comment below and submit a revised version.

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.
For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).
For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Wednesday, July 21, 2021 9:26 AM
To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>
Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is

attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: gij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday-Friday

2-5pm EST Saturday & 12-3pm EST Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Wednesday, July 21, 2021 7:20 AM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good Morning VTF,

The author has made changes and we are requesting a re review. Please find clean and tracked copies attached.

Deadline for review is **7/22 by 8 AM**

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Tuesday, July 20, 2021 9:05 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>

Subject: RE: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced

risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please find attached the clean and track changes of MMWR on reinfections and vaccination. Please let me know if anything further is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Saturday, July 17, 2021 1:22 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF did not clear your MMWR. Please address the comments in the attached file and return clean and tracked copies for re-review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Saturday, July 17, 2021 1:08 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Epi,

The below document is **not cleared** by VTF. Please return clean and tracked changes copies for re-review.

[Reinfection and vaccination status_07.14.21_clean.docx](#)
[Clearance Request Form_July 14_reinfection.docx](#)

Thanks,

Dany

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8am-8pm EST Monday-Friday

12pm-5pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Saturday, July 17, 2021 12:41 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lk66@cdc.gov>
Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Please advise the status of the requested cross-clearance review of the MMWR titled "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky." The review was due **Friday, 7/16, at 10 a.m.**

[Reinfection and vaccination status_07.14.21_clean.docx](#)

We request the courtesy of a response with a status update.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 16, 2021 2:29 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Reminder - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Epi TF still requests your comments on this Tier 1 MMWR. As a reminder, here is the link:

[Reinfection and vaccination status_07.14.21_clean.docx](#)

Comments were due at 10 a.m., so please return your comments as soon as possible so that we can proceed with the clearance process.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 16, 2021 11:28 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Reminder - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear HSWS and VTF,

This is a gentle reminder that your cross-clearance of this MMWR was due today at 10 a.m.

[Reinfection and vaccination status_07.14.21_clean.docx](#)

This is a Tier 1 MMWR. Please return your review as quickly as possible.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Thursday, July 15, 2021 10:04 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response CICP ADS/Clearance <eocdgmqsitrep@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF, HSWS, and CICP TFs,

Epi TF requests cross-clearance of the **Tier 1 MMWR**, "*COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky.*"

Please use the SharePoint link below during your review. Please indicate whether you clear the manuscript with major/minor comments, with no comments, or do not clear.

The deadline for your review is **7/16 at 10:00 a.m.**

- [Reinfection and vaccination status_07.14.21_clean.docx](#)

CICP clearance coordinators: please forward this MMWR for review to your new POC ASAP, as we are aware your ADS/TF are no longer accepting submissions. Thank you.

Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, July 14, 2021 6:13 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please see attached track and clean changes where all comments were addressed.

I am also attaching the clearance form. I deleted the section about cross task force review. I apologize for the confusion. That was filled in with the template that was sent me and I didn't see it. Therefore I hadn't deleted that section before submitting the form for this MMWR.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, July 13, 2021 12:24 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Epi ADS re-reviewed and cleared your MMWR with comments in the attached document. Please address comments and resubmit both a **clean copy** and a **tracked changes copy** to proceed with cross-clearance.

Also, your clearance request form originally stated that this MMWR article has been cleared by STLT, HSWS, and CICP. You and STLT have confirmed that Epi TF is the only TF to have reviewed it yet. When you resubmit, please update your clearance request form to reflect that only Epi TF has cleared it thus far.

Thank you!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Tuesday, July 13, 2021 11:42 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Clearance Team—this review is complete.

Reviewer: Lisa Grohskopf (ADS), Ruth Link-Gelles (SME)
Decision: Cleared with comments, some mandatory
Comments: please see attached
Please send to Lab TF as informational (not for cross clearance).

Thank,
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, July 12, 2021 7:20 AM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <llkg6@cdc.gov>
Subject: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning Epi ADS,

Lisa -- Alyson Cavanaugh is submitting her **Tier 1 MMWR** for re-review: *“COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky”*. Attached includes a clean copy and a tracked changes copy. See your initial decision record below:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

The deadline for your re-review of this expedited article is **7/13 at 7:30AM**.

Thank you,

Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Sent: Sunday, July 11, 2021 9:56 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Thank you very much for the review. Please see attached clean and track changes of edits based on the suggestions. All comments have been addressed.

This paper has only been reviewed by epi TF to date. Am I supposed to send to the other task forces for cross-clearance? No other task forces have yet reviewed this.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department of Public Health

275 E. Main St.

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Sunday, July 11, 2021 8:00 AM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>

Subject: Fwd: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS < >

Subject: Fw: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

Epi TF has reviewed and **does not clear** this MMWR. Please see the following comments:

Reviewer: Lisa Grohskopf (ADS)

Decision: Not Cleared, with comments (some mandatory).

Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Please address the comments in the attached document and submit clean and tracked copies for re-review. Additionally, please provide documentation of cross-clearance by STLT, CICIP, and HSWS.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Saturday, July 10, 2021 12:22 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Clearance Team! This review is complete.

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Thanks!
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 12:32 PM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Team,

The attached Tier 1 MMWR, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky," is submitted for review. The deadline for review is **Saturday, 7/10, at 12:30 p.m.**

The clearance request form notes that CICP, STLT, and HSWS have already cleared this.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 12:24 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Please see attached clearance form for MMWR 1464.

Let me know if I need to do anything additionally at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 9:18 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Thank you, Anna!

Alyson,

I see you attached the manuscript but mention that it still needs co-author feedback, is that correct? When you are ready to submit for JIC clearance please send the manuscript and the completed request form I have attached. I have also attached the SOP for moving MMWRs through clearance to help with any questions on the process going forward.

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Friday, July 9, 2021 9:09 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Hi Katie,

Epi TF has "adopted" this manuscript for COVID-19 Clearance and Alyson has submitted to begin the clearance process with Epi TF. Let me know if you have any questions.

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 8:28 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Alyson,

Is this an FYI that this MMWR is coming for review? Are you asking for any action from the Epi TF at this time?

Best,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 7:06 AM
To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Good morning,

Attached is the manuscript for MMWR 1464 regarding reinfections and vaccination status.

I am making some edits based on co-authors' feedback for 1459, but hope to have the paper ready tomorrow.

I believe both will be "adopted" by the vaccine task force because they involve vaccine effectiveness. Please let me know any next steps for this submission.

V/R,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Thursday, July 8, 2021 2:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Dear Alyson,

Following up on your VE/VB MMWR manuscripts, the COVID-19 Response Incident Manager would like to have both 1459 and 1464 published in about a month (see email below). I have copied the Epi Clearance Coordinators (eocevent210@cdc.gov) and Epi ADS (eocevent496@cdc.gov), who are ready to help you begin the COVID-19 Clearance Process. When do you anticipate submitting these manuscripts?

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Thursday, July 8, 2021 10:07 AM
To: Anderson, Mark (CDC/DDPHSS/CGH/DGHP) <mea6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <jyn3@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Mark, as mentioned yesterday, Peggy would really like to have these published by end of month-early August. They are top response priorities. Is there anything I can do to facilitate process?

1464	Reinfection associated with vaccination status - Kentucky, May-June 2021 (Alyson Cavanaugh)	Concept approved 6/30
1459	Low county-level vaccination coverage increases the risk of breakthrough infections among fully vaccinated Kentucky residents – Kentucky, May 2021 (Alyson Cavanaugh)	Concept approved 6/30

Apologies for not sending this note yesterday.

Best,
Charlotte

Charlotte Kent, PhD, MPH
Editor-in-Chief, *Morbidity and Mortality Weekly Report (MMWR)* Series
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Monday, August 2, 2021 12:05:06 PM
Attachments: [image002.png](#)
[Cavanaugh_07.30_clean_copy_HC_MDA_IMPDM.docx](#)
[TABLE 2_07.29.21_SSU1_HC_MDA.docx](#)
[TABLE 1_07.29.21_SSU1_HC_MDA.docx](#)
[FIGURE Supplementary_07.30.21_HC_MDA.docx](#)
[TABLE 3_07.29.21_SSU1_HC_MDA.docx](#)

Good afternoon,

Here are comments on manuscript, tables, and figure.

I will begin working on manuscript at this time. Here is the link for any suggestions for manuscript:



Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, August 2, 2021 11:42 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Fw: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi Alyson,

JIC is returning your MMWR with comments. Please note these remarks:

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The

authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.

- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Please address their comments and submit clean copies for OS review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Monday, August 2, 2021 11:39 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi,

Please revise and submit clean copies for OS Review.

Please see below from IM/PDIM,

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Thank you,

Kaliyah Hunter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <lyn3@cdc.gov>

Sent: Monday, August 2, 2021 11:35 AM

To: CDC IMS JIC Emergency Clearance-3 <eojjcclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eo cdhslno2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: Re: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained

free from reinfection" could more simply be stated as "persons who were not reinfected".

Brian

Brian A. King, PhD, MPH

Lead, *Strategic Science Unit, CDC COVID-19 Response*

Guest Science Editor, *Morbidity and Mortality Weekly Report Series*

E-mail: baking@cdc.gov

Phone: 770.488.5107 / 770.570.6330

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:43 PM

To: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsln2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

IM/PDIM,

We are requesting your review of the attached MMWR (ID# 1464). Please return your comments by 6pm on 8/2.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>

Sent: Sunday, August 1, 2021 9:57 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Cleared with no additional comments

Paul Mead, MD, MPH
Deputy Incident Manager (Epi, Lab, Data Visualization Task Forces)
CDC COVID-19 Response
Cell: 970-567-5024

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Sunday, August 1, 2021 4:57 PM
To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi DIMs,

This is a Tier 1 report and we provided the wrong deadline. Please return your comments by 6pm on 8/2, if possible. This one is expected to publish at the end of the week.

Apologies for the inconvenience.

Thank you,

Brian Panasuk
JIC Emergency Clearance: eocjicclear3@cdc.gov
COVID-19 Response Joint Information Center (JIC)
Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Sunday, August 1, 2021 10:28 AM
To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>
Subject: For DIM Review by 10:30am on 8/3/21: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

DIM Review,

Attached is the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review.

Comments are due by 10:30am on 8/3/21.

Thank you,

Jeanita Porter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>

Sent: Saturday, July 31, 2021 5:06 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPPH/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPPH/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rs14@cdc.gov>

Cc: CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

This MMWR has been reviewed by 2 rADS, Mary D. Ari and Harrell Chesson, and is cleared with the understanding that comments will be addressed and considered as noted.

Thanks for the opportunity to review.

Best regards,
Harrell

Harrell Chesson, PhD
COVID-19 Response ADS Team Reviewer
404-639-8182
404-551-7377

Division of STD Prevention

Centers for Disease Control and Prevention
CDC Mail-Stop US12-3
1600 Clifton Road
Atlanta, GA 30319

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:56 PM

To: Cassell, Cynthia H. (CDC/DDPHSIS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPPH/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSIS/CPR/OD) <sxs8@cdc.gov>; Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPPH/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <ruv4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

ADS Team...

Attached you will find the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review. Comments are due by 6:00p on 8/2/21.

HEADS-UP: They have requested expedited review and are seeking DIM approval so this deadline may chance.

Regards,

Lisa Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 30, 2021 7:35 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Request for Review: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

JIC,

Epi TF is submitting Alyson Cavanaugh's **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky" for **expedited** review. Attached includes tracked changes and clean copies of the Article, Tables 1-3 a Supplementary figure and the clearance request form. This document has been cross-cleared by VTF, HSWS, SSU, and CHEO TFs.

Thank you,
Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 30, 2021 7:16 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

I have track changes that address the minor comments from SSU. I know CHEO cleared with comments, but I am unsure where to find additional comments from CHEO. I have e-mailed for further clarification.

The supplementary figure was edited in terms of placement of arrows/boxes and track changes weren't used for formatting, per comments.

Clean copies of manuscript, three tables, and supplementary figure are attached.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Thursday, July 29, 2021 7:29 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Thank you for clarifying!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Thursday, July 29, 2021 7:27 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Yes – it’s an odd step in the current protocol – but currently you are required to handle this review with SSU and CHEO. We recommend cc’ing the Epi Clearance mailbox (eocevent210@cdc.gov) so that we can keep an eye on how it’s moving, and help you follow up as needed.

I think they may be revisiting this procedure soon; I’m sorry this part is so complicated/unusual. But yes, please proceed with SSU and CHEO clearance.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance

COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:21 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I did not sent this to CHEO and SSU. Should I?

In the past, the clearance coordinator sent my manuscript to them. However, the instructions from MMWR pre-review said:

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance.

I wanted to check with you to see if I should send to SSU and CHEO or should clearance coordinator be managing this part?

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Thursday, July 29, 2021 7:18 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance

<eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

To clarify, *did* you already send this to SSU and CHEO for pre-clearance? If so, please update your clearance request form to reflect this, and then we can proceed with JIC clearance. If not, you will need to complete that step independently before we (epi clearance) take it from you and go on to JIC.

Thanks!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I received feedback from MMWR pre-review. I am attaching the clean copies of the manuscript, tables and figure for MMWR 1464. I was told to e-mail to CHEO and SSU. However, I believe you will pass this on? Please let me know if I should be sending this anywhere else at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If

the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 12:44 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I think that "4289" in the subject line was used by VTF when they re-reviewed it, and we can disregard that entirely.

Actually, the next step is for you to submit this to MMWR pre-clearance. We do not handle that step in the process. Epi TF clearance coordinators should be looped back in after you receive clearance from Brian King and his group.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 25, 2021 12:33 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached clean and track versions.

I believe this is MMWR 1464. Is that correct? I added 1464 on the clearance request form, but this may need to be edited (The subject heading says 4289).

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Sunday, July 25, 2021 11:25 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF has cleared your MMWR. Please address the comments in the link below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Your next step is to send clean and tracked versions, along with an updated clearance request form, to MMWR pre-clearance.

Once you have been cleared by MMWR pre-clearance, please return the latest clean and tracked copies, and an updated clearance request form, to this mailbox for submission to SSU and CHEO.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Sunday, July 25, 2021 11:04 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

Please see following from JIC:

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Saturday, July 24, 2021 4:06 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is cleared by VTF ADS with comments that should be addressed.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Friday, July 23, 2021 2:04 PM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSSELS/OD) <pzs1@cdc.gov>

Subject: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,

Kimberly
Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov
Dany Hall: qjj7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday
11am-1pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 23, 2021 1:11 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE-REVIEW due 7/24 at 1:30PM - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

VTF,

Alyson Cavanaugh is submitting this **Tier 1 MMWR article** for your re-review. Attached is a clean copy and tracked changes copy with comments addressed. The requested deadline for your re-review is **7/24 at 1:30PM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov
Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays
Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 23, 2021 12:58 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached track and clean copies of revised paper. We believe the changes in analysis are appropriate to address concerns. However, if additional changes are suggested, please let us know.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Wednesday, July 21, 2021 3:45 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson,

VTF did not clear your MMWR article. Please see their comments in the attached Word doc. Additional notes from reviewers below:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.
For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).
For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).
We are happy to discuss further with authors if they have any questions or concerns.

Please address comments and resubmit a clean copy and tracked changes copy for re-review with VTF.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Wednesday, July 21, 2021 3:27 PM
To: Bunting, Hannah (CDC/DDID/NCIRD/OD) (CTR) <rou3@cdc.gov>
Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

The below document is **not cleared** by VTF. Please address comments in the below link and return clean and tracked changes copies for re-review. Additionally, please note the following:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

**Hours of Operation: 8:30am-5:30pm EST Monday-Friday
2-5pm EST Saturday & 12-3pm EST Sunday**

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>
Sent: Wednesday, July 21, 2021 2:45 PM
To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSLS/OD) <pzs1@cdc.gov>
Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>
Subject: RE: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is not cleared by VTF ADS. Please see comment below and submit a revised version.

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Wednesday, July 21, 2021 9:26 AM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday-Friday

2-5pm EST Saturday & 12-3pm EST Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Wednesday, July 21, 2021 7:20 AM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good Morning VTF,

The author has made changes and we are requesting a re review. Please find clean and tracked copies attached.

Deadline for review is **7/22 by 8 AM**

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, July 20, 2021 9:05 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please find attached the clean and track changes of MMWR on reinfections and vaccination. Please let me know if anything further is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Saturday, July 17, 2021 1:22 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF did not clear your MMWR. Please address the comments in the attached file and return clean and tracked copies for re-review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Saturday, July 17, 2021 1:08 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Epi,

The below document is **not cleared** by VTF. Please return clean and tracked changes copies for re-review.

[Reinfection and vaccination status_07.14.21_clean.docx](#)
[Clearance Request Form_July 14_reinfection.docx](#)

Thanks,
Dany

Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qjj7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8am-8pm EST Monday-Friday

12pm-5pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Saturday, July 17, 2021 12:41 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <llkg6@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Please advise the status of the requested cross-clearance review of the MMWR titled "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky." The review was due **Friday, 7/16, at 10 a.m.**

[Reinfection and vaccination status_07.14.21_clean.docx](#)

We request the courtesy of a response with a status update.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

**Katie Garvin gqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov**

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 16, 2021 2:29 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Epi TF still requests your comments on this Tier 1 MMWR. As a reminder, here is the link:

[Reinfection and vaccination status_07.14.21_clean.docx](#)

Comments were due at 10 a.m., so please return your comments as soon as possible so that we can proceed with the clearance process.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE**

eoevent210@cdc.gov

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Sent: Friday, July 16, 2021 11:28 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eoevent229@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eoevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear HSWS and VTF,

This is a gentle reminder that your cross-clearance of this MMWR was due today at 10 a.m.

 [Reinfection and vaccination status_07.14.21_clean.docx](#)

This is a Tier 1 MMWR. Please return your review as quickly as possible.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eoevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin ggz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Sent: Thursday, July 15, 2021 10:04 AM
To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eoevent229@cdc.gov>; CDC IMS 2019 NCOV Response CICP ADS/Clearance <ocdgmqsitrep@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eoevent454@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eoevent210@cdc.gov>
Subject: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF, HSWS, and CICP TFs,

Epi TF requests cross-clearance of the **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky."

Please use the SharePoint link below during your review. Please indicate whether you clear the manuscript with major/minor comments, with no comments, or do not clear.

The deadline for your review is 7/16 at 10:00 a.m.

- [Reinfection and vaccination status_07.14.21_clean.docx](#)

CICP clearance coordinators: please forward this MMWR for review to your new POC ASAP, as we are aware your ADS/TF are no longer accepting submissions. Thank you.

Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin gqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, July 14, 2021 6:13 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please see attached track and clean changes where all comments were addressed.

I am also attaching the clearance form. I deleted the section about cross task force review. I apologize for the confusion. That was filled in with the template that was sent me and I didn't see it. Therefore I hadn't deleted that section before submitting the form for this MMWR.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, July 13, 2021 12:24 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Epi ADS re-reviewed and cleared your MMWR with comments in the attached document. Please address comments and resubmit both a **clean copy** and a **tracked changes copy** to proceed with cross-clearance.

Also, your clearance request form originally stated that this MMWR article has been cleared by STLT, HSWS, and CICP. You and STLT have confirmed that Epi TF is the only TF to have reviewed it yet. When you resubmit, please update your clearance request form to reflect that only Epi TF has cleared it thus far.

Thank you!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Tuesday, July 13, 2021 11:42 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Clearance Team—this review is complete.

Reviewer: Lisa Grohskopf (ADS), Ruth Link-Gelles (SME)
Decision: Cleared with comments, some mandatory
Comments: please see attached
Please send to Lab TF as informational (not for cross clearance).

Thank,
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, July 12, 2021 7:20 AM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lg6@cdc.gov>
Subject: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning Epi ADS,

Lisa -- Alyson Cavanaugh is submitting her **Tier 1 MMWR** for re-review: "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky". Attached includes a clean copy and a tracked changes copy. See your initial decision record below:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

The deadline for your re-review of this expedited article is **7/13 at 7:30AM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Sunday, July 11, 2021 9:56 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Thank you very much for the review. Please see attached clean and track changes of edits based on the suggestions. All comments have been addressed.

This paper has only been reviewed by epi TF to date. Am I supposed to send to the other task forces for cross-clearance? No other task forces have yet reviewed this.

Thank you,
Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department of Public Health
275 E. Main St.
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 11, 2021 8:00 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: Fwd: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <>
Subject: Fw: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

Epi TF has reviewed and **does not clear** this MMWR. Please see the following comments:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Please address the comments in the attached document and submit clean and tracked copies for re-review. Additionally, please provide documentation of cross-clearance by STLT, CICP, and HSWS.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Saturday, July 10, 2021 12:22 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Clearance Team! This review is complete.

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Thanks!
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 12:32 PM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Team,

The attached Tier 1 MMWR, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk

of reinfection – May through June, 2021 - Kentucky," is submitted for review. The deadline for review is Saturday, 7/10, at 12:30 p.m.

The clearance request form notes that CICP, STLT, and HSWS have already cleared this.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 12:24 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Please see attached clearance form for MMWR 1464.

Let me know if I need to do anything additionally at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 9:18 AM
To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Thank you, Anna!

Alyson,

I see you attached the manuscript but mention that it still needs co-author feedback, is that correct? When you are ready to submit for JIC clearance please send the manuscript and the completed request form I have attached. I have also attached the SOP for moving MMWRs through clearance to help with any questions on the process going forward.

Best Regards,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin ggz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Sent: Friday, July 9, 2021 9:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Hi Katie,

Epi TF has "adopted" this manuscript for COVID-19 Clearance and Alyson has submitted to begin the clearance process with Epi TF. Let me know if you have any questions.

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 8:28 AM

To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Alyson,

Is this an FYI that this MMWR is coming for review? Are you asking for any action from the Epi TF at this time?

Best,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 9, 2021 7:06 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Good morning,

Attached is the manuscript for MMWR 1464 regarding reinfections and vaccination status.

I am making some edits based on co-authors' feedback for 1459, but hope to have the paper ready tomorrow.

I believe both will be "adopted" by the vaccine task force because they involve vaccine effectiveness. Please let me know any next steps for this submission.

V/R,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and

destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Thursday, July 8, 2021 2:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Dear Alyson,

Following up on your VE/VB MMWR manuscripts, the COVID-19 Response Incident Manager would like to have both 1459 and 1464 published in about a month (see email below). I have copied the Epi Clearance Coordinators (eocevent210@cdc.gov) and Epi ADS (eocevent496@cdc.gov), who are ready to help you begin the COVID-19 Clearance Process. When do you anticipate submitting these manuscripts?

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Thursday, July 8, 2021 10:07 AM
To: Anderson, Mark (CDC/DDPHSS/CGH/DGHP) <mea6@cdc.gov>
Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <jyn3@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Mark, as mentioned yesterday, Peggy would really like to have these published by end of month-early August. They are top response priorities. Is there anything I can do to facilitate process?

1464	Reinfection associated with vaccination status - Kentucky, May-June 2021 (Alyson Cavanaugh)	Concept approved 6/30
1459	Low county-level vaccination coverage increases the risk of breakthrough infections among fully vaccinated Kentucky residents – Kentucky, May 2021 (Alyson Cavanaugh)	Concept approved 6/30

Apologies for not sending this note yesterday.

Best,
Charlotte

Charlotte Kent, PhD, MPH

Editor-in-Chief, *Morbidity and Mortality Weekly Report (MMWR)* Series
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Monday, August 2, 2021 4:55:58 PM
Attachments: [image002.png](#)
[Cavanaugh_08.02_track.docx](#)
[Cavanaugh_08.02_clean.docx](#)
[TABLE 1_08.02.21_track.docx](#)
[TABLE 1_08.02.21_clean.docx](#)
[TABLE 2_08.02.21_clean.docx](#)
[TABLE 3_08.2.21_clean.docx](#)
[TABLE 3_08.2.21_track.docx](#)
[TABLE 2_08.02.21_track.docx](#)

For your records – and in case anyone wants to re-look at this prior to next round of revisions.

(Also – remind me of this day if I ever think about an MMWR concept proposal again).

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Monday, August 2, 2021 4:51 PM
To: 'CDC IMS 2019 NCOV Response EPI Clearance' <eocevent210@cdc.gov>
Subject: RE: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good afternoon,

I am attaching track changes for manuscript and three tables, as well as clean copies of all. We will not be including the supplementary figure in submission.

Please let me know if anything else is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, August 2, 2021 11:42 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Fw: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi Alyson,

JIC is returning your MMWR with comments. Please note these remarks:

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
-

Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.

- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Please address their comments and submit clean copies for OS review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Monday, August 2, 2021 11:39 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Returning for Revision (OS Review Next) - (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi,

Please revise and submit clean copies for OS Review.

Please see below from IM/PDIM,

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").
- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Thank you,

Kaliyah Hunter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

From: King, Brian a. (CDC/DDNID/NCCDPHP/OSH) <iyn3@cdc.gov>

Sent: Monday, August 2, 2021 11:35 AM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eocdhsln2@cdc.gov>; Christie, Athalia (CDC/DDPHSIS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: Re: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Approved for IM/PDIM with the expectation that comments and edits in the attached are addressed. A few key points:

- A more robust acknowledgment of the non-significant partial vaccination findings should be noted in the abstract paragraph so as to not inadvertently suggest that an attempt is being made to bury them. The authors appropriately include a discussion of the potential reason for the lack of significance in the Discussion section, which may be due to limited statistical power. Similar framing should be used in the abstract paragraph as well. Of note, I disagree with a previous reviewer's suggestion around framing of these findings; I believe the authors took the correct approach by being forthright about stating the finding was non-significant in the Results, while using the Discussion to articulate what might have led to that finding and what the implications are.
- Several sections of the manuscript are overly verbose and technical, which could limit the ability to fully realize the report's potential for informing public health practice. I've made several suggestions throughout to tighten up the text, as well as to simplify the public health practice take-home (i.e. These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. Persons with previous infection should be encouraged to be fully vaccinated to reduce their risk of reinfection).
- Care should be taken to not overstate the findings based on the employed study design. A case-control study is a strong epidemiological approach to ascertain an association, but it is retrospective and isn't as fully robust at identifying a causal relationship as a prospective design. That said, the limitations narrative should be further fleshed out to acknowledge this, while also reinforcing the importance of further prospective research to assess this issue.
- A limitation also needs to be added that more directly broaches the external validity of the findings (i.e. generalizability). The study was conducted in a single state, over a two-month time period, and with a sample of a few hundred people. It's an important contribution to the literature, but these factors need to be duly acknowledged and the findings tempered accordingly (e.g. "findings suggest that").

- Please ensure that terminology, particularly around the measures, is described as clearly as it could be. For example, the existing narrative suggests varying criteria were used to define vaccination status in cases versus controls, which wasn't actually the case. Similarly, phrases such as "persons who remained free from reinfection" could more simply be stated as "persons who were not reinfected".

Brian

Brian A. King, PhD, MPH

Lead, *Strategic Science Unit, CDC COVID-19 Response*

Guest Science Editor, *Morbidity and Mortality Weekly Report Series*

E-mail: baking@cdc.gov

Phone: 770.488.5107 / 770.570.6330

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:43 PM

To: CDC IMS 2019 NCOV Response IM-PDIM Special Assts <eocevent446@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS Incident Manager Senior Advisor -2 <eodchslno2@cdc.gov>; Christie, Athalia (CDC/DDPHSS/CGH/OD) <akc9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; Protzel Berman, Pamela (ATSDR/OPPE) <pxp5@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For IM/DIM Review by 6pm on 8/2: (ID1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

IM/PDIM,

We are requesting your review of the attached MMWR (ID# 1464). Please return your comments by 6pm on 8/2.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>

Sent: Sunday, August 1, 2021 9:57 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Cleared with no additional comments

Paul Mead, MD, MPH
Deputy Incident Manager (Epi, Lab, Data Visualization Task Forces)
CDC COVID-19 Response
Cell: 970-567-5024

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 4:57 PM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPPH/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPPH/DPH) <cht2@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Updated Deadline - For DIM Review by 6pm on 8/2: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi DIMs,

This is a Tier 1 report and we provided the wrong deadline. Please return your comments by 6pm on 8/2, if possible. This one is expected to publish at the end of the week.

Apologies for the inconvenience.

Thank you,

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Sunday, August 1, 2021 10:28 AM

To: CDC IMS 2019 NCOV Response Deputy Incident Manager <eocevent259@cdc.gov>; Hacker, Karen (CDC/DDNID/NCCDPHP/OD) <pju3@cdc.gov>; Mead, Paul (CDC/DDID/NCEZID/DVBD) <pfm0@cdc.gov>; Thomas, Craig W. (CDC/DDNID/NCCDPHP/DPH) <cht2@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For DIM Review by 10:30am on 8/3/21: (ID1464)MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

DIM Review,

Attached is the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review.

Comments are due by 10:30am on 8/3/21.

Thank you,

Jeanita Porter

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>

Sent: Saturday, July 31, 2021 5:06 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Cassell, Cynthia H. (CDC/DDPHSS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPHP/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSS/CPR/OD) <sxs8@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPHP/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>

Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: RE: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

This MMWR has been reviewed by 2 rADS, Mary D. Ari and Harrell Chesson, and is cleared with the understanding that comments will be addressed and considered as noted.

Thanks for the opportunity to review.

Best regards,
Harrell

Harrell Chesson, PhD
COVID-19 Response ADS Team Reviewer
404-639-8182
404-551-7377

Division of STD Prevention
Centers for Disease Control and Prevention
CDC Mail-Stop US12-3
1600 Clifton Road
Atlanta, GA 30319

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Friday, July 30, 2021 7:56 PM

To: Cassell, Cynthia H. (CDC/DDPHSS/CGH/DGHP) <ivv7@cdc.gov>; George, Mary G. (CDC/DDNID/NCCDPHP/DHDSP) <coq5@cdc.gov>; CDC IMS 2019 NCOV Response ADS <eocevent264@cdc.gov>; Parham, Mary Angela (CDC/DDID/NCIRD/OD) (CTR) <ydl2@cdc.gov>; Steiner, Sandra (CDC/DDPHSS/CPR/OD) <sxs8@cdc.gov>; Chesson, Harrell (CDC/DDID/NCHHSTP/DSTDP) <hbc7@cdc.gov>; Robinson, Tashina (CDC/NIOSH/SMRD/MHB) <ngg9@cdc.gov>; Muthumalaiappan, Kuzhali (CDC/DDID/NCIRD/OD) (CTR) <rui3@cdc.gov>; Eiter, Brianna (CDC/NIOSH/SMRD/MHB) <viy3@cdc.gov>; DeSisto, Carla Lucia (CDC/DDNID/NCCDPHP/DRH) <WUP5@cdc.gov>; Rajakumar, Augustine (CDC/DDID/NCIRD/OD) (CTR) <rux4@cdc.gov>; Ari, Mary D. (CDC/DDPHSS/OS/OSQ) <mkb9@cdc.gov>; Leeb, Rebecca (CDC/DDNID/NCBDDD/DHDD) <rsl4@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response Policy <eocevent209@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: For ADS Review by 6:00p on 8/2/21: MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

ADS Team...

Attached you will find the MMWR-COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 – Kentucky for your review. Comments are due by 6:00p on 8/2/21.

HEADS-UP: They have requested expedited review and are seeking DIM approval so this deadline may change.

Regards,

Lisa Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 30, 2021 7:35 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Request for Review: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

JIC,

Epi TF is submitting Alyson Cavanaugh's **Tier 1 MMWR**, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky" for **expedited** review. Attached includes tracked changes and clean copies of the Article, Tables 1-3 a Supplementary figure and the clearance request form. This document has been cross-cleared by VTF, HSWS, SSU, and CHEO TFs.

Thank you,

Hannah

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 30, 2021 7:16 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

I have track changes that address the minor comments from SSU. I know CHEO cleared with comments, but I am unsure where to find additional comments from CHEO. I have e-mailed for further clarification.

The supplementary figure was edited in terms of placement of arrows/boxes and track changes weren't used for formatting, per comments.

Clean copies of manuscript, three tables, and supplementary figure are attached.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Thursday, July 29, 2021 7:29 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Thank you for clarifying!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Yes – it’s an odd step in the current protocol – but currently you are required to handle this review with SSU and CHEO. We recommend cc’ing the Epi Clearance mailbox (eocevent210@cdc.gov) so that we can keep an eye on how it’s moving, and help you follow up as needed.

I think they may be revisiting this procedure soon; I’m sorry this part is so complicated/unusual. But yes, please proceed with SSU and CHEO clearance.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:21 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I did not sent this to CHEO and SSU. Should I?

In the past, the clearance coordinator sent my manuscript to them. However, the instructions from MMWR pre-review said:

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance.

I wanted to check with you to see if I should send to SSU and CHEO or should clearance coordinator be managing this part?

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 29, 2021 7:18 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

To clarify, *did* you already send this to SSU and CHEO for pre-clearance? If so, please update your clearance request form to reflect this, and then we can proceed with JIC clearance. If not, you will need to complete that step independently before we (epi clearance) take it from you and go on to JIC.

Thanks!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:09 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

I received feedback from MMWR pre-review. I am attaching the clean copies of the manuscript, tables and figure for MMWR 1464. I was told to e-mail to CHEO and SSU. However, I believe you will pass this on? Please let me know if I should be sending this anywhere else at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Sunday, July 25, 2021 12:44 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I think that "4289" in the subject line was used by VTF when they re-reviewed it, and we can disregard that entirely.

Actually, the next step is for you to submit this to MMWR pre-clearance. We do not handle that step in the process. Epi TF clearance coordinators should be looped back in after you receive clearance from Brian King and his group.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 25, 2021 12:33 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached clean and track versions.

I believe this is MMWR 1464. Is that correct? I added 1464 on the clearance request form, but this may need to be edited (The subject heading says 4289).

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Sunday, July 25, 2021 11:25 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF has cleared your MMWR. Please address the comments in the link below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Your next step is to send clean and tracked versions, along with an updated clearance request form, to MMWR pre-clearance.

Once you have been cleared by MMWR pre-clearance, please return the latest clean and tracked copies, and an updated clearance request form, to this mailbox for submission to SSU and CHEO.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Sunday, July 25, 2021 11:04 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced

risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

Please see following from JIC:

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: gij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday

11am-1pm EST Saturday & Sunday

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Saturday, July 24, 2021 4:06 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is cleared by VTF ADS with comments that should be addressed.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Friday, July 23, 2021 2:04 PM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.23.21_clean.docx](#)

Thanks,
Kimberly
Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday - Friday
11am-1pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 23, 2021 1:11 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>

Subject: RE-REVIEW due 7/24 at 1:30PM - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

VTF,

Alyson Cavanaugh is submitting this **Tier 1 MMWR article** for your re-review. Attached is a clean copy and tracked changes copy with comments addressed. The requested deadline for your re-review is **7/24 at 1:30PM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 23, 2021 12:58 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CELS/DSEPD) <qds1@cdc.gov>

Subject: RE: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Please see attached track and clean copies of revised paper. We believe the changes in analysis are appropriate to address concerns. However, if additional changes are suggested, please let us know.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Wednesday, July 21, 2021 3:45 PM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: VTF NOT CLEARED - Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson,

VTF did not clear your MMWR article. Please see their comments in the attached Word doc. Additional notes from reviewers below:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

Please address comments and resubmit a clean copy and tracked changes copy for re-review with VTF.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Wednesday, July 21, 2021 3:27 PM
To: Bunting, Hannah (CDC/DDID/NCIRD/OD) (CTR) <rou3@cdc.gov>
Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Hannah,

The below document is **not cleared** by VTF. Please address comments in the below link and return clean and tracked changes copies for re-review. Additionally, please note the following:

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
DeAngelo

Clearance Coordinator | Vaccine Task Force
COVID-19 Response
eocevent454@cdc.gov

VTF Clearance Coordinators:
Kimberly Sende: uwa0@cdc.gov
Dany Hall: qij7@cdc.gov
DeAngelo Bryant: lwk9@cdc.gov

**Hours of Operation: 8:30am-5:30pm EST Monday-Friday
2-5pm EST Saturday & 12-3pm EST Sunday**

From: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>

Sent: Wednesday, July 21, 2021 2:45 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Cc: Hadler, Stephen (CDC/DDID/NCIRD/DBD) (CTR) <sch1@cdc.gov>

Subject: RE: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

This is not cleared by VTF ADS. Please see comment below and submit a revised version.

While the authors addressed the comments well, their analyses of full and partially vaccinated are misleading and probably should be redone.

For the primary analysis, we suggest comparing fully vaccinated to unvaccinated (rather than to everyone who is not fully vaccinated, including partially vaccinated).

For the secondary analysis, we suggest comparing those who received only 1 dose to unvaccinated (rather than those who received at least 1 dose).

We are happy to discuss further with authors if they have any questions or concerns.

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Sent: Wednesday, July 21, 2021 9:26 AM

To: Hariri, Susan (CDC/DDID/NCIRD/DBD) <bse4@cdc.gov>; McNamara, Lucy Alexandra (CDC/DDID/NCIRD/DBD) <xdf4@cdc.gov>; Siegel, Paul Z. (CDC/DDPHSS/CSELS/OD) <pzs1@cdc.gov>

Subject: 4289 Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi all,

The author has addressed your comments and returned this document for re-review. The tracked changes version is attached for reference. However, please make any additional comments in the clean version linked below.

[Reinfection and vaccination status_07.20.21_clean.docx](#)

Thanks,
Kimberly

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8:30am-5:30pm EST Monday-Friday

2-5pm EST Saturday & 12-3pm EST Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Wednesday, July 21, 2021 7:20 AM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re Review Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good Morning VTF,

The author has made changes and we are requesting a re review. Please find clean and tracked copies attached.

Deadline for review is **7/22 by 8 AM**

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Tuesday, July 20, 2021 9:05 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please find attached the clean and track changes of MMWR on reinfections and vaccination. Please let me know if anything further is needed at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Saturday, July 17, 2021 1:22 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: Not Cleared Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

VTF did not clear your MMWR. Please address the comments in the attached file and return clean and tracked copies for re-review.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>
Sent: Saturday, July 17, 2021 1:08 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination

after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Epi,

The below document is **not cleared** by VTF. Please return clean and tracked changes copies for re-review.

[Reinfection and vaccination status_07.14.21_clean.docx](#)
[Clearance Request Form_July 14_reinfection.docx](#)

Thanks,

Dany

Clearance Coordinator | Vaccine Task Force

COVID-19 Response

eocevent454@cdc.gov

VTF Clearance Coordinators:

Kimberly Sende: uwa0@cdc.gov

Dany Hall: qij7@cdc.gov

DeAngelo Bryant: lwk9@cdc.gov

Hours of Operation: 8am-8pm EST Monday-Friday

12pm-5pm EST Saturday & Sunday

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Saturday, July 17, 2021 12:41 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lkg6@cdc.gov>

Subject: Fw: 3rd Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Please advise the status of the requested cross-clearance review of the MMWR titled "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky." The review was due **Friday, 7/16, at 10 a.m.**

[Reinfection and vaccination status_07.14.21_clean.docx](#)

We request the courtesy of a response with a status update.

Thank you,

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 16, 2021 2:29 PM

To: CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF,

Epi TF still requests your comments on this Tier 1 MMWR. As a reminder, here is the link:

[Reinfection and vaccination status_07.14.21_clean.docx](#)

Comments were due at 10 a.m., so please return your comments as soon as possible so that we can proceed with the clearance process.

Thank you,
Leza

**Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov**

**Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays**

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 16, 2021 11:28 AM

To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: Reminder: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear HSWS and VTF,

This is a gentle reminder that your cross-clearance of this MMWR was due today at 10 a.m.

 [Reinfection and vaccination status_07.14.21_clean.docx](#)

This is a Tier 1 MMWR. Please return your review as quickly as possible.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Thursday, July 15, 2021 10:04 AM

To: CDC IMS 2019 NCOV Response HSWS TF Clearance <eocevent229@cdc.gov>; CDC IMS 2019 NCOV Response CICP ADS/Clearance <eocdgmqsitrep@cdc.gov>; CDC IMS 2019 NCOV Response VTF Clearance <eocevent454@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Urgent - Cross-Clearance due 7/16 at 10AM: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear VTF, HSWS, and CICP TFs,

Epi TF requests cross-clearance of the **Tier 1 MMWR**, "*COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky.*"

Please use the SharePoint link below during your review. Please indicate whether you clear the manuscript with major/minor comments, with no comments, or do not clear.

The deadline for your review is **7/16 at 10:00 a.m.**

-  [Reinfection and vaccination status_07.14.21_clean.docx](#)

CICP clearance coordinators: please forward this MMWR for review to your new POC ASAP, as we are aware your ADS/TF are no longer accepting submissions. Thank you.

Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Wednesday, July 14, 2021 6:13 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Subject: RE: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Please see attached track and clean changes where all comments were addressed.

I am also attaching the clearance form. I deleted the section about cross task force review. I apologize for the confusion. That was filled in with the template that was sent me and I didn't see it. Therefore I hadn't deleted that section before submitting the form for this MMWR.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Tuesday, July 13, 2021 12:24 PM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Epi CLEARs (Next up: Cross-Clearance): Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

Epi ADS re-reviewed and cleared your MMWR with comments in the attached document. Please address comments and resubmit both a **clean copy** and a **tracked changes copy** to proceed with cross-clearance.

Also, your clearance request form originally stated that this MMWR article has been cleared by STLT, HSWS, and CICP. You and STLT have confirmed that Epi TF is the only TF to have reviewed it yet. When you resubmit, please update your clearance request form to reflect that only Epi TF has cleared it thus far.

Thank you!
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:

Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Tuesday, July 13, 2021 11:42 AM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Clearance Team—this review is complete.

Reviewer: Lisa Grohskopf (ADS), Ruth Link-Gelles (SME)
Decision: Cleared with comments, some mandatory
Comments: please see attached
Please send to Lab TF as informational (not for cross clearance).

Thank,
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Monday, July 12, 2021 7:20 AM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Grohskopf, Lisa A. (CDC/DDID/NCIRD/ID) <lkg6@cdc.gov>
Subject: FOR LISA RE-REVIEW: Due 7/13 at 7:30am: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning Epi ADS,

Lisa -- Alyson Cavanaugh is submitting her **Tier 1 MMWR** for re-review: "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky". Attached includes a clean copy and a tracked changes copy. See your initial decision record below:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

The deadline for your re-review of this expedited article is **7/13 at 7:30AM**.

Thank you,
Hannah

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Sunday, July 11, 2021 9:56 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: RE: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good evening,

Thank you very much for the review. Please see attached clean and track changes of edits based on the suggestions. All comments have been addressed.

This paper has only been reviewed by epi TF to date. Am I supposed to send to the other task forces for cross-clearance? No other task forces have yet reviewed this.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department of Public Health
275 E. Main St.
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Sunday, July 11, 2021 8:00 AM
To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Subject: Fwd: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <>
Subject: Fw: Epi TF Review Complete: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is

associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Alyson,

Epi TF has reviewed and **does not clear** this MMWR. Please see the following comments:

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Please address the comments in the attached document and submit clean and tracked copies for re-review. Additionally, please provide documentation of cross-clearance by STLT, CICIP, and HSWS.

Thank you,
Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Sent: Saturday, July 10, 2021 12:22 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Clearance Team! This review is complete.

Reviewer: Lisa Grohskopf (ADS)
Decision: Not Cleared, with comments (some mandatory).
Comments: See comments in the attached. Also, please send documentation of cross clearance by the TFs listed on the clearance sheet as having already cleared it. Will additionally require cross-clearance by VTF.

Thanks!
Lisa

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Friday, July 9, 2021 12:32 PM
To: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Fw: For Expedited Review, Due 7/10 at 12:30 p.m.: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Dear Team,

The attached Tier 1 MMWR, "COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky," is submitted for review. The deadline for review is **Saturday, 7/10, at 12:30 p.m.**

The clearance request form notes that CICP, STLT, and HSWS have already cleared this.

Leza

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 9, 2021 12:24 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Please see attached clearance form for MMWR 1464.

Let me know if I need to do anything additionally at this time.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 9:18 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Thank you, Anna!

Alyson,

I see you attached the manuscript but mention that it still needs co-author feedback, is that correct? When you are ready to submit for JIC clearance please send the manuscript and the completed request form I have attached. I have also attached the SOP for moving MMWRs through clearance to help with any questions on the process going forward.

Best Regards,
Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Sent: Friday, July 9, 2021 9:09 AM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Hi Katie,

Epi TF has "adopted" this manuscript for COVID-19 Clearance and Alyson has submitted to begin the clearance process with Epi TF. Let me know if you have any questions.

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Sent: Friday, July 9, 2021 8:28 AM

To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: Re: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Alyson,

Is this an FYI that this MMWR is coming for review? Are you asking for any action from the Epi TF at this time?

Best,

Katie

Epi Task Force Clearance Coordinator
CDC IMS EPI TF Clearance
COVID-19 RESPONSE
eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F
8am-5pm Weekends and Holidays

Coordinators:
Katie Garvin qqz9@cdc.gov
Hannah Bunting rou3@cdc.gov
Leza Young wzv6@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Friday, July 9, 2021 7:06 AM

To: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>

Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>

Subject: RE: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Good morning,

Attached is the manuscript for MMWR 1464 regarding reinfections and vaccination status.

I am making some edits based on co-authors' feedback for 1459, but hope to have the paper ready tomorrow.

I believe both will be "adopted" by the vaccine task force because they involve vaccine effectiveness. Please let me know any next steps for this submission.

V/R,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Sent: Thursday, July 8, 2021 2:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response EPI TF ADS <eocevent496@cdc.gov>; CDC IMS 2019 NCOV Response STLT ADS <eocevent410@cdc.gov>
Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Dear Alyson,

Following up on your VE/VB MMWR manuscripts, the COVID-19 Response Incident Manager would like to have both 1459 and 1464 published in about a month (see email below). I have copied the Epi Clearance Coordinators (eocevent210@cdc.gov) and Epi ADS (eocevent496@cdc.gov), who are ready to help you begin the COVID-19 Clearance Process. When do you anticipate submitting these manuscripts?

Best Regards,

Anna

Anna Llewellyn, PhD
Associate Director for Science
State, Tribal, Local, and Territorial Support Task Force
COVID-19 Emergency Response
Centers for Disease Control and Prevention
Office: 404-639-1538 | Cell: 678-887-5058
eocevent410@cdc.gov

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>

Sent: Thursday, July 8, 2021 10:07 AM

To: Anderson, Mark (CDC/DDPHSIS/CGH/DGHP) <mea6@cdc.gov>

Cc: Lubar, Debra (CDC/DDID/NCEZID/OD) <dpl9@cdc.gov>; Honein, Margaret (Peggy) (CDC/DDID/NCEZID/DPEI) <mrh7@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>

Subject: Kentucky Reports Urgently Requested for Clearance and MMWR Publication

Mark, as mentioned yesterday, Peggy would really like to have these published by end of month-early August. They are top response priorities. Is there anything I can do to facilitate process?

1464	Reinfection associated with vaccination status - Kentucky, May-June 2021 (Alyson Cavanaugh)	Concept approved 6/30
1459	Low county-level vaccination coverage increases the risk of breakthrough infections among fully vaccinated Kentucky residents – Kentucky, May 2021 (Alyson Cavanaugh)	Concept approved 6/30

Apologies for not sending this note yesterday.

Best,
Charlotte

Charlotte Kent, PhD, MPH

Editor-in-Chief, *Morbidity and Mortality Weekly Report (MMWR)* Series
Center for Surveillance, Epidemiology, and Laboratory Services
Centers for Disease Control and Prevention

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Friday, July 30, 2021 5:12:37 PM
Attachments: [Cavanaugh_07.29_clean_SSU1.docx](#)
[TABLE 1_07.29.21_SSU1.docx](#)
[TABLE 2_07.29.21_SSU1.docx](#)
[TABLE 3_07.29.21_SSU1.docx](#)
[FIGURE_Supplementary_SSU1.docx](#)

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today ☺) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

***NOTICE OF CONFIDENTIALITY:** This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eoevent172@cdc.gov>; CDC IMS

2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>

Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>

Sent: Thursday, July 29, 2021 9:55 AM

To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>

Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

CDC IMS 2019 NCOV Response Strategic Scientific Unit

Email: eocevent538@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: [Morbidity and Mortality Weekly Report](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: MMWR - Account Created in ScholarOne Manuscripts
Date: Tuesday, August 3, 2021 9:56:18 PM

03-Aug-2021

Dear Mr. Glick:

A manuscript titled, "Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021 (CDC-2021-0104)," has been submitted by Dr. Alyson Cavanaugh to MMWR.

You are listed as a co-author for this manuscript. The online system, ScholarOne Manuscripts, automatically creates a user account for you. Your USER ID and PASSWORD for your account is as follows:

Site URL:

[REDACTED]

USER ID:

[REDACTED]

PASSWORD: For security reasons your password is not contained in this email. To set your password click the link below.

[REDACTED]

You can use the above USER ID and PASSWORD (once set) to log in to the site and check the status of papers you have authored/co-authored. Please log in to

[REDACTED]

to update your account information via the edit account tab at the top right.

Thank you for your participation.

Sincerely,
Editorial Office, MMWR

Log in to Remove This Account -

[REDACTED]

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Wednesday, August 4, 2021 7:09:03 AM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw dat.docx](#)

I think it looks great, and I do like the protective OR's now.

I only found an additional period, an additional space, and a missing comma worth revising. I think the rest was fine with Kathleen's revisions.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Tuesday, August 3, 2021 11:25 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, August 3, 2021 9:58 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,
Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 2:25 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 12:17 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>
Sent: Monday, August 2, 2021 5:09 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

**MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection
May through June, 2021 Kentucky**

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date:

8/3/2021

Forecasted Completion:

8/16/2021

Intended Use:

Publication: MMWR: Recommendations & Reports

Path:

/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Audience:

Public health, medical professionals, and general public

Topics:

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Tuesday, August 3, 2021 11:24:59 PM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw.docx](#)

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, August 3, 2021 9:58 PM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 9:46 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Tuesday, August 3, 2021 6:47 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you

have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,
Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3

<eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>

Sent: Monday, August 2, 2021 5:09 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)

eClearance banner



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review

My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review

Document Description

Filename:

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Targeted Completion Date: 8/3/2021

Forecasted Completion: 8/16/2021

Intended Use:

Publication: MMWR: Recommendations & Reports

Path:

/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Audience:

Public health, medical professionals, and general public

Topics:

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky
Date: Wednesday, August 4, 2021 7:43:24 AM
Attachments: [COPY EOC Cavanaugh 08.03 clean kw dat ks.docx](#)

Hello Alyson,

A few additional edits/comments for your consideration. Sorry to be late.

Best,

Kevin

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Wednesday, August 4, 2021 7:09 AM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

I think it looks great, and I do like the protective OR's now.

I only found an additional period, an additional space, and a missing comma worth revising. I think the rest was fine with Kathleen's revisions.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Tuesday, August 3, 2021 11:25 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick,

Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

With my edits/comments, for your consideration.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Tuesday, August 3, 2021 9:58 PM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: FW: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Hi all,

Here are the most recent version just submitted. If there is feedback please let me know early tomorrow. They needed this tonight to start working on getting the proof ready

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)

Sent: Tuesday, August 3, 2021 9:46 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Good evening,

Please find attached track and clean changes of manuscript, Table 1, and Table 2.

There is no longer a table 3 and Tables 2 and 3 were combined.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Tuesday, August 3, 2021 6:47 PM
To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: RE: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Thank you. Working on it now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Sent: Tuesday, August 3, 2021 6:38 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Fw: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Alyson,

Congratulations!

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Best Regards,
Katie

Epi Task Force Clearance Coordinator

CDC IMS EPI TF Clearance

COVID-19 RESPONSE

eocevent210@cdc.gov

Hours of operation: 7am-8:30pm M-F

8am-5pm Weekends and Holidays

Coordinators:

Cara Cowan rwj9@cdc.gov

Katie Garvin qqz9@cdc.gov

Hannah Bunting rou3@cdc.gov

Leza Young wzv6@cdc.gov

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 6:36 PM

To: CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Cc: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; Reynolds, Mary (CDC/DDPHSS/OS/OSQ) <nzr6@cdc.gov>

Subject: CLEARED WITH COMMENTS: (#ID 1464) MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 – Kentucky

Epi TF...

The OS approves this MMWR with the following comments: *The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. **Please consider this approved contingent on authors making the requested changes.***

Please provide a final clean copy of this MMWR package for our records and to finalize the eClearance process.

Regards,
Lia Lynch

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 6:30 PM
To: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Panasuk, Brian J. (CDC/DDPHSS/CPR/DEO) <fwf2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

JIC,

The manuscript requires revision and changes to convey the findings in a more clear way, making it easier for the reader. Please consider this approved contingent on authors making the requested changes.

I will also F/U via eClearance.

Thank you.
Shambavi

From: Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Sent: Tuesday, August 3, 2021 4:45 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>; Zhu, Bao-Ping (CDC/DDPHSS/OS/OSQ) <BXZ3@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thanks for update. We must put this into production tomorrow. Would be great if it could happen tonight.

Many thanks, Charlotte

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 2:27 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>
Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you, Shambavi. Copying Charlotte so she is aware.

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Sent: Tuesday, August 3, 2021 2:25 PM

To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>

Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

I am awaiting statistical review from Bao-Ping, so it may be delayed till late night or early tomorrow AM.

Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Sent: Tuesday, August 3, 2021 12:18 PM

To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>

Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>

Subject: Re: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Thank you!!

Brian

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Sent: Tuesday, August 3, 2021 12:17 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>
Subject: RE: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Brian,

Review is currently ongoing. I believe that it will be cleared with comments.

Best,
Shambavi

From: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Sent: Tuesday, August 3, 2021 12:09 PM
To: Subbarao, Shambavi (CDC/DDPHSS/OS/OSQ) <sfs2@cdc.gov>
Cc: OADS Clearance (CDC) <oadsclearance@cdc.gov>; CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: Status - MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Hi Shambavi,

MMWR was asking for a status update on this report currently under review by OS. I think they need a cleared copy submitted today. Will OS be able to clear this today or do you expect that you will need more time or will not clear?

Thanks!

Brian Panasuk

JIC Emergency Clearance: eocjicclear3@cdc.gov

COVID-19 Response Joint Information Center (JIC)

Response Clearance Hours (ET): Mon-Fri (9am-6pm), Sat/Sun (10am-3pm)

JIC Emergency Clearance Coordinators

Lisa Lynch | Jeanita Porter | Kaliyah Hunter | Joya Faruque | Eurkita Ford | Brian Panasuk

From: Publishing HD (CDC) <PublishingHD@cdc.gov>
Sent: Monday, August 2, 2021 5:09 PM
To: CDC IMS JIC Emergency Clearance-3 <eocjicclear3@cdc.gov>
Subject: eClearance - eClearance - Review Requested for MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

If you are having trouble reading this email click here to [view your task](#)



The following content has been submitted to the eClearance process for your review and approval as the JIC Clear Coord. 2 before CDC ADS review.

MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

ID: -EOC-8/2/21-93775

Type: Clearance Review as the JIC Clear Coord. 2 before CDC ADS review


My Due Date: **8/9/2021**

Date Received: 8/2/2021

Priority: Urgent Priority Reason: COVID-19 Response

Clearing Author: EOC_JIC_Clearance3

Author Comments: This is cleared by ADS, DIM, IM/PDIM. Ready for OS Review



Document Description

Filename:	MMWR-COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky
Targeted Completion Date:	8/3/2021
Forecasted Completion:	8/16/2021
Intended Use:	Publication: MMWR: Recommendations & Reports
Path:	/EOC/_eClearance Folders and Files/2021/MMWR-COVID-19

Audience:

vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection May through June, 2021 Kentucky

Topics:

Public health, medical professionals, and general public

Description:

A case control design was performed including KY residents aged 18 and older with SARS-CoV-2 infections through December 31, 2020. Reinfection cases were individuals who tested positive for SARS-CoV-2 by antigen or NAAT test in May through June 2021. Controls remained free of reinfection through June 2021. Controls were matched in a 1:1 ratio to cases by gender, age (within 3 years), and time of initial infection (within 1 week) with cases. Vaccination information from the Kentucky Immunization registry was used to determine fully vaccinated status, defined as receipt of two doses of mRNA vaccine or one dose of J&J. Odd ratio was calculated to determine association of reinfection risk with vaccination status. Previously-infected KY residents who became reinfected were significantly more likely to be unvaccinated compared to those who remained free of reinfection.

CDC ADS Notification Criteria:

Other

Please do not reply to this email. For questions or issues, please contact the eClearance administrator for your CIO.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE
Date: Monday, August 2, 2021 10:23:18 AM

Good morning all,

Just to update – the report got stuck in JIC clearance but is now escalated for expedited review. I have not yet received any official feedback, but I received notification that it is still expected this report gets published Friday. I was told to expect feedback this afternoon and have revisions prepared/submitted by this evening. I will work to do that, if possible.

If you haven't already e-mailed COI form, please do so by close of business today.

In addition, please send me a separate email so that I can archive for records that statement:

"I, FULL NAME , agree to be included as an author on the manuscript, "**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**" and certify that I meet the qualifications for authorship for this article

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Saturday, July 31, 2021 8:30 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: COI_disclosure forms - due COB Monday

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 8:52:51 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy ks.docx](#)

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 10:21:27 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC dat.docx](#)

I think I only had one or two comments to consider.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 10:00 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

One more change to be aware of. I changed the reference order. One of the lab studies focuses more on reduced neutralization for convalescent plasma on newer variants, but not specifically on vaccination. The order is more appropriate to the lines in the manuscript now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the

individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:51 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Thank you, Alyson. I think you have done an admirable job.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:42 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health

275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on report no. 1464
Date: Wednesday, July 28, 2021 5:39:38 PM

Thank you, Alyson. I made a couple of edits and comments in the sharepoint document.

I have no edits/comments on the tables.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, July 27, 2021 6:24 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Comments on report no. 1464

Hi all,

Here are comments from MMWR from pre-review. In general, I agree with most edits.

- I agree with suggestion to use Figure 1 in supplemental and include the three tables in the MMWR.
- The one section I am unsure of is Page 5. This paragraph on single dose was added per comments from vaccine task force. Any suggestions for shortening would be appreciated, but I think some talk on the topic is needed.
- For the actual manuscript, if you have suggestions/edits/comments, please use the link: https://kymsoffice-my.sharepoint.com/:w/g/personal/alyson_cavanaugh_ky_gov/EZYxVWqbJ1pFnaIdyX75zHYBBd3cJK1e16C3m-hZQjUkPQ

I plan to resubmit early morning (6am ish) on 7/29/21. The next submission step is higher levels of CDC clearance (CHEO/JIC). This is nearing the end of the process for clearance.

FYI – they edited the tables without track changes, so I will need to make some adjustments. Table 3 is confusing as laid out. I need to check these in more detail since track changes weren't used. If you have changes on tables, let me know. There is not a sharedrive link for tables.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>

Sent: Tuesday, July 27, 2021 4:19 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>

Subject: Comments on report no. 1464

Dear Dr. Cavanaugh,

I appreciated the opportunity to review your draft manuscript (**Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021**) on behalf of MMWR before it undergoes further COVID-19 Response pre-clearance and JIC clearance.

I've made a number of edits to your manuscript in track changes in the attached files to enhance clarity and to further align with MMWR author guidelines, and have also included some comments and questions. You do not need to accept any edits that may have inadvertently introduced inaccuracies or deviated from the original intent of the narrative. However, please accept all other edits and make a concerted effort to address the comments and questions before sending a clean version to the next stage of pre-clearance. This will ultimately help facilitate more timely processing of the manuscript once it is eventually submitted to MMWR for official consideration of publication.

Please pay attention to the following:

1. MMWR reports are allowed to have a maximum of 3 tables and/or figures in any combination; you have submitted 3 tables and 1 figure; I suggest that you make the figure a supplementary figure; it will be archived in CDC Stacks, and there will be a clickable link within the report to access it.
2. I formatted your tables for MMWR; in the future, please be aware that table cells cannot have any hard returns nor can there be any empty cells.

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance. Once cleared by JIC, you will then be directed to submit the manuscript to MMWR via ScholarOne (<https://mc.manuscriptcentral.com/mmwr>); at that time, please remember to include an ICMJE conflict of interest form for each co-author with your submission. If there is a group author on the byline, then the persons listed in the group will be indexed in PubMed as contributors rather than authors, and no ICMJE form is necessary for those persons.

As your manuscript continues through clearance, please remember that MMWR allows up to 1,650 words for COVID-19 reports and up to 10 references. You and your coauthors will likely receive requests for additional narrative to be added from the next several reviewers; but please ensure that the final submission to MMWR is less than 1,650 words with no more than 10 references or it will require another round of editorial review, which could delay processing of the report.

Please let me know if you have any questions.

With kind regards,

Jacqueline Gindler, MD
Editor, MMWR Weekly

404-639-8829
jgindler@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on report no. 1464
Date: Wednesday, July 28, 2021 6:58:53 PM

Thank you!

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Wednesday, July 28, 2021 5:40 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Comments on report no. 1464

Thank you, Alyson. I made a couple of edits and comments in the sharepoint document.

I have no edits/comments on the tables.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Tuesday, July 27, 2021 6:24 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Comments on report no. 1464

Hi all,

Here are comments from MMWR from pre-review. In general, I agree with most edits.

- I agree with suggestion to use Figure 1 in supplemental and include the three tables in the MMWR.
- The one section I am unsure of is Page 5. This paragraph on single dose was added per comments from vaccine task force. Any suggestions for shortening would be appreciated, but I think some talk on the topic

is needed.

- For the actual manuscript, if you have suggestions/edits/comments, please use the link: https://kymsoffice-my.sharepoint.com/:w:/g/personal/alyson_cavanaugh_ky_gov/EZYxVWqbJ1pFnaIdyX75zHYBBd3cJK1e16C3m-hZ0jUkPQ

I plan to resubmit early morning (6am ish) on 7/29/21. The next submission step is higher levels of CDC clearance (CHEO/JIC). This is nearing the end of the process for clearance.

FYI – they edited the tables without track changes, so I will need to make some adjustments. Table 3 is confusing as laid out. I need to check these in more detail since track changes weren't used. If you have changes on tables, let me know. There is not a sharedrive link for tables.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Gindler, Jacqueline (CDC/DDPHSS/CSELS/OD) <jsg5@cdc.gov>
Sent: Tuesday, July 27, 2021 4:19 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; Kent, Charlotte (CDC/DDPHSS/CSELS/OD) <cgk3@cdc.gov>; King, Brian a. (CDC/DDNID/NCCDPPH/OSH) <iyn3@cdc.gov>
Subject: Comments on report no. 1464

Dear Dr. Cavanaugh,

I appreciated the opportunity to review your draft manuscript (**Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination — Kentucky, May–June 2021**) on behalf of *MMWR* before it undergoes further COVID-19 Response pre-clearance and JIC clearance.

I've made a number of edits to your manuscript in track changes in the attached files to enhance clarity and to further align with *MMWR* author guidelines, and have also included some comments and questions. You do not need to accept any edits that may have inadvertently introduced inaccuracies or deviated from the original intent of the narrative. However, please accept all other edits and make a concerted effort to address the comments and questions before sending a clean version to the next stage of pre-clearance. This will ultimately help facilitate more timely processing of the manuscript once it is eventually submitted to *MMWR* for official consideration of publication.

Please pay attention to the following:

1. MMWR reports are allowed to have a maximum of 3 tables and/or figures in any combination; you have submitted 3 tables and 1 figure; I suggest that you make the figure a supplementary figure; it will be archived in CDC Stacks, and there will be a clickable link within the report to access it.
2. I formatted your tables for MMWR; in the future, please be aware that table cells cannot have any hard returns nor can there be any empty cells.

In accordance with the current COVID-19 Response clearance protocol, your next step is to simultaneously send clean copies of your manuscript files to both the Strategic Science Unit (SSU, eocevent538@cdc.gov) and the Chief Health Equity Officer (CHEO, eocevent559@cdc.gov) for pre-clearance. Please ensure that the MMWR functional box (eocevent172@cdc.gov) is copied on your submission e-mail to SSU and CHEO. Once both SSU and CHEO have cleared your manuscript, it can then be submitted to the Response JIC for clearance. Once cleared by JIC, you will then be directed to submit the manuscript to MMWR via ScholarOne (<https://mc.manuscriptcentral.com/mmwr>); at that time, please remember to include an ICMJE conflict of interest form for each co-author with your submission. If there is a group author on the byline, then the persons listed in the group will be indexed in PubMed as contributors rather than authors, and no ICMJE form is necessary for those persons.

As your manuscript continues through clearance, please remember that MMWR allows up to 1,650 words for COVID-19 reports and up to 10 references. You and your coauthors will likely receive requests for additional narrative to be added from the next several reviewers; but please ensure that the final submission to MMWR is less than 1,650 words with no more than 10 references or it will require another round of editorial review, which could delay processing of the report.

Please let me know if you have any questions.

With kind regards,

Jacqueline Gindler, MD
Editor, MMWR Weekly
404-639-8829
jgindler@cdc.gov

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review
Date: Thursday, August 5, 2021 2:36:44 PM
Attachments: [COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review_kw.docx](#)

Lots of edits to the talking points – for your discretion.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 1:54 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

Hi all,

Here is the revised Comms package, not yet fully approved. If you think there needs to be additional edits, let me know before 4 pm.

Interestingly, a comment by the media team made me recognize an edit needed for final proof. December 31 to May 1 is (>4 months) not (>=5 months) as stated in discussion.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Thursday, August 5, 2021 1:28 PM

To: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <gds1@cdc.gov>

Subject: COVID-19 MMWR Comms Package_Reinfection and Vaccination Status_DRAFT for Final Author Review

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:55:05 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks3.docx](#)

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Sent: Thursday, August 5, 2021 9:03 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 7:48 PM

To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday’s eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I’ll request the same from reviewers.

If anything needs to be deconflicted, I’ll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:13:50 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks2.docx](#)

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH

DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>

Sent: Thursday, August 5, 2021 4:15 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 9:02:54 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC ks.docx](#)

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 7:48:07 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC.docx](#)

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C

Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Final Proof of Your Early Release

Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Friday, August 6, 2021 5:52:19 AM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC CG2.docx](#)

I have to submit before 7. I am going to look at everything one or two more times but I believe this will be the version used.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Sent: Thursday, August 5, 2021 11:05 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Final Proof of Your Early Release

Only a minor suggestion or two. Thanks!

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:55 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

***NOTICE OF CONFIDENTIALITY:** This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Thursday, August 5, 2021 3:10 PM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Final Proof of Your Early Release

Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: Re: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:29:31 PM

Its actually just a written statement that is in the other email I just sent. I just checked with Melissa and there will be no live messaging.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, August 6, 2021 12:23 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP); Thoroughman, Douglas (CHFS DPH); Glick, Connor (CHFS DPH DEHP); Winter, Kathleen T (CHFS DPH DEHP)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street

Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Delta variant case study

Rapid increase in Mesa County, CO, April-June 2021

Mesa County, CO

COVID-19 vaccination low: **36%***

Hospitalizations
ICU use
Deaths

TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places

*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
vks0@cdc.gov

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:23:05 PM

Hi Alyson,

Do you know how to access/listen to Dr. Walensky?

Thanks.

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, August 6, 2021 12:09 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health

275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>
Sent: Friday, August 6, 2021 11:08 AM
To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>
Subject: MMWR Embargoed eBook for 8/6 Early Release



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places



*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 6:18:19 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC KW.docx](#)

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:17:12 AM
Attachments: [Reinfection - vaccination status FIRST PROOF AC KW DAT.docx](#)

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.

- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 6:35:10 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC ks.docx](#)

Hi Alyson,

Nice work as always. Sorry, but I was $\frac{3}{4}$ way through when I saw Kathleen's email come through. Just a few edits/comments for consideration.

Best,

Kevin

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Friday, July 30, 2021 5:55:35 PM
Attachments: [Cavanaugh 07.29 clean SSU1 ks.docx](#)

Hi Alyson,

I took a (quick) look and think you have done a very nice job. I did make a couple of edits/comments for your consideration. No issues with the tables or figure.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 5:13 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today ☺) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Sent: Thursday, July 29, 2021 9:55 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

CDC IMS 2019 NCOV Response Strategic Scientific Unit

Email: eocevent538@cdc.gov

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, July 29, 2021 7:27 AM

To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>

Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>

Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD

Lieutenant, U.S. Public Health Service Corps

CDC Epidemic Intelligence Service Officer

Assigned to Kentucky Department for Public Health

275 East Main Street

Frankfort, KY 40621

E-mail: Alyson.cavanaugh@ky.gov

Phone: 502-564-3261 x4231

Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the*

individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky
Date: Sunday, August 1, 2021 8:06:57 AM
Attachments: [Cavanaugh 07.29 clean SSU1 ks kw.docx](#)

With a few additional edits and comments. No need to incorporate if you have already resubmitted. I added my UK affiliation also.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Friday, July 30, 2021 5:56 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

I took a (quick) look and think you have done a very nice job. I did make a couple of edits/comments for your consideration. No issues with the tables or figure.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Friday, July 30, 2021 5:13 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good afternoon,

Both CHEO and scientific unit cleared the report with minor comments. I will address (haven't gotten to it yet today ☺) and plan to submit tomorrow.

If there are ANY additional comments from KDPH team, please address now. It does look like they are trying to reach the August 6 publication date.

We can always make some minor edit changes through the rest of the process. However, anything bigger, please comment at this point. This still has JIC clearance and MMWR submission, but it seems this is moving quickly at this point.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Sent: Thursday, July 29, 2021 7:24 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Subject: RE: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hi Alyson,

The SSU pre-clearance team has reviewed your manuscript and we have some required comments that we request be addressed (see attached; comments on the Supplementary Figure provided in the body of the manuscript). Contingent on the authors adequately addressing these comments from SSU and any comments you may have received from CHEO, you can proceed to submit it to the JIC for clearance.

We do not need to review the revised manuscript that addresses our comments. Please let me know if you have questions.

Best wishes,

Barbara Ellis, PhD, MS (on behalf of the SSU pre-clearance team)
Cell: 404-216-8294

From: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>
Sent: Thursday, July 29, 2021 9:55 AM
To: Cavanaugh, Alyson (CDC ky.gov) <alyson.cavanaugh@ky.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>; Ellis, Barbara (CDC/DDPHSS/OS/OD) (CTR) <bae7@cdc.gov>
Subject: Re: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Hello Alyson,

Thank you for your submission. Our reviewers have received your request and will provide feedback within 24 hours. Please let us know if you have any questions in the interim.

If there is any correspondence between the author and reviewer, please copy the Strategic Science Unit mailbox (eocevent538@cdc.gov) for tracking purposes.

Thank you,

*CDC IMS 2019 NCOV Response Strategic Scientific Unit
Email: eocevent538@cdc.gov*

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, July 29, 2021 7:27 AM
To: CDC IMS 2019 NCOV Response Strategic Scientific Unit <eocevent538@cdc.gov>; CDC IMS 2019 NCOV Response CHEO Team Clearance <eocevent559@cdc.gov>
Cc: CDC IMS 2019 NCOV Response MMWR and Publications <eocevent172@cdc.gov>; CDC IMS 2019 NCOV Response EPI Clearance <eocevent210@cdc.gov>
Subject: Tier 1 MMWR: COVID-19 vaccination after SARS-CoV-2 infection is associated with reduced risk of reinfection – May through June, 2021 - Kentucky

Good morning,

Please see clean copies of the manuscript, 3 tables, and 1 figure for MMWR 1464 – Vaccination associated with reduced risk of reinfection - May-June, 2021 Kentucky.

Please let me know if anything further is needed at this time.

Thank you,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection
Date: Friday, August 6, 2021 12:22:57 PM
Attachments: [image002.png](#)
[EMBARGOED UNTIL 1PM Media Statement MMWR.pdf](#)
[MMWR ER - Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States - August 6, 2021.pdf](#)
[MMWR ER - Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado - August 6, 2021.pdf](#)
[MMWR ER - Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky - August 6, 2021.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Sorry for flooding e-mail but this went out to media and has more info than the previous message I forwarded.

I also heard from AP reporter that there is a JAMA article being released today that again finds higher antibody response after vaccination of previously-infected individuals.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Brower, Melissa (CDC/DDPHSS/CSELS/OD) <ggk5@cdc.gov>
Sent: Friday, August 6, 2021 12:20 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

This went out to CDC's media list while we were talking to Mike. Just FYI

From: Media@cdc.gov (CDC) <sohco@cdc.gov>

Sent: Friday, August 6, 2021 11:49 AM

To: Media@cdc.gov (CDC) <sohco@cdc.gov>

Subject: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection



CENTERS FOR DISEASE
CONTROL AND PREVENTION

The MMWR is Embargoed until Friday, August 6, 2021 at 1PM ET



Morbidity and Mortality Weekly Report

know what matters.

August 6, 2021

Please see the attached E-books for:

“Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

“Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

“Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — 13 states, COVID-NET, February–April 2021”

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Thank you,

CDC News Media Branch
404-639-3286



CENTERS FOR DISEASE
CONTROL AND PREVENTION

The Media Statement is Embargoed until Friday, August 6, 2021 at 1PM ET

Media Statement

EMBARGOED FOR 1PM ET
Friday, August 6, 2021

Contact: [CDC Media Relations](#)
(404) 639-3286

New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

In today's MMWR, a study of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2 shows that unvaccinated individuals are more than twice as likely to be reinfected with COVID-19 than those who were fully vaccinated after initially contracting the virus. These data further indicate that COVID-19 vaccines offer better protection than natural immunity alone and that vaccines, even after prior infection, help prevent reinfections.

"If you have had COVID-19 before, please still get vaccinated," said CDC Director Dr. Rochelle Walensky. "This study shows you are twice as likely to get infected again if you are unvaccinated. Getting the vaccine is the best way to protect yourself and others around you, especially as the more contagious Delta variant spreads around the country."

The study of hundreds of Kentucky residents with previous infections through June 2021 found that those who were unvaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated. The findings suggest that among people who have had COVID-19 previously, getting fully vaccinated provides additional protection against reinfection.

Additionally, a second publication from MMWR shows vaccines prevented COVID-19 related hospitalizations among the highest risk age groups. As cases, hospitalizations, and deaths rise, the data in today's MMWR reinforce that COVID-19 vaccines are the best way to prevent COVID-19.

COVID-19 vaccines remain safe and effective. They prevent severe illness, hospitalization, and death. Additionally, even among the uncommon cases of COVID-19 among the fully or partially vaccinated vaccines make people more likely to have a milder and shorter illness compared to those who are unvaccinated. CDC continues to recommend everyone 12 and older get vaccinated against COVID-19.

###

[U.S. Department of Health and Human Services](#)

CDC works 24/7 protecting America's health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 8:33:15 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy.docx](#)

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this

afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: First Proof of Your MMWR Early Release
Date: Wednesday, August 4, 2021 1:30:51 PM
Attachments: [Reinfection - vaccination status FIRST PROOF.docx](#)

First proof!

Please provide any edits prior to 9pm tonight (or e-mail/text me if you want to review but it will not be possible before 9).

I will likely submit first thing tomorrow morning.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Wednesday, August 4, 2021 1:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: First Proof of Your MMWR Early Release

Hi Alyson,

Please provide any edits by **8:00 Thursday** morning. Reviewers have been asked to provide any comments by that time as well. I'll consolidate the comments and get them to you by 9:00.

We'll then need to resolve any issues raised by the comments by midday to allow sufficient time to produce the final proof.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:06:50 PM
Attachments: [MMWR_ER_-_Effectiveness_of_COVID-19_Vaccines_in_Preventing_Hospitalization_Among_Adults_Aged_≥65_Years_-_COVID-NET_13_States_-_August_6,_2021.pdf](#)
[MMWR_ER_-_Rapid_Increase_in_Circulation_of_the_SARS-CoV-2_B.1.617.2_\(Delta\)_Variant_-_Mesa_County_Colorado_-_August_6,_2021.pdf](#)
[MMWR_ER_-_Reduced_Risk_of_Reinfection_with_SARS-CoV-2_After_COVID-19_Vaccination_-_Kentucky_-_August_6,_2021.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>
Sent: Friday, August 6, 2021 11:08 AM
To: CDC MMWR ER Ebook <MMWRERbook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release

MMWR

Morbidity and Mortality Weekly Report



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

Delta variant case study

Rapid increase in Mesa County, CO, April-June 2021

Mesa County, CO

COVID-19 vaccination low: **36%***

Hospitalizations
ICU use
Deaths

TO DECREASE SPREAD:

- ✓ Increase COVID-19 vaccination as soon as possible
- ✓ Encourage vaccinated and unvaccinated people to wear masks in indoor public places

*May 2021

bit.ly/MMWR8621b

MMWR

Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
yks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: FW: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021
Date: Monday, August 9, 2021 2:17:28 PM

Hi all,

This e-mail actually made me cry some happy tears! I wanted to share with you all.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Don Weiss <Dweiss@health.nyc.gov>
Sent: Monday, August 9, 2021 2:01 PM
To: qds1@cdc.gov
Subject: Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Quick note to say this MMWR article was very well written. Succinct and to the point. Kudos to the writing and editing team.

Don Weiss, MD, MPH
Director of Surveillance
Bureau of Communicable Disease
New York City Department of Health and Mental Hygiene
Gotham Center, CN# 22a
42-09 28th Street, 6th Floor
Queens, New York 11101-4132

Desk (347) 396-2626
Fax (347) 396-2753

Sent from the New York City Department of Health & Mental Hygiene. This email and any files transmitted with it may contain confidential information and are intended solely for the use of the individual or entity to whom they are addressed. This footnote also confirms that this email message has been swept for the presence of computer viruses.

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:42:07 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP)

<connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Sent: Thursday, August 5, 2021 8:33 AM

To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>

Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated ☺

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: *This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Thursday, August 5, 2021 8:25 AM

To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>

Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:59:32 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)

One more change to be aware of. I changed the reference order. One of the lab studies focuses more on reduced neutralization for convalescent plasma on newer variants, but not specifically on vaccination. The order is more appropriate to the lines in the manuscript now.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:51 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Thank you, Alyson. I think you have done an admirable job.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:42 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Here are my edits and comments. I ended up just taking out the first sentence because I kept rephrasing and it was awkward.

There was an addition L1 comment that was also added:

Dr. Smith's comment: L1: In this study, reinfection is assumed in all cases.

Revision: “Although in some cases the repeat positive test result could be indicative of prolonged viral shedding or failure to clear the initial viral infection (9), given the time between initial and subsequent positive molecular tests (≥ 5 months), reinfection is the most likely explanation.”

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 8:53 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: Comments on First Proof of Your MMWR Early Release

Hello Alyson,

Didn't attempt to make any more edits, but did have a couple of comments in response to comments.

KS

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 8:33 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: Comments on First Proof of Your MMWR Early Release

They gave me an 11am deadline (thought it was noon). Doug called the comments on first statement.

I do not believe there are good references about this in the literature so it may need to be framed differently. Any suggestions are appreciated 😊

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 8:25 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Comments on First Proof of Your MMWR Early Release

Dear Alyson,

Attached is the first proof of your report with edits you provided, comments from senior

reviewers, and several recommended edits.

The two most substantive of the comments refer to the statement re vaccine hesitancy in the first sentence.

Please reply with applicable edits in response to the reviewers' comments (with the changes tracked) by **11:00 am**. We'll then be able to develop the final proof and distribute it this afternoon.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS
Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: MMWR Embargoed eBook for 8/6 Early Release
Date: Friday, August 6, 2021 12:08:51 PM

Statement from Dr. Wallensky will be at 1:00pm.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Friday, August 6, 2021 12:07 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>

Sent: Friday, August 6, 2021 11:23 AM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: FW: MMWR Embargoed eBook for 8/6 Early Release

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Here is the eBook of your report, along with the other two that are being released today.

Many thanks for the opportunity to assist you.

All the best,

Glenn

From: MMWR Communications (CDC) <MMWRCommunications@cdc.gov>

Sent: Friday, August 6, 2021 11:08 AM

To: CDC MMWR ER Ebook <MMWREREBook@cdc.gov>

Subject: MMWR Embargoed eBook for 8/6 Early Release

MMWR
Morbidity and Mortality Weekly Report



The MMWR is embargoed until 1:00 pm ET Friday, August 6, 2021

Please find the ebooks for today's MMWR Early Release attached.

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant – Mesa County, Colorado, April-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e2.htm?s_cid=mm7032e2_w

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination – Kentucky, May-June 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e1.htm?s_cid=mm7032e1_w

Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – 13 states, COVID-NET, February-April 2021

Link when live: https://www.cdc.gov/mmwr/volumes/70/wr/mm7032e3.htm?s_cid=mm7032e3_w

**Delta variant
case study**

Rapid increase in Mesa County, CO, April–June 2021



Best,
Shelton

Shelton Bartley, MPH
Health Communication Specialist
Morbidity and Mortality Weekly Report (MMWR)
Office of the Director
Center for Surveillance, Epidemiology, and Laboratory Services

Centers for Disease Control and Prevention (CDC)
1600 Clifton Road, NE, MS V25-5, Atlanta, GA 30333
404.808.4485 (cell)
vks0@cdc.gov

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Glick, Connor \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 7:12:34 AM
Attachments: [Reinfection - vaccination status FIRST PROOF 8.5.21_clean.docx](#)
[Reinfection - vaccination status FIRST PROOF 8.5.21.docx](#)

THANK YOU ALL!

I think I used most suggestions except:

- I kept title the same for now – I think it is simple and we do discuss lower odds of reinfection in vaccinated. I can change if there are strong opinions on this.
- I used “odds” in abstract paragraph, results, and summary box. However, in discussion I continue to use terms like “twice as likely.” Reinfections are rare outcome in epi terms (If using the standard 10% cut-off). Therefore the OR should be a good estimate of RR. For public health messaging purposes, “odds” is a term that is hard for general public (outside gamblers) to understand.

Hopefully these changes meet everyone’s input. We will get reviewer feedback by 9 am and I need to resubmit by noon so they can create final proof.

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Sent: Thursday, August 5, 2021 12:21 AM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP)

<alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>

Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great work. Thank you, Alyson!

I just had one comment on the interpretation of the estimates, and I know I have brought this up before, but I could not find any previous feedback or comments that addressed this specifically so I figure I would bring this up again.

“2.34 times more likely” and “2.34 times as likely” imply probability, but we’re reporting an odds ratio so (from what I understand) it would only be correct to say “2.34 times the odds”.

If I missed something, though – please point me in the right direction!

Best,
CG

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>

Sent: Thursday, August 5, 2021 12:17 AM

To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>

Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Glick, Connor \(CHFS DPH DEHP\)](#)
Subject: Reinfection - vaccination status FIRST PROOF_AC
Date: Wednesday, August 4, 2021 5:09:12 PM
Attachments: [Reinfection - vaccination status FIRST PROOF AC.docx](#)

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Glick, Connor \(CHFS DPH DEHP\)](#)
To: [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#)
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE
Date: Monday, August 2, 2021 10:35:00 AM
Attachments: [CG_disclosure.pdf](#)

I, Connor Glick, agree to be included as an author on the manuscript, “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021” and certify that I meet the qualifications for authorship for this article.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Monday, August 2, 2021 10:23 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: RE: COI_disclosure forms - due COB Monday - UPDATE

Good morning all,

Just to update – the report got stuck in JIC clearance but is now escalated for expedited review. I have not yet received any official feedback, but I received notification that it is still expected this report gets published Friday. I was told to expect feedback this afternoon and have revisions prepared/submitted by this evening. I will work to do that, if possible.

If you haven’t already e-mailed COI form, please do so by close of business today.

In addition, please send me a separate email so that I can archive for records that statement:

“I, FULL NAME , agree to be included as an author on the manuscript, “**Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021**” and certify that I meet the qualifications for authorship for this article

Thanks,

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you

have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP)
Sent: Saturday, July 31, 2021 8:30 AM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Subject: COI_disclosure forms - due COB Monday

Good morning all,

Each author will need to complete a conflict of interest form for the upcoming MMWR. I am attaching the ICMJE conflict of interest form. If you have no conflicts of interest, please make sure that every box is marked none. There is also a question at the end that would need to be marked.

I added the manuscript title. There is no number assigned yet so please leave it blank.

Please complete this and return it to me by Monday 8/2 at the latest.

Thank you all !

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

***NOTICE OF CONFIDENTIALITY:** This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.*

From: [Glick, Connor \(CHFS DPH DEHP\)](#)
To: [Spicer, Kevin B \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: RE: Final Proof of Your Early Release
Date: Thursday, August 5, 2021 11:05:00 PM
Attachments: [mm7032e1 - Reinfection - vaccination status FINAL PROOF AC CG.docx](#)

Only a minor suggestion or two. Thanks!

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:55 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Sorry, but another comment to the comment. I believe there will be issues with first talking about a finding (with no details) in the Discussion. I would hate to leave it out entirely, because I believe it does add support to the main finding and has additional support in the literature.

Best,

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 9:14 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Thanks – adding my current plan for revision based on these comments.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and

exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>
Sent: Thursday, August 5, 2021 9:03 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Hi Alyson,

Just a few minor comments/edits and one major comment for your consideration.

Thanks!

Kevin

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 7:48 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

I added only two edits thus far. I should have mentioned before but please check names and affiliations!

Let me know any additional edits you may have.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 4:15 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Final Proof of Your Early Release

Looks great, Alyson. I don't have any comments to add. Very short and concise now.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Thursday, August 5, 2021 3:37 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: FW: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Final proof. I will need to give edits prior to 7 am tomorrow.

Alyson M. Cavanaugh, DPT, MPH, PhD
Lieutenant, U.S. Public Health Service Corps
CDC Epidemic Intelligence Service Officer
Assigned to Kentucky Department for Public Health
275 East Main Street
Frankfort, KY 40621
E-mail: Alyson.cavanaugh@ky.gov
Phone: 502-564-3261 x4231
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Damon, Glenn (CDC/DDPHSS/CSELS/OD) (CTR) <nwx1@cdc.gov>
Sent: Thursday, August 5, 2021 3:10 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Subject: Final Proof of Your Early Release
Importance: High

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hi Alyson,

Attached are two versions of the final proof. The PDF is an early edition of Friday's eBook to show you the final layout. Please make any final edits to the text in the Word document.

Please provide any final edits **by 7:00 tomorrow morning**. I'll request the same from reviewers.

If anything needs to be deconflicted, I'll reach out to you by 7:30.

All the best,

Glenn Damon
Technical Writer-Editor, *MMWR*
CDC/OPHSS/CSELS

Contractor, Tanaq Government Services
gdamon@cdc.gov
Mobile: 404-606-0107

From: [Glick, Connor \(CHFS DPH DEHP\)](#)
To: [Thoroughman, Douglas \(CHFS DPH\)](#); [Winter, Kathleen T \(CHFS DPH DEHP\)](#); [Cavanaugh, Alyson \(CHFS DPH DEHP\)](#); [Spicer, Kevin B \(CHFS DPH DEHP\)](#)
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC
Date: Thursday, August 5, 2021 12:20:00 AM
Attachments: [Reinfection - vaccination status FIRST PROOF CG.docx](#)

Great work. Thank you, Alyson!

I just had one comment on the interpretation of the estimates, and I know I have brought this up before, but I could not find any previous feedback or comments that addressed this specifically so I figure I would bring this up again.

“2.34 times more likely” and “2.34 times as likely” imply probability, but we’re reporting an odds ratio so (from what I understand) it would only be correct to say “2.34 times the odds”.

If I missed something, though – please point me in the right direction!

Best,
CG

From: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>
Sent: Thursday, August 5, 2021 12:17 AM
To: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Re: Reinfection - vaccination status FIRST PROOF_AC

Great job, Alyson! I didn't see any numbers that got mixed up in the transition.

I did have several comments/questions and some suggested last-minute revisions to consider. I added to Kathleen's version, but I did agree with Kevin's title change comment. I differed from Kevin on the tense of the one verb, so you have a vote on each side - your decision!

Doug

Doug Thoroughman, PhD, MS
State Epidemiologist (Acting)
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are

notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>
Sent: Wednesday, August 4, 2021 6:18 PM
To: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: RE: Reinfection - vaccination status FIRST PROOF_AC

Great job. Here are my suggestions.

From: Cavanaugh, Alyson (CHFS DPH DEHP) <alyson.cavanaugh@ky.gov>
Sent: Wednesday, August 4, 2021 5:09 PM
To: Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Winter, Kathleen T (CHFS DPH DEHP) <kathleen.winter@ky.gov>; Glick, Connor (CHFS DPH DEHP) <connor.glick@ky.gov>
Subject: Reinfection - vaccination status FIRST PROOF_AC

- Here are my initial edits – I have flipped the OR to show unvaccinated vs. vaccinated.
- I added some group acknowledgements – I am not sure if they are worded correctly.

Please review and make suggestions. I will probably compile everything tomorrow morning so deadline is now 6 am 😊

Thanks all,
Alyson

From: [Thoroughman, Douglas \(CHFS DPH\)](#)
To: [Alexander, Kelly N \(CHFS DPH\)](#)
Cc: [Winter, Kathleen T \(CHFS DPH DEHP\)](#)
Subject: FW: 22-00035-FOIA: Request for Documents
Date: Wednesday, October 20, 2021 3:51:24 PM
Attachments: [Request for underlying Data regarding report in MMWR August 13, 2021 Vol. 70 No. 32.pdf](#)
[FOIA Response Form.pdf](#)

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

Hello, Kelly,

Alyson received, through CDC, a FOIA request asking CDC to provide the underlying data for the MMWR article on risk of reinfection comparing vaccinated to unvaccinated individuals. This is probably something that will need to go to legal. Alyson can provide a dataset with deidentified data, and hopefully she can do it in a way that protects us against HIPAA violations. My biggest concern is that the person requesting doesn't seem to know a lot about testing for COVID-19 and so I would say that there is a high potential for mis-use of this data. But I don't know that we have a call in that.

Let us know what next steps are.

Doug

Doug Thoroughman, PhD, MS
CAPT, USPHS
CDC Career Epidemiology Field Officer
Kentucky Department for Public Health
275 E. Main St., HS 2GW-C
Frankfort, KY 40621
Phone: 502-564-3418 x4315
Fax: 502-564-9626

NOTICE OF CONFIDENTIALITY: This e-mail, including any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain confidential information that is legally privileged and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are notified that any review, use, disclosure, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please contact the sender by reply e-mail and destroy all copies of the original message.

From: Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Sent: Wednesday, October 20, 2021 3:01 PM
To: Thoroughman, Douglas (CHFS DPH) <douglas.thoroughman@ky.gov>; Spicer, Kevin B (CHFS DPH DEHP) <kevin.spicer@ky.gov>; Beavers, Suzanne (CDC/DDPHSS/CSELS/DSEPD) <fgx5@cdc.gov>
Subject: FW: 22-00035-FOIA: Request for Documents

****CAUTION** PDF attachments may contain links to malicious sites. Please contact the COT Service Desk ServiceCorrespondence@ky.gov for any assistance.**

From: Macomber, Jonathan (CDC/DDPHSS/CSELS/OD) <qxf1@cdc.gov>
Sent: Wednesday, October 20, 2021 2:55 PM
To: Rutledge, Terisa (CDC/DDPHSS/CSELS/OD) <txr7@cdc.gov>; Cavanaugh, Alyson (CDC/DDPHSS/CSELS/DSEPD) <qds1@cdc.gov>
Cc: Henry, Roberto (CDC/DDPHSS/CSELS/OD) <ypj7@cdc.gov>; Macomber, Jonathan (CDC/DDPHSS/CSELS/OD) <qxf1@cdc.gov>
Subject: 22-00035-FOIA: Request for Documents

Good Afternoon All,

Below please find an incoming FOIA request regarding [this MMW article](#). **The requestor has asked for CDC to:** "Please provide the agency records of the background data related to the study upon which the paper in question was based upon." Please provide a response to this request by COB Friday 10/29, thank you!

Please note: The FOIA office has informed me the attached original request is for background only, the requestor has limited the scope of their inquiry to just the highlighted question above.

Best,
Jon Macomber, MPA
Public Health Analyst (Policy & Issue MGT)
CSELS | CDC
M: 337-238-8129
E: jmacomber@cdc.gov

Subject: FW: CDC MMWR Early Releases and Media Statement: New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection

Date: Friday, August 6, 2021 12:23:39 PM

Attachments: [image002.png](#)
[EMBARGOED UNTIL 1PM Media Statement MMWR.pdf](#)
[MMWR ER - Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States - August 6, 2021.pdf](#)
[MMWR ER - Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 \(Delta\) Variant — Mesa County, Colorado - August 6, 2021.pdf](#)
[MMWR ER - Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky - August 6, 2021.pdf](#)

Subject: FW: Comments on First Proof of Your MMWR Early Release
Date: Thursday, August 5, 2021 9:43:23 AM
Attachments: [Reinfection - vaccination status FIRST PROOF working copy AC.docx](#)
